

MYLAN TRIBAL SETTLEMENT AGREEMENT

This Mylan Settlement Agreement dated as of April 4, 2025 (this “*Agreement*”) sets forth the terms of settlement between and among the TLC, Participating Tribes, and Mylan (in each case as defined below), to take effect as of the Effective Date (as defined below).

Table of Contents

I.	Definitions.....	2
II.	Release	8
III.	Monetary Relief and Payments.....	13
IV.	Allocation and Use of Settlement Funds	14
V.	Participation by Tribes.....	19
VI.	Defendants to be Released Upon Meeting Threshold Requirements	21
VII.	Plaintiffs’ Attorneys’ Fees and Costs	21
VIII.	Dispute Resolution.....	22
IX.	Miscellaneous	22
•	<u>EXHIBIT A-1 Litigating Tribes</u>	A-1-1
•	<u>EXHIBIT A-2 Non-Litigating Tribes</u>	A-2-1
•	<u>EXHIBIT B Alleged Harms</u>	B-1
•	<u>EXHIBIT C List of Tribes and Tribal Allocation Voting Percentages</u>	C-1
•	<u>EXHIBIT D TAFT XV Trust Agreement (including exhibits)</u>	D-1
•	<u>EXHIBIT E Tribal Participation Form</u>	E-1
•	<u>EXHIBIT F Mylan Subsidiaries, Affiliates, and Joint Ventures</u>	F-1
•	<u>EXHIBIT H-1 Payment Schedule and Product</u>	H-1-1
•	<u>EXHIBIT H-2 Allocation Between TAFT and Attorney Fee Fund</u>	H-2-1

I. Definitions

Unless otherwise specified, the following definitions apply:

1. “*Abatement Fund*” or “*TAFT XV*” means the Tribal Abatement Fund Trust XV, a Delaware Statutory Trust to be formed in accordance with the Tribal Abatement Fund Trust XV Trust Agreement, which shall provide for distributions to Participating Tribes to be used for Opioid Remediation.
2. “*Agreement*” means this Mylan Settlement Agreement, inclusive of all Exhibits.
3. “*Alleged Harms*” The alleged past, present, and future damages, harms, losses, and related expenditures allegedly incurred by the Participating Tribes arising out of the use of Products, non-exclusive examples of which are described in the documents listed on **Exhibit B**, that have allegedly arisen as a result of the physical and bodily injuries sustained by individuals suffering from opioid-related addiction, death, and other related diseases and disorders, and that have allegedly been caused by Released Entities.
4. “*Annual Payment*” means the total amount payable into the Mylan Settlement Trust by Mylan on each Payment Date as set forth in **Exhibit H-1**.
5. “*Attorney Fee Fund*” means a segregated fund within the Mylan Settlement Trust set aside to pay attorneys’ fees and reimburse attorneys’ costs in accordance with Section IV.B.1 of this Agreement.
6. “*Claim*” Any past, present or future cause of action, claim for relief, cross-claim or counterclaim, theory of liability, demand, derivative claim, request, assessment, charge, covenant, damage, debt, lien, loss, fine, penalty, restitution, reimbursement, disgorgement, expenses, judgment, right, obligation, dispute, suit, contract, controversy, agreement, *parens patriae* claim, promise, performance, warranty, omission, or grievance of any nature whatsoever, whether legal, equitable, statutory, regulatory or administrative, whether arising under federal, state, tribal, or local common law, statute, regulation, guidance, ordinance or principles of equity, whether filed or unfiled, whether asserted or unasserted, whether known or unknown, whether accrued or unaccrued, whether foreseen, unforeseen or unforeseeable, whether discovered or undiscovered, whether suspected or unsuspected, whether fixed or contingent, and whether existing or hereafter arising, in all such cases, including but not limited to any request for declaratory, injunctive, or equitable relief, compensatory, punitive, or statutory damages, absolute liability, strict liability, restitution, remediation, subrogation, contribution, indemnity, apportionment, disgorgement, reimbursement, attorney fees, expert fees, consultant fees, fines, penalties,

expenses, costs or any other legal, equitable, civil, administrative, or regulatory remedy whatsoever.

7. “*Claim-Over*” means a Claim asserted by a Non-Released Entity against a Released Entity on the basis of contribution, indemnity, or other claim-over on any theory relating to a Non-Party Covered Conduct Claim asserted by a Releasor.
8. “*Covered Conduct*” means any actual or alleged act, failure to act, negligence, statement, error, omission, breach of any duty, conduct, event, transaction, agreement, service, work, sale, misstatement, misleading statement, or other activity of any kind whatsoever from the beginning of time through the Effective Date (and any past, present, or future consequence of any such act, failure to act, negligence, statement, error, omission, breach of duty, conduct, event, transaction, agreement, service, work, sale, misstatement, misleading statement, or other activity) arising from or relating in any way to (a) compounding, counseling, and documentation related to any Product or class of Products; (b) the availability, discovery, research, development, manufacture, packaging, repackaging, marketing, promotion, advertising, labeling, relabeling, recall, withdrawal, distribution, delivery, monitoring, reporting, regulatory compliance, supply, sale, prescribing, dispensing, physical security, warehousing, use or abuse of, or operating procedures relating to any Product, or any system, plan, policy, procedure, or advocacy relating to any Product or class of Products, including but not limited to any unbranded or branded promotion, marketing, or advertising, information, patient support or assistance, educational programs, consultancy, research, other programs, or campaigns, lobbying, grants, sponsorships, charitable donations, or other funding relating to any Product or class of Products; (c) the characteristics, properties, risks, or benefits of any Product or class of Products; (d) the monitoring or non-monitoring of orders placed of any Product; (e) reporting, disclosure, non-monitoring, non-reporting or non-disclosure to federal, state or other regulators of orders for any Product placed with any Released Entity; (f) the selective breeding, harvesting, extracting, purifying, exporting, importing, applying for quota for, procuring quota for, handling, promoting, manufacturing, processing, packaging, supplying, distributing, converting, or selling of, or otherwise engaging in any activity relating to, precursor or component Products, including but not limited to natural, synthetic, semi-synthetic or chemical raw materials, starting materials, finished active pharmaceutical ingredients, drug substances, or any related intermediate Products; or (g) diversion control programs, suspicious order monitoring, or regulatory compliance related to any Product
9. “*Effective Date*” means the date that the TLC delivers (or causes to be obtained and delivered) to Mylan the Tribal Participation Forms signed by 85% of Litigating Tribes, as determined by the Tribal Allocation Voting Percentages set forth in **Exhibit C** to this Agreement. The Effective Date

shall be no later than October 31, 2025, provided, however, that the deadline may be extended for up to 45 days upon the request of the TLC or any defendant company listed in the Tribal Participation Form.

10. “*Eligible Entities*” has the meaning set forth in Section V.E.
11. “Gross Settlement Amount” is \$9,591,584, which is comprised of the Abatement Fund and the Attorney Fee Fund, as reflected herein and in **Exhibits H-1** and **H-2** hereto. Notwithstanding any other language or provisions in this or any other agreement, the Gross Settlement Amount is the maximum dollar amount Mylan can pay in connection with the Agreement.
12. “*Litigating Tribe*” means a Tribe (or Tribe official asserting the right of or for the Tribe to recover for Alleged Harms to the Tribe and/or its members thereof) that (i) is identified on **Exhibit A-1**, or (ii) has brought any Claims regarding Covered Conduct as of the Effective Date.
13. “*MDL Court*” means the United States District Court for the Northern District of Ohio, Eastern Division in *In re: National Prescription Opiate Litigation*, No. 1:17-md-2804 (N.D. Ohio), or that district court generally if such case is no longer active.
14. “*Mylan*” means Viatris Inc.
15. “*Mylan Settlement Trust*” means the interest-bearing fund (or sub-fund) held in a “qualified settlement fund” within the meaning of 26 C.F.R. §§ 1.468B-1 *et seq* established by the MDL Court in MDL No. 2804 into which all payments by Mylan will be made and which shall be administered by the Special Master.
16. “*Non-Litigating Tribes*” means those Tribes that have not brought any Claims regarding Covered Conduct as of the Effective Date and/or are not set forth on **Exhibit A-1**. **Exhibit A-2** is intended to identify all Non-Litigating Tribes, provided, however, that to the extent there is any conflict between **Exhibit A-2** and the definitions of Litigating Tribe and/or Non-Litigating Tribe, the definitions control.
17. “*Non-Participating Tribe*” means any Tribe that does not execute a Tribal Participation Form within three years of the Effective Date of this Agreement or any Tribe that, within three years of the Effective Date of this Agreement, affirmatively opt-outs of this settlement and provides written notice to the Special Master, the TLC, and Mylan of its intent to litigate its Claims against Mylan.
18. “*Non-Party Covered Conduct Claim*” means a Claim against any Non-Released Entity involving, arising out of, or related to Covered Conduct (or conduct that would be Covered Conduct if engaged in by a Released Entity).

19. “*Non-Party Settlement*” means a settlement by any Releasor that settles any Non-Party Covered Conduct Claim and includes a release of any Non-Released Entity.
20. “*Non-Released Entity*” means an entity that is not a Released Entity.
21. “*Ongoing Common Benefit Order*” has the meaning set forth in Section III.A.4.
22. “*Opioid Remediation*” means care, treatment, and other programs and expenditures (including reimbursement for past such programs or expenditures¹ except where this Agreement restricts the use of funds solely to future Opioid Remediation) designed to (1) address the use of opioid products, (2) treat or mitigate opioid use or related disorders, or (3) mitigate other alleged effects of, including on those injured as a result of, the opioid epidemic. **Schedule B** of the TAFT XV TDP provides a list of programs, services and activities that qualify as expenditures for Opioid Remediation. In addition, **Schedule D** of the TAFT XV TDP provides a non-exhaustive list of Tribal Abatement expenditures that also qualify as being paid for Opioid Remediation. Qualifying expenditures may include reasonable related administrative expenses in connection with the above.
23. “*Participating Tribe*” means any Tribe that executes a Tribal Participation Form and uploads the Tribal Participation Form on the Portal within three years of the Effective Date. For the avoidance of doubt, a Participating Tribe does not become a Releasor until the Effective Date.
24. “*Parties*” means Mylan, the TLC, and Participating Tribes (each, a “*Party*”).
25. “*Payment Date.*” The date by which Mylan makes its Annual Payment pursuant to Section III.A and Exhibit H. The Payment Date shall be July 25, 2025 for Payment Year 1 and March 1 for each subsequent Payment Year.
26. “*Payment Year.*” The calendar year during which the applicable Annual Payments are due. Payment Year 1 is 2025, Payment Year 2 is 2026 and so forth. References to payment “for a Payment Year” mean the Annual Payment due during that year. References to eligibility “for a Payment Year” mean eligibility in connection with the Annual Payment due during that year.
27. “*Portal*” means the Tribal Opioid Settlement Portal at which (a) the Tribal Participation Agreements shall be received and maintained by the TLC for review and approval by Mylan and (b) the information related to the Tribal Allocation Distribution Percentage shall be maintained.

¹ Reimbursement includes amounts paid to any Participating Tribes for past expenditures or programs.

28. *“Product.”* Any chemical substance, whether used for medicinal or non-medicinal purposes, and whether natural, synthetic, or semi-synthetic, or any finished pharmaceutical product made from or with such substance, that is: (1) an opioid or opiate, as well as any product containing any such substance; (2) benzodiazepine, carisoprodol, or gabapentin; or (3) a combination or “cocktail” of chemical substances prescribed, sold, bought, or dispensed to be used together that includes opioids or opiates. “Product” shall include, but is not limited to, any substance consisting of or containing buprenorphine, butorphanol, codeine, diphenoxylate, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone, naltrexone, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanyl, tapentadol, tramadol, opium, heroin, carfentanyl, diazepam, estazolam, quazepam, alprazolam, clonazepam, oxazepam, flurazepam, triazolam, temazepam, midazolam, carisoprodol, gabapentin, or any variant of these substances or any similar substance. “Product” also includes any natural, synthetic, semi-synthetic or chemical raw materials, starting materials, finished active pharmaceutical ingredients, drug substances, and any intermediate products used or created in the manufacturing process for any of the substances described above.
29. *“Released Claims.”* Any and all Claims that directly or indirectly are based on, arise out of, or in any way relate to or concern the Covered Conduct and/or Alleged Harms occurring prior to the Effective Date. Without limiting the foregoing, Released Claims include any Claims that have been asserted against Released Entities by any Tribe in any federal, state, or local action or proceeding (whether judicial, arbitral, or administrative) based on, arising out of, or relating to, in whole or in part, the Covered Conduct and/or Alleged Harms, or any such Claims that could be or could have been asserted now or in the future in those actions or in any comparable action or proceeding brought by a Tribe or any Releasors (whether or not such Tribe or Releasor has brought such action or proceeding). Released Claims also include all Claims against Released Entities asserted in any proceeding to be dismissed pursuant to the Agreement, whether or not such claims related to Covered Conduct and/or Alleged Harms. The Parties intend that this term, “Released Claims,” be interpreted broadly. This Agreement does not release Claims by private individuals. It is the intent of the Parties that Claims by private individuals be treated in accordance with applicable law. Released Claims is also used herein to describe claims brought by a non-party Tribe that would have been Released Claims if they had been brought by a Releasor against a Released Entity.
30. *“Released Entities”* has the meaning set forth in Section VI.A.
31. *“Releasors”* With respect to Released Claims, (1) each Participating Tribe; and (2) without limitation and to the maximum extent of the power of each Participating Tribe to release Claims, (a) the Participating Tribe’s departments, agencies, divisions, boards, commissions, subdivisions,

districts, instrumentalities of any kind and attorneys, and any person in his or her official capacity whether elected or appointed to serve any of the foregoing and any agency, person, or other entity claiming by or through any of the foregoing, (b) any public entities, public instrumentalities, public educational institutions, unincorporated districts, fire districts, irrigation districts, water districts, emergency services districts, school districts, healthcare districts, hospital districts, Sheriffs and law enforcement districts, library districts, coroner's offices, public transportation authorities, and other special districts of the Participating Tribes, including those with the regulatory authority to enforce state, federal and tribal controlled substances acts or the authority to bring Claims related to Covered Conduct seeking money (including abatement (or remediation and/or restitution)) or revoke a pharmaceutical distribution license, within the territory governed by a Participating Tribe, and (c) any person or entity acting in a *parens patriae*, sovereign, quasi-sovereign, private attorney general, *qui tam*, taxpayer, or other capacity seeking relief, including but not limited to fines, penalties, or punitive damages, on behalf of or generally applicable to the general public with respect to a Participating Tribe, whether or not any of them participate in this Agreement. Each Participating Tribe's [representative] represents that he or she has obtained (or will obtain no later than the Effective Date) the authority set forth in Section II.G (Representation and Warranty). In addition to being a Releasor as provided herein, a Participating Tribe shall also provide the Tribal Participation Form referenced in Section V, providing for a release to the fullest extent of the Participating Tribe's authority.

32. "*Special Master*" means David R. Cohen, or his successor, appointed by the MDL Court in MDL No. 2804.
33. "*TAFT XV Directors*" or "the *Directors*" means the individuals Mary Smith, Dean Kevin Washburn, and Kathy Hannan, or their successors, appointed by the MDL Court in MDL No. 2804.
34. "*TAFT XV Trust Agreement*" means the Tribal Abatement Fund Trust XV Trust Agreement, to be effective as of the Effective Date in substantially in the form attached hereto as **Exhibit D**.
35. "*TAFT XV TDP*" means the Trust Distribution Procedures set forth as **Exhibit 4** of the TAFT XV Trust Agreement.
36. "*TLC*" means the Tribal Leadership Committee appointed by the Court in MDL No. 2804.
37. "*Total Remediation Amount*" has the meaning set forth in Section IV.B.1.
38. "*Tribal Allocation Appointee*" means David R. Cohen who was appointed by the MDL Court to set the procedures by which the inter-tribal allocation

was completed and who, jointly with Layn Phillips, determined the final inter-tribal allocation resulting in each Tribe's Tribal Allocation Distribution Percentage.

- 39. *"Tribal Allocation Distribution Percentage"* means a Tribe's percentage as determined by the Tribal Allocation Appointees pursuant to Section IV.D. The aggregate Tribal Allocation Distribution Percentages of all Tribes shall equal 100%.
- 40. *"Tribal Opioid Abatement Report"* means an annual report on the Approved Tribal Opioid Abatement Uses, as required under Section 2.5 of the TAFT XV Trust Agreement.
- 41. *"Tribal Participation Form"* means the form attached hereto as **Exhibit E**.
- 42. *"Tribe"* or *"Tribes"* means one or more Eligible Entity set forth on **Exhibit A-1** or **Exhibit A-2** of this Agreement.

II. Release

- A. *Scope.* As of the Effective Date, the Released Entities are hereby released and forever discharged from all of the Releasors' Released Claims. Each Participating Tribe (for itself and its Releasors) hereby absolutely, unconditionally, and irrevocably covenants not to bring, file, or claim, or to cause, assist in bringing, or permit to be brought, filed, or claimed, or to otherwise seek to establish liability for any Released Claims against any Released Entity in any forum whatsoever. The releases provided for in this Agreement are intended by the Parties to be broad and shall be interpreted so as to give the Released Entities the broadest possible bar against any liability relating in any way to Released Claims and extend to the full extent of the power of each Releasor to release Claims. The releases shall be a complete bar to any Released Claim.
- B. *Claim-Over and Non-Party Settlement.*
 - 1. *Statement of Intent.* It is the intent of the Parties that:
 - a. Released Entities should not seek contribution or indemnification (other than pursuant to an insurance contract) from other parties for their payment obligations under this Agreement;
 - b. the payments made under this Agreement shall be the sole payments made by the Released Entities to the Releasors involving, arising out of, or related to Covered Conduct (or conduct that would be Covered Conduct if engaged in by a Released Entity);
 - c. Claims by Releasors against non-Parties should not result in additional payments by Released Entities, whether through contribution, indemnification or any other means; and

- d. the Agreement meets the requirements of the Uniform Contribution Among Joint Tortfeasors Act and any similar state law or doctrine that reduces or discharges a released party's liability to any other parties.
2. The provisions of this Section II.B are intended to be implemented consistent with these principles. This Agreement and the releases and dismissals provided for herein are made in good faith.
3. *Non-Party Settlement.* To the extent that, on or after the Effective Date, any Releasor enters into a Non-Party Settlement, including in any bankruptcy case or through any plan of reorganization, the Releasor will include (or in the case of a Non-Party Settlement made in connection with a bankruptcy case, will cause the debtor to include), unless prohibited from doing so under applicable law, in the Non-Party Settlement a prohibition on contribution or indemnity of any kind substantially equivalent to that required from Mylan in Section II.B.2, or a release from such Non-Released Entity in favor of the Released Entities (in a form equivalent to the releases contained in this Agreement) of any Claim-Over. The obligation to obtain the prohibition and/or release required by this subsection is a material term of this Agreement.
4. *Claim-Over.* In the event that any Releasor obtains a judgment with respect to Non-Party Covered Conduct against a Non-Released Entity that does not contain a prohibition like that described in Section II.B.3, or any Releasor files a Non-Party Covered Conduct Claim against a Non-Released Entity in bankruptcy or a Releasor is prevented for any reason from obtaining a prohibition/release in a Non-Party Settlement as provided in Section II.B.3, and such Non-Released Entity asserts a Claim-Over against a Released Entity, the Released Entity shall be relieved of the prohibition in Section II.B.2 with respect to Non-Released Entity and that Releasor and Mylan shall take the following actions to ensure that the Released Entities do not pay more with respect to Covered Conduct to the Releasor or to Non-Released Entities than the amounts owed under this Settlement Agreement by Mylan:
 - a. Mylan shall notify that Releasor of the Claim-Over within sixty (60) calendar days of the assertion of the Claim-Over or sixty (60) calendar days of the Effective Date of this Settlement Agreement, whichever is later;
 - b. Mylan and that Releasor shall meet and confer concerning the means to hold Released Entities harmless and ensure that Mylan is not required to pay more with respect to Covered Conduct than the amounts owed by Mylan to the Releasor under this Agreement.

- c. The Releasor and Mylan shall take steps sufficient and permissible under the law of the state of the Releasor to hold Released Entities harmless from the Claim-Over and ensure Released Entities are not required to pay more with respect to Covered Conduct than the amounts owed by Mylan under this Agreement. Such steps may include, where permissible:
 - (1) Filing of motions to dismiss or such other appropriate motion by Mylan or Released Entities, and supported by Releasor, in response to any claim filed in litigation or arbitration;
 - (2) Reduction of that Releasor's Claim and any judgment it has obtained or may obtain against such Non-Released Entity by whatever amount or percentage is necessary to extinguish such Claim-Over under applicable law, up to the amount that Releasor has obtained, may obtain, or has authority to control from such Non-Released Entity;
 - (3) Placement into escrow of funds paid by the Non-Released Entities such that those funds are available to satisfy the Claim-Over;
 - (4) Return of monies paid by Mylan to the Releasor under this Agreement to permit satisfaction of a judgment against or settlement with the Non-Released Entity to satisfy the Claim-Over;
 - (5) Payment of monies to Mylan by the Releasor to ensure it is held harmless from such Claim-Over, up to the amount that Releasor has obtained, may obtain, or has authority to control from such Non-Released Entity;
 - (6) Credit to Mylan under this Agreement to reduce the overall amounts to be paid under the Agreement such that it is held harmless from the Claim-Over; and
 - (7) Such other actions as that Releasor and Mylan may devise to hold Mylan harmless from the Claim-Over.
- d. The actions of the Releasor and Mylan taken pursuant to paragraph (c) must, in combination, ensure Mylan is not required to pay more with respect to Covered Conduct than the amounts owed to the Releasor by Mylan under this Agreement.
- e. In the event of any dispute over the sufficiency of the actions taken pursuant to paragraph (c), the Releasor and Mylan may seek review by the MDL Court. The MDL Court shall have the authority to

require Releasors to implement a remedy that includes one or more of the actions specified in the above paragraph (c) sufficient to hold the Released Entities, including Mylan, fully harmless. In the event that the MDL Court's actions do not result in Released Entities being held fully harmless, Mylan shall have a claim for breach of this Agreement by Releasors, with the remedy being payment of sufficient funds to hold Mylan harmless from the Claim-Over up to the amount that Releasor has obtained, may obtain, or has authority to control from such Non-Released Entity. For the avoidance of doubt, the prior sentence does not limit or eliminate any other remedy that Mylan may have.

5. To the extent that the Claim-Over is based on a contractual indemnity, the obligations under Section II.B.4 shall extend solely to a Non-Party Covered Conduct Claim against a pharmacy, clinic, hospital or other purchaser, distributor or dispenser of Products, a manufacturer that sold Products, a consultant, and/or a pharmacy benefit manager or other third-party payor. Mylan shall notify the Participating Tribes, to the extent permitted by applicable law, in the event that any of these types of Non-Released Entities asserts a Claim-Over arising out of contractual indemnity against it.

C. *Indemnification and Contribution Prohibited.* No Released Entity shall seek to recover for amounts paid under this Agreement based on indemnification, contribution, or any other theory, from a manufacturer, pharmacy, hospital, pharmacy benefit manager, health insurer, third-party vendor, trade association, distributor, or health care practitioner. For the avoidance of doubt, nothing herein shall prohibit a Released Entity from recovering amounts owed pursuant to insurance contracts.

D. *General Release.* In connection with the releases provided for in the Agreement, each Participating Tribe (for itself and its Releasors) expressly waives, releases, and forever discharges any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or tribal or other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to §1542 of the California Civil Code, which reads:

General Release; extent. A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that if known by him or her, would have materially affected his or her settlement with the debtor or released party.

A Releasor may hereafter discover facts other than or different from those which it knows, believes, or assumes to be true with respect to the Released Claims, but each Participating Tribe (for itself and its Releasors) hereby expressly waives and fully, finally, and forever settles, releases, and discharges, upon the Effective Date, any and all Released Claims that may exist as of such date but which Releasors do

not know or suspect to exist, whether through ignorance, oversight, error, negligence or through no fault whatsoever, and which, if known, would materially affect the Participating Tribes' decision to enter into the Agreement or the Participating Tribes' decision to participate in this Agreement.

- E. *Res Judicata.* Nothing in this Agreement shall be deemed to reduce the scope of the res judicata or claim preclusive effect that the settlement memorialized in this Agreement, and/or any stipulation of dismissal with prejudice or judgment entered on this Agreement, gives rise to under applicable law.
- F. *Effectiveness.* The releases set forth in this Agreement shall not be impacted in any way by any dispute that exists, has existed, or may later exist between or among the Releasors. Nor shall such releases be impacted in any way by any current or future law, regulation, ordinance, or court or agency order limiting, seizing, or controlling the distribution or use of the Mylan Settlement Trust or any portion thereof, or by the enactment of future laws, or by any seizure of the Mylan Settlement Trust or any portion thereof.
- G. *Representation and Warranty.* The signatories on behalf of their respective Participating Tribes expressly represent and warrant that they have authority to enter this Agreement on behalf of their respective Participating Tribes and that their respective Participating Tribes will obtain on or before the Effective Date (or have already obtained) the authority to settle and release, to the maximum extent of each Participating Tribe's power, all Released Claims of (1) their respective Participating Tribes; and (2) all Releasors of their respective Participating Tribes.
- H. *Assigned Interest Waiver.* To the extent that any Participating Tribe has any direct or indirect interest in any rights of a third-party that is a debtor under the Bankruptcy Code as a result of a claim arising out of Covered Conduct by way of assignment or otherwise, including as a result of being the beneficiary of a trust or other distribution entity, to assert claims against Mylan (whether derivatively or otherwise), under any legal or equitable theory, including for indemnification, contribution, or subrogation, the Participating Tribe waives the right to assert any such claim, or to receive a distribution or any benefit on account of such claim and such claim, distribution, or benefit shall be deemed assigned to Mylan.
- I. *Cooperation.* Releasors (i) will not encourage any person or entity to bring or maintain any Released Claim against any Released Entity and (ii) will reasonably cooperate with and not oppose any effort by a Released Entity to secure the prompt dismissal of any and all Released Claims, including suits brought by non-Releasors based on Released Claims. Releasors will meet and confer and make reasonable efforts to resolve any action that is filed by any other Releasor against a Released Entity on or after the Effective Date. This provision shall not require a Participating Tribe to make any monetary payment or adjustment to allocation or incur other obligation.

- J. *Non-Released Claims.* Notwithstanding the foregoing or anything in the definition of Released Claims, the Agreement does not waive, release or limit any criminal liability, Claims for outstanding liability under any tax or securities law, Claims against parties who are not Released Entities, Claims by private individuals, and any claims arising under this Agreement for enforcement of this Agreement.

III. Monetary Relief and Payments

A. *Structure of Payments*

1. All payments under this Section III shall be made into the Mylan Settlement Trust. The payments in the Mylan Settlement Trust shall be allocated and used only as specified in Section IV of this Agreement.
2. Subject to Section III.B, Mylan shall make eight (8) Annual Payments into the Mylan Settlement Trust for a total sum of \$9,591,584, under the terms and conditions of this Agreement, subject to the reductions described in Section IV.E. Annual Payments shall be made on or before the Payment Date for each Payment Year. The Settlement Payment Schedule is set forth in **Exhibit H-1** and the allocation is defined below:
 - a. Mylan shall pay into the Mylan Settlement Trust \$1,438,737.60 to be paid in installments over eight (8) years as set forth in **Exhibit H-2**, subject to the reductions described in Section IV.E. These funds shall be allocated by the Special Master to the Attorney Fee Fund.
 - b. Mylan shall pay into the Mylan Settlement Trust \$8,152,846.40 to be paid in installments over eight (8) years as set forth in **Exhibit H-2**, subject to the reductions described in Section IV.E. These funds shall be allocated by the Special Master to TAFT XV.
3. For the avoidance of doubt, Mylan shall not be called upon to make any payments pursuant to this Agreement that together exceed the Gross Settlement Amount.
4. Mylan's payment into the Mylan Settlement Trust includes the amount necessary to comply with the Ongoing Common Benefit Order (Dkt. #4428) in *In re National Prescription Opiate Litigation*, case no. 1:17-md-2804, pending in the United States District Court for the Northern District of Ohio Eastern Division (the "Ongoing Common Benefit Order"). The Special Master shall hold the amount necessary to ensure compliance with the Ongoing Common Benefit Order until further order by the MDL Court. It is expressly understood that Mylan's Payment into the Mylan Settlement Trust under III.A.2 fulfills its obligations under the Ongoing Common Benefit Order.

B. *Timing of Distributions from the Mylan Settlement Trust*

1. For Payment Year 1, the Special Master shall transfer funds from the Mylan Settlement Trust pursuant to Section IV within 60 days of the dismissal with prejudice of all claims by Participating Litigating Tribes pursuant to Section V.D. For the avoidance of doubt, although the Payment Date for Payment Year 1 predates the Effective Date, no funds may be distributed unless and until the condition of Section V.D is met upon the Effective Date. For all other Payment Years, the Special Master shall transfer funds from the Mylan Settlement Trust within 60 days (with one 30 day extension available in his discretion) after receiving the funds pursuant to Section III.A.2 and in accordance with Exhibit H.
2. If 85% of the Litigating Tribes as determined by the Tribal Allocation Voting Percentages set forth in Exhibit C to this Agreement do not sign the Tribal Participation Form by October 31, 2025, or such later date as it may be extended to pursuant to Section I.9 , such that the Effective Date does not occur, then: (a) any payments made by Mylan to the Mylan Settlement Trust shall immediately be refunded to Mylan, along with all interest accrued, (b) Mylan shall make no further payments, and (c) this Agreement will have no further effect, and all releases and other commitments or obligations contained herein will be void; provided, however, that the deadline may be extended for up to 45 days upon the request of the TLC or any defendant company listed in the Tribal Participation Form.

IV. Allocation and Use of Settlement Funds

- A. *Components of Settlement Fund.* Subject to Section IV.B.3, the Mylan Settlement Trust shall be comprised of funds earmarked for Opioid Remediation and for the Attorney Fee Fund as set forth in Section IV.B.
- B. *Use of Settlement Payments.*
 1. The Special Master shall allocate and transfer funds from the Mylan Settlement Trust as follows: 85% of such funds (the “Total Remediation Amount”) shall be paid to TAFT XV for distribution to Participating Tribes to use for Opioid Remediation in accordance with the TAFT XV Trust Agreement and the TAFT XV TDP; and 15% of such funds shall be set aside by the Special Master for the Attorney Fee Fund, including the portion to be withheld pursuant to Section III.A.4.
 2. The TAFT XV Directors shall set aside and hold back the funds allocable to each of the following Tribes proportionate to the Tribe’s Tribal Allocation Distribution Percentage:
 - a. A Non-Litigating Tribe that has not become a Participating Tribe at the time of such distribution, and the provisions of Section IV.E.1 shall apply with respect to such Non-Litigating Tribe.

- b. A Litigating Tribe that has not become a Participating Tribe at the time of such distribution, and the provisions of Section IV.E.2 shall apply with respect to such Litigating Tribe.
3. The Special Master shall deduct the costs and expenses incurred in the administration of the Mylan Settlement Trust out of the interest accrued on the Mylan Settlement Trust, and thereafter from the principal of the Mylan Settlement Trust.
4. In no event may less than 85% of Mylan's payments to the Mylan Settlement Trust be spent on Opioid Remediation. The Parties acknowledge and agree that the payments disbursed to the Tribes from TAFT XV in accordance with this Section IV and Schedules B and D of the TAFT XV TDP are exclusively for Opioid Remediation.

C. *Duties and Expenses of the Directors.*

1. The Directors shall have the duties set forth in this Agreement and in the TAFT XV Trust Agreement. For the avoidance of doubt, the Directors will have duties and responsibilities comparable to those the same individuals exercise as trustees as set forth in the proposed Tribal Abatement Fund Trust Agreement filed 08/23/21 (Doc. 3634) with the Fifteenth Plan Supplement under the Eighth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors (the "*Purdue Plan*"), confirmed by the Bankruptcy Court in *In re Purdue Pharma L.P.*, No. 19-23649 (RDD) (S.D.N.Y) (without regard to the effectiveness of any other orders, documents, agreements or similar authorities that may otherwise be applicable to the Purdue Plan).
2. Any expenses, costs and fees associated with or arising out of the duties of the Directors shall be paid out of interest accrued on the Abatement Fund and from the principal in the Abatement Fund should such interest prove insufficient.

D. *Duties and Expenses of Tribal Allocation Appointees.*

1. David R. Cohen and Layn Phillips, in their capacities as Tribal Allocation Appointees, conducted a process with regard to the Janssen Tribal Master Settlement Agreement by which Tribal Allocation Distribution Percentages were determined, which shall also form the basis for the distributions to Participating Tribes in accordance with this Section IV. A copy of those Allocation Distribution Percentages is attached hereto as **Exhibit C**. For the avoidance of doubt, such process included:
 - a. Each Participating Tribe had the right to meaningfully participate in the final allocation process and a right to be heard prior to entry of the final allocation order specific to this opioid crisis.

- b. The Directors provided notice of the settlement to the unrepresented tribes. The Directors coordinated with Special Master David Cohen and Layn Phillips in their capacities as Tribal Allocation Appointees to set forth the procedures by which notice was provided.
 - c. Unrepresented Participating Tribes had the same rights as the represented tribes within the settlement allocation process.
- 2. Mylan acknowledges and expressly agrees that it had no role whatsoever in the inter-tribal allocation, the inter-tribal allocation matrix, or the underlying metrics and methodology used to determine the allocation. The application of the inter-tribal allocation to this Agreement shall not constitute a position by Mylan, nor shall it restrict Mylan's ability to take positions in contexts unrelated to this Agreement.
 - 3. For the avoidance of doubt, any expenses, costs, and fees associated with or arising out of the duties of David R. Cohen in his capacity as Tribal Allocation Appointee (including expenses of retaining experts or other professionals to assist him in the allocation issues including BrownGreer and trust counsel), shall be paid from the Gross Settlement Amount and Mylan shall have no further obligation to pay such costs..

E. *Treatment of Non-Participating Tribes.*

- 1. Non-Litigating Tribes. Non-Litigating Tribes shall have a period of three years after the Effective Date to execute a Tribal Participation Form. If a Non-Litigating Tribe executes a Tribal Participation Form within three years after the Effective Date, it shall receive the amount (including accumulated holdback amounts) allocable to its Tribal Allocation Distribution Percentage from the Abatement Fund. If a Non-Litigating Tribe does not execute a Tribal Participation Form within three years after the Effective Date, the amount (including accumulated holdback amounts) allocable to its Tribal Allocation Distribution Percentage will be reallocated and paid to all Participating Tribes pro rata at the end of the three year period following the Effective Date, provided however that if a Non-Litigating Tribe does not execute a Tribal Participation Form within three years after the Effective Date but files Released Claims against one or more Released Entities anytime in that same three-year period, the amount (including accumulated holdback amounts) allocable to such Non-Litigating Tribe pursuant to its Tribal Allocation Distribution Percentage shall revert to Mylan, to be paid to Mylan within sixty (60) days after the third anniversary of the Effective Date.
- 2. Litigating Tribes. Any Litigating Tribe that does not execute a Tribal Participation Form within three years after the Effective Date of this Agreement or any Litigating Tribe that affirmatively opt-outs of this settlement and provides written notice to the Special Master, the TLC and

Mylan of its intent to litigate any Released Claims against any Released Entities shall forego its right to participate in distributions contemplated by this Agreement, in which case the amount (including accumulated holdback amounts) allocable to such Litigating Tribe pursuant to its Tribal Allocation Distribution Percentage shall revert to Mylan, to be paid to Mylan within sixty (60) days after the third anniversary of the Effective Date.

F. *Provisions Regarding Abatement Fund.*

1. The funds distributed by TAFT XV to each Participating Tribe shall be used solely for Opioid Remediation.
2. The TAFT XV Directors shall, in consultation with the TLC, design and implement a system of annual reporting by Participating Tribes relating to Opioid Remediation expenditures made using funds received from TAFT XV. The TAFT XV Directors shall provide an annual Tribal Opioid Abatement Report to Mylan and the Special Master, which annual report may be filed by the Special Master, in his discretion, with the MDL Court.

G. *Nature of Payment.*

1. Mylan and the TLC acknowledge and agree that notwithstanding anything to the contrary in this Agreement, including, but not limited to, the scope of the Released Claims:
 - a. Mylan has entered into this Agreement to avoid the delay, expense, inconvenience, and uncertainty of further litigation;
 - b. Tribes sought restitution and remediation (within the meaning of 26 U.S.C. § 162(f)(2)(A)) as damages for the Alleged Harms allegedly suffered by the Tribes;
 - c. By executing the Tribal Participation Form, the Participating Tribes acknowledge that: (a) the Total Remediation Amount is no greater than the amount, in the aggregate, of the Alleged Harms allegedly suffered by the Participating Tribes; and (b) the portion of the Total Remediation Amount received by each Participating Tribe is no greater than the amount of the Alleged Harms allegedly suffered by such Participating Tribe;
 - d. The payment of the Total Remediation Amount by Mylan constitutes, and is paid for, restitution and remediation (within the meaning of 26 U.S.C. § 162(f)(2)(A)) for alleged damage or harm (as compensation for alleged damage or harm arising out of alleged bodily injury) allegedly caused by Mylan;
 - e. The Total Remediation Amount is being paid as restitution and remediation (within the meaning of 26 U.S.C. § 162(f)(2)(A)) in

order to restore, in whole or in part, the Participating Tribes and persons to the same position or condition that they would be in had the Participating Tribes and persons not suffered the Alleged Harms and constitutes restitution and remediation for damage or harm allegedly caused by the potential violation of a law and/or is an amount paid to come into compliance with the law;

- f. For the avoidance of doubt: (a) no portion of the Total Remediation Amount represents reimbursement to any Participating Tribe, or other person or entity, for the costs of any investigation or litigation, including without limitation attorneys' fees, (b) the entire Total Remediation Amount is properly characterized as described in Section IV.G.1.e, and (c) none of the amounts paid by Mylan under Section III constitutes disgorgement or is paid for or in place of any fine, penalty, punitive damages, other punitive assessments, or attorneys' fees; and
- g. The Muscogee (Creek) Nation, (or the designated "appropriate official" within the meaning of Treasury Regulation Section 1.6050X-1(f)(1)(ii)(B)), on behalf of all Participating Tribes (the "Form 1098-F Filer") shall complete and file Form 1098-F with the Internal Revenue Service on or before February 28 (March 31 if filed electronically) of the year following the calendar year in which the Effective Date occurs. On the Form 1098-F, the Form 1098-F Filer shall identify the entire Total Remediation Amount as remediation/restitution. The Form 1098-F Filer shall also, on or before January 31 of the year following the calendar year in which the Effective Date occurs, furnish Copy B of such Form 1098-F (or an acceptable substitute statement) to Mylan.

2. Tax Reporting and Cooperation

- a. Each Participating Tribe shall cooperate in good faith with Mylan with respect to any tax claim, dispute, investigation, audit, examination, contest, litigation, or other proceeding relating to this Agreement.
- b. Upon request by Mylan, the Participating Tribes (and any respective designated "appropriate official" within the meaning of Treasury Regulation Section 1.6050X-1(f)(1)(ii)(B)) agree to perform such further acts and to execute and deliver such further documents as may be reasonably necessary for Mylan to establish the statements set forth in Section IV.G to the satisfaction of their tax advisors, their independent financial auditors, the Internal Revenue Service, or any other governmental authority, including as contemplated by 26 C.F.R. § 1.162-21(b)(3)(ii) and any subsequently proposed or finalized relevant regulations or administrative guidance.

- c. Pursuant to 26 C.F.R.. § 1.6050X-1(a) and (b), the Muscogee (Creek) Nation shall designate one of its officers or employees to act as the “appropriate official” within the meaning of Treasury Regulation Section 1.6050X-1(f)(1)(ii)(B).
- d. For the avoidance of doubt, except as explicitly set forth in this Agreement, neither Mylan, the TLC, any Tribe, or counsel to any of the foregoing make any warranty or representation as to the tax consequences of the payment of the Total Remediation Amount (or any portion thereof).

V. Participation by Tribes

- A. *Presentation of Aggregated Settlement Offer, Informed Consent and Compliance with Ethical Rules.* The TLC, on behalf of the Tribes, negotiated the terms of this Agreement with Mylan and believes the Gross Settlement Amount and term of years to be reasonable and recommends moving forward to present this Agreement and informed consent documentation to all Litigating Tribes identified on **Exhibit A-1** and all Non-Litigating Tribes identified on **Exhibit A-2**, and if applicable, to their counsel. Mylan, the Released Entities, and the TLC recognize the ultimate decision to settle rests with each Tribe. The TLC will work with all counsel to present the proposed aggregate settlement and allocation procedures to all Tribes and will use best efforts to secure 100% participation. At all times, including in the roll out and presentation of this Agreement to the Tribes, each Tribe’s attorney’s duty of loyalty and disclosure is to his or her tribal clients.
- B. *Notice to Unrepresented Tribes.* The Directors shall provide notice of the settlement to each Non-Litigating Tribe.
- C. *Tribal Participation Form.* Attached hereto as **Exhibit E** is the Tribal Participation Form. A Tribe’s executed Participation Form is evidence of its status as a Party to this Agreement, and the executed Participation Forms and their terms are incorporated herein by reference.
- D. *Dismissal of Claims.* Each Participating Litigating Tribe, either directly or through its counsel, shall provide a dismissal with prejudice of all Released Claims by that Tribe against Released Entities. Dismissal of a Litigating Tribe’s complaint against Released Entities shall be filed only upon the occurrence of the Effective Date. The Parties will coordinate a streamlined dismissal process with the MDL Court that has been approved in previous tribal global settlements, that allows for a bulk filing of the agreed dismissals with prejudice.
- E. *Eligible Entities.* **Exhibits A-1** and **A-2** together set forth all entities eligible to participate in this Agreement (“*Eligible Entities*”):
 - 1. Each entity listed on **Exhibit A-1** is either (1) a federally recognized tribe that the U.S. Secretary of the Interior acknowledges as an Indian Tribe, as provided in the Federally Recognized Tribe List Act of 1994, 25 U.S.C. §

5130, and that has filed an opioid case in MDL No. 2804, in federal court outside the MDL, or in State court, or (2) a “tribal organization,” as defined in 25 U.S.C. § 5304(I), or an “inter-tribal consortium,” as defined in 25 U.S.C. § 5381(a)(5), that provides health care pursuant to contracts/compacts with the Indian Health Service, and that has filed an opioid case in MDL No. 2804, in federal court outside the MDL, or in State court. **Exhibit A-1** includes the filing docket number and counsel of record for the listed entity. Each entity listed on **Exhibit A-1** is entitled to participate in the settlement.

2. **Exhibit A-2** includes entities that are federally recognized tribes that the U.S. Secretary of the Interior acknowledges as an Indian Tribe, as provided in the Federally Recognized Tribe List Act of 1994, 25 U.S.C. § 5130, and that have not filed an opioid case in MDL No. 2804, in federal court outside the MDL, or in State court. **Exhibit A-2** also includes Alaska Native “tribal organizations,” as defined in 25 U.S.C. § 5304(I) and “inter-tribal consortia,” as defined in 25 U.S.C. § 5381(a)(5), that provide health care pursuant to contracts/compacts with the Indian Health Service, and that have not filed an opioid case in MDL No. 2804, in federal court outside the MDL, or in State court. Each entity listed on **Exhibit A-2** is entitled to participate in the settlement.

F. *Calculating Tribal Allocation Voting Percentages for Tribal Health Organizations and Inter-Tribal Consortia.*

1. In Alaska: For purposes of determining whether the 85% participation threshold has been met, the full amount of the Tribal Allocation Voting Percentage as listed on **Exhibit C** shall be used for each litigating Alaska Tribal Health Organization, litigating Alaska inter-tribal consortium, or litigating Alaska Tribe which is participating in the settlement. In the event that a litigating Alaska Tribe which is not listed in **Exhibit C**, and which is a member of a listed Alaska Tribal Health Organization or Alaska inter-tribal consortium, affirmatively decides not to participate in the settlement, then the Tribal Allocation Voting Percentage, as computed pursuant to the footnote set forth in **Exhibit C**, of that nonparticipating Alaska Tribe shall be calculated and deducted from the Tribal Allocation Voting Percentage of its Tribal Health Organization or inter-tribal consortium for purposes of determining whether the 85% participation threshold has been met.
2. Outside of Alaska: Litigating Tribal Health Organizations and inter-tribal consortia outside of Alaska have no Tribal Allocation Voting Percentage listed on **Exhibit C**, and accordingly their participation in the settlement shall not count toward the Participation Threshold.

G. *Deadline for the 85% participation threshold* . If the 85% participation threshold, as determined by the Tribal Allocation Voting Percentages set forth in **Exhibit C** to this Agreement, has not been satisfied by October 31, 2025, this Agreement will

have no further effect and all releases and other commitments or obligations contained herein will be void, provided, however, that the deadline may be extended for up to 45 days, upon the request of the TLC or any defendant company listed in the Tribal Participation Form..

VI. Defendants to be Released Upon Meeting Threshold Requirements

- A. The following are to be Released Entities and shall be released and claims against them to be dismissed with prejudice upon the Effective Date: Mylan and (1) all past and present subsidiaries, divisions, affiliates, predecessors, successors, and assigns (in each case, whether direct or indirect) of Mylan; (2) all past and present subsidiaries and divisions (in each case, whether direct or indirect) of any entity described in subsection (1); (3) the respective past and present officers, directors, members, trustees, and employees of any of the foregoing (each for actions that occurred during and related to their work for, or employment with, any of Mylan or the foregoing entities); (4) all past and present joint ventures (whether direct or indirect) of Mylan or its subsidiaries, including in any entity's capacity as a participating member in such joint venture; (5) all direct or indirect parents and shareholders of Mylan (solely in their capacity as parents or shareholders of Mylan with respect to Covered Conduct); and (6) any insurer of Mylan or any person or entity otherwise described in subsections (1)-(5) (solely in its role as insurer of such person or entity and subject to the last sentence of Section X.C). A list of Mylan's joint ventures, subsidiaries and affiliates and predecessor entities is set forth in Exhibit F. Any person or entity described in subsections (3)-(6) shall be a Released Entity solely in the capacity described in such clause and shall not be a Released Entity with respect to its conduct in any other capacity. Any entity acquired, or joint venture entered into, by Mylan after the Effective Date is not a Released Entity. Further and notwithstanding anything else in this paragraph, no entity sued in *In re: National Prescription Opiate Litigation*, No. 1:17-md-2804 (N.D. Ohio) is included as a Released Entity other than the entities listed on Exhibit F.

VII. Plaintiffs' Attorneys' Fees and Costs

- A. The procedures to allocate and disburse the Attorney Fee Fund to Litigating Tribes' counsel shall be the subject of a separate document to which Mylan and the Released Entities shall not be parties, but which shall be consistent with Section III.A.2 of this Agreement. Any costs incurred in allocating and disbursing the Attorney Fee Fund shall be borne by the Attorney Fee Fund.
- B. An attorney representing the Participating Tribes may not receive any payment from the Attorney Fee Fund unless such attorney presents this settlement to each tribal opioid client in good faith and uses best efforts to secure participation as set forth in Section V.A above.
- C. For the avoidance of doubt, the TLC shall propose and receive any necessary approval from the MDL Court for any funds to be paid to the appropriate Attorney Fee Fund or Common Benefit Fund, as set forth in Judge Polster's May 9, 2022

Order (ECF No. 4428), such that Mylan is under no obligation to hold back any funds for any Common Benefit Assessment. Any funds owed to the Common Benefit Fund shall be paid from the Attorney Fee Fund. The Allocation of Common Benefit Funds will be determined by the Fee Panel.

VIII. Dispute Resolution

- A. Any disputes arising out of this Agreement shall be heard before Special Master David Cohen as the arbitrator designated by the parties to resolve disputes through binding arbitration.

IX. Miscellaneous

- A. *No Admission.* Mylan does not admit liability or wrongdoing. This Agreement shall not be considered, construed, or represented to be (1) an admission, concession, or evidence of liability or wrongdoing or (2) a waiver or any limitation of any defense otherwise available to Mylan.
- B. *Third-Party Beneficiaries.* Except as expressly provided in this Agreement, no portion of this Agreement shall provide any rights to, or be enforceable by, any person or entity that is not a Participating Tribe or Released Entity. No Participating Tribe may assign or otherwise convey any right to enforce any provision of this Agreement and no entity except the TLC shall have the right to enforce any provision of this Agreement on behalf of all Participating Tribes. Nothing in this Agreement extends to the TLC or Participating Tribes the authority to enforce injunctive terms provided in state-court consent judgments implementing Mylan's national settlement with state and local governments, which shall be enforceable only as provided therein; however, Mylan acknowledges that said injunctive terms apply equally on tribal and non-tribal lands within a State.
- C. *Construction.* None of the Parties and no Participating Tribe shall be considered to be the drafter of this Agreement or of any of its provisions for the purpose of any statute, case law, or rule of interpretation or construction that would or might cause any provision to be construed against the drafter of this Agreement. The headings of the provisions of this Agreement are not binding and are for reference only and do not limit, expand, or otherwise affect the contents or meaning of this Agreement.
- D. *Cooperation.* Each Party agrees to use its best efforts and to cooperate with the other Parties to cause this Agreement to become effective, to obtain all necessary approvals, consents and authorizations, if any, and to execute all documents and to take such other action as may be appropriate in connection herewith. Consistent with the foregoing, each Party agrees that it will not directly or indirectly assist or encourage any challenge to this Agreement by any other person, and will support the integrity and enforcement of the terms of this Agreement.
- E. *Entire Agreement.* This Agreement, its Exhibits and any other attachments, embody the entire agreement and understanding between and among the Parties relating to the subject matter hereof and supersedes (1) all prior agreements and

understandings relating to such subject matter, whether written or oral and (2) all purportedly contemporaneous oral agreements and understandings relating to such subject matter.

- F. *Execution.* This Agreement may be executed in counterparts and by different signatories on separate counterparts, each of which shall be deemed an original, but all of which shall together be one and the same Agreement. One or more counterparts of this Agreement may be delivered by facsimile or electronic transmission with the intent that it or they shall constitute an original counterpart hereof. One or more counterparts of this Agreement may be signed by electronic signature.
- G. *Good Faith and Voluntary Entry.* Each Party warrants and represents that it negotiated the terms of this Agreement in good faith. Each of the Parties and signatories to this Agreement warrants and represents that it freely and voluntarily entered into this Agreement without any degree of duress or compulsion. The Parties state that no promise of any kind or nature whatsoever (other than the written terms of this Agreement) was made to them to induce them to enter into this Agreement.
- H. *No Prevailing Party.* The Parties each agree that they are not the prevailing party in this action, for purposes of any claim for fees, costs, or expenses as prevailing parties arising under common law or under the terms of any statute, because the Parties have reached a good faith settlement.
- I. *Waive Challenge.* The Parties each further waive any right to challenge or contest the validity of this Agreement on any ground, including, without limitation, that any term is unconstitutional or is preempted by, or in conflict with, any current or future law.
- J. *Non-Admissibility.* The settlement negotiations resulting in this Agreement have been undertaken by the Parties in good faith and for settlement purposes only, and no evidence of negotiations or discussions underlying this Agreement shall be offered or received in evidence in any action or proceeding for any purpose. This Agreement shall not be offered or received in evidence in any action or proceeding for any purpose other than in an action or proceeding arising under or relating to this Agreement, except that Released Entities may file or use this Agreement in any action (1) involving a determination regarding insurance coverage; (2) involving a determination of the taxable income or tax liability of any Released Entities; (3) to support a defense or counterclaim based on principles of res judicata, collateral estoppel, release, good-faith settlement, judgment bar or reduction or on any other theory of claim preclusion or issue preclusion or similar defense or counterclaim; (4) to support a claim for contribution and/or indemnification; or (5) to support any other argument or defense by a Released Entity that the Remediation Payments provide a measure of compensation for asserted harms or otherwise satisfy the relief sought.

- K. *Notices.* All notices or other communications under this Agreement shall be in writing (including but not limited to electronic communications) and shall be given to the recipients indicated below:

For the Tribal Leadership Committee:

Lloyd Miller/Don Simon/Whitney Leonard
Sonosky, Chambers, Sachse, Miller & Monkman, LLP
510 L Street, Suite 310
Anchorage, AK 99501
lloyd@sonosky.net
dsimon@sonosky.com
whitney@sonosky.net
(907) 258-6377

Geoffrey Strommer/Caroline Mayhew/Edmund Goodman
Hobbs, Straus, Dean & Walker, LLP
215 SW Washington St., Suite 200
Portland, OR 97204
gstrommer@hobbsstrauss.com
cmayhew@hobbsstrauss.com
egoodman@hobbsstrauss.com
(503) 242-1745

Tara Sutton/Tim Purdon
Robins Kaplan LLP
800 LaSalle Avenue, Suite 2800
Minneapolis, Minnesota 55402
TSutton@RobinsKaplan.com
TPurdon@RobinsKaplan.com
(612) 349-8500

Lynn Sarko
Keller Rohrback, L.L.P.
1201 Third Avenue, Suite 3200
Seattle, WA 98101
lsarko@kellerrohrback.com
(206) 623.1900

Roe Frazer
Frazer PLC
30 Burton Hills Blvd, Suite 450
Nashville, TN 37215
roe@frazer.law
(615) 647-6464

Peter Mougey
Levin, Papantonio, Rafferty, Proctor,
Buchanan, O'Brien, Barr & Mougey, P.A.
316 S. Baylen Street, Suite 600
Pensacola, FL 32502-5996
pmougey@levinlaw.com
(850) 435-7068

Elizabeth J. Cabraser/Dan Drachler/Eric Fastiff
Lieff Cabraser Heimann & Bernstein LLP
275 Battery Street, 29th Floor
San Francisco, CA 94111
ecabraser@lchb.com
ddrachler@lchb.com
efastiff@lchb.com
(415) 956-1000

Steve Skikos/Mark Crawford
Skikos, Crawford, Skikos & Joseph LLP
One Sansome Street, Suite 2830
San Francisco, CA 94104
sskikos@skikos.com
mcrawford@skikos.com
(415) 546.7300

For Mylan:

Adam K. Levin
HOGAN LOVELLS US LLP
Columbia Square
555 Thirteenth Street, NW
Washington, DC 20004
Tel: (202) 637-6846
adam.levin@hoganlovells.com

Rebecca C. Mandel
HOGAN LOVELLS US LLP
Columbia Square
555 Thirteenth Street, NW
Washington, DC 20004
Tel: (202) 637-5488
rebecca.mandel@hoganlovells.com

Douglas Miner
Viatris Inc.
General Counsel, North America
1000 Mylan Boulevard

Canonsburg, PA 15317
Tel: +1-724-514-1483
douglas.miner@viatris.com

Any Party or the TLC may change or add the contact information of the persons designated to receive notice on its behalf by notice given (effective upon the giving of such notice) as provided in this subsection.

- L. *No Waiver.* The waiver of any rights conferred hereunder shall be effective only if made by written instrument executed by the waiving Party or Parties. The waiver by any Party of any breach of this Agreement shall not be deemed to be or construed as a waiver of any other breach, whether prior, subsequent, or contemporaneous, nor shall such waiver be deemed to be or construed as a waiver by any other Party.
- M. *Preservation of Privilege.* Nothing contained in this Agreement, and no act required to be performed pursuant to this Agreement, is intended to constitute, cause, or effect any waiver (in whole or in part) of any attorney-client privilege, work product protection, or common interest/joint defense privilege, and each Party agrees that it shall not make or cause to be made in any forum any assertion to the contrary.
- N. *Successors.* This Agreement shall be binding upon, and inure to the benefit of, Mylan and its respective successors and assigns.
- O. *Modification, Amendment, Alteration.* After the Effective Date, any modification, amendment, or alteration of this Agreement by the Parties shall be binding only if evidenced in writing signed by Mylan along with the signatures of the Tribal Leadership Committee. In the event the TLC or Mylan concludes prior to the Effective Date that technical corrections are required to this Agreement, the TLC and Mylan shall meet and confer in good faith and make such amendments as they agree are appropriate.
- P. *Termination.*
 - 1. Unless otherwise agreed to by Mylan and the Tribe in question, this Agreement and all of its terms shall be canceled and terminated with respect to that Tribe, and the Agreement shall become null and void and of no effect with respect to that Tribe, if one or more of the following conditions applies:
 - a. The Tribe in question does not sign the Tribal Participation Form;
or
 - b. An insufficient number of Tribes sign the Tribal Participation Form, consistent with Section V.G such that the Effective Date does not occur.
 - 2. If this Agreement is terminated with respect to any or all Tribes, then:

- a. An applicable statute of limitation or any similar time requirement (excluding any statute of repose) shall be tolled from the date of this Agreement until the later of the time permitted by applicable law or for one year from the date of such termination, with the effect that Mylan and the Participating Tribe in question shall be in the same position with respect to the statute of limitation as they were at the time the Participating Tribe filed its action; and
 - b. Mylan and the Participating Tribe in question shall jointly move the relevant court of competent jurisdiction for an order reinstating the actions and claims dismissed pursuant to the terms of this Agreement governing dismissal, with the effect that Mylan and the Tribe in question shall be in the same position with respect to those actions and claims as they were at the time the action or claim was stayed or dismissed.
- Q. *Governing Law.* Except (1) as otherwise provided in the Agreement or (2) as necessary, in the sole judgment of Special Master David Cohen, to promote uniformity of interpretation for matters, this Agreement shall be governed by and interpreted in accordance with the respective laws of the State of Ohio without regard to the conflict of law rules of such State. Notwithstanding any other provision in this subsection on governing law, the United States District Court for the Northern District of Ohio shall retain jurisdiction to enforce this Agreement.
- R. *Severability.* In the event any one or more immaterial provisions of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement.

For the Tribal Leadership Committee:

Lloyd Miller / Don Simon / Whitney Leonard
Sonosky, Chambers, Sachse, Miller &
Monkman, LLP

Steve Skikos / Mark Crawford
Skikos, Crawford Skikos & Joseph LLP

For Mylan:

[INSERT MYLAN SIGNATORY]

EXHIBIT A-1¹

Litigating Tribes

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Akiak Native Community	Sonosky Chambers; Leiff Cabraser	1:18-op-46309-DAP
Alaska Native Tribal Health Consortium	Hobbs Straus Dean & Walker	1:18-op-46293-DAP
Aleutian Pribilof Islands Association	Hobbs Straus Dean & Walker	1:19-op-45024-DAP
Apache Tribe of Oklahoma	The Bruehl Law Firm, PLLC	1:19-op-46119-DAP
Arctic Slope Native Association	Sonosky Chambers; Leiff Cabraser	1:18-op-46268-DAP
Aroostook Band of Micmacs	Greene Ketchum Farrell Bailey & Tweel LLP	1:19-op-45349-DAP
Asa'carsarmiut Tribe	Sonosky Chambers; Leiff Cabraser	1:18-op-46309-DAP
Bad River Band of the Lake Superior Tribe of Chippewa Indians of the Bad River Reservation, Wisconsin	Frazer PLC	1:19-op-45256-DAP 1:19-op-45270-DAP 1:19-op-45297-DAP
Bay Mills Indian Community, Michigan	Skikos	1:19-op-45287-DAP
Bear River Band of the Rohnerville Rancheria, California	Lieff Cabraser Heimann & Bernstein, LLP	1:18-op-46362-DAP
Big Sandy Rancheria of Western Mono Indians of California	Ceiba Legal, LLP	1:18-op-45923-DAP
Big Valley Band of Pomo Indians of the Big Valley Rancheria, California	Ceiba Legal, LLP	1:18-op-45922-DAP
Blackfeet Tribe of the Blackfeet Indian Reservation of Montana	Powell & Majestro, PLLC	1:18-op-45749-DAP
Bristol Bay Area Health Corporation	Hobbs Straus Dean & Walker	1:19-op-46175-DAP

¹ Mylan is relying on the representations of the TLC regarding the accuracy of this list. Any ambiguity or inaccuracy should be construed against the TLC.

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Cahto Tribe of the Laytonville Rancheria	Frazer PLC	1:19-op-45038-DAP
Catawba Indian Nation	Fields PLLC	1:20-op-45234-DAP
Cayuga Nation	Robins Kaplan LLP	1:20-op-45153-DAP
Cher-Ae Heights Indian Community of the Trinidad Rancheria, California	Frazer PLC	1:19-op-45038-DAP
Cherokee Nation	Boies Schiller Whitten Burrage Fields law Filed	1:18-OP-45695-DAP
Cheyenne and Arapaho Tribes, Oklahoma	Frazer PLC	1:19-op-45231-DAP
Cheyenne River Sioux Tribe of the Cheyenne River Reservation, South Dakota	Domina Law Group	1:19-op-45114-DAP
Chickasaw Nation	Whitten Burrage	1:19-op-45066-DAP 1:20-op-45201-DAP
Chippewa Cree Indians of the Rocky Boy's Reservation, Montana	Skikos	1:19-op-45395-DAP
Chitimacha Tribe of Louisiana	Frazer PLC	1:18-op-45825-DAP
Choctaw Nation of Oklahoma	Whitten Burrage	1:19-op-45065-DAP 1:20-op-45202-DAP
Chugachmiut	Sonosky Chambers; Leiff Cabraser	1:18-op-46268-DAP
Citizen Potawatomi Nation, Oklahoma	The Bruehl Law Firm, PLLC	1:19-op-46013-DAP
Cloverdale Rancheria of Pomo Indians of California	Robins Kaplan LLP	1:18-op-46241-DAP
Coeur D'Alene Tribe	Skikos	1:19-op-45115-DAP
Comanche Nation, Oklahoma	Skikos	1:19-op-45442-DAP
Confederated Salish and Kootenai Tribes of the Flathead Reservation	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:19-op-45364-DAP
Confederated Tribes and Bands of the Yakama Nation	Askman Law Firm LLC	1:18-op-46202-DAP

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Confederated Tribes of the Colville Reservation	Skikos	1:19-op-45312-DAP
Confederated Tribes of the Goshute Reservation, Nevada and Utah	Frazer PLC	1:19-op-45972-DAP
Confederated Tribes of the Grand Ronde Community of Oregon	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:19-op-45097-DAP
Confederated Tribes of the Umatilla Indian Reservation	Skikos	1:18-op-45541-DAP
Confederated Tribes of the Warm Springs Reservation of Oregon	Skikos	1:19-op-45069-DAP
Consolidated Tribal Health Project, Inc.	Ceiba Legal, LLP; Beggs & Lane	1:18-op-45919-DAP
Copper River Native Association	Sonosky Chambers; Leiff Cabraser	1:18-op-46268-DAP
Coquille Indian Tribe	Frazer PLC	1:19-op-45970-DAP
Coushatta Tribe of Louisiana	Levin Papantonio	1:19-op-45438-DAP
Cow Creek Band of Umpqua Tribe of Indians	Robins Kaplan LLP	1:18-op-45417-DAP
Coyote Valley Band of Pomo Indians of California	Ceiba Legal, LLP	1:18-op-45918-DAP
Delaware Nation, Oklahoma	The Bruehl Law Firm, PLLC	1:19-op-46011-DAP
Dry Creek Rancheria Band of Pomo Indians, California	Skikos	1:20-op-45147-DAP
Eastern Aleutian Tribes	Sonosky Chambers; Leiff Cabraser	1:18-op-46268-DAP
Eastern Band of Cherokee Indians	Baron & Budd	1:18-op-45098-DAP
Eastern Shoshone Tribe of the Wind River Reservation, Wyoming	Skikos	1:19-op-45412-DAP
Ely Shoshone Tribe of Nevada	Frazer PLC	1:18-op-46003-DAP
Ewiiapaayp Band of Kumeyaay Indians, California	Frazer PLC	1:19-op-45038-DAP
Feather River Tribal Health, Inc.	Berkey Williams; Lieff Cabraser	1:19-op-45334-DAP

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Flandreau Santee Sioux Tribe of South Dakota	Robins Kaplan LLP	1:18-op-45095-DAP
Fond du Lac Band of the Minnesota Chippewa Tribe, Minnesota	Frazer PLC	1:18-op-46146-DAP 1:18-op-46295-DAP 1:20-op-45250-DAP
Forest County Potawatomi Community, Wisconsin	Robins Kaplan LLP	1:18-op-46342-DAP
Fort Belknap Indian Community of the Fort Belknap Reservation of Montana	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:19-op-45364-DAP
Gila River Indian Community of the Gila River Indian Reservation, Arizona	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:19-op-45366-DAP
Grand Traverse Band of Ottawa and Chippewa Indians, Michigan	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:19-op-45078-DAP
Guidiville Rancheria of California	Ceiba Legal, LLP	1:18-op-45917-DAP
Ho-Chunk Nation of Wisconsin	Frazer PLC	1:19-op-45076-DAP
Hoopa Valley Tribe, California	Lieff Cabraser Heimann & Bernstein, LLP	1:18-op-46361-DAP
Hopi Tribe of Arizona	Keller Rohrback LLP	1:20-op-45204-DAP
Hopland Band of Pomo Indians, California	Ceiba Legal, LLP	1:18-op-45913-DAP
Houlton Band of Maliseet Indians	Farrell Law	1:19-op-45315-DAP
Hualapai Indian Tribe of the Hualapai Indian Reservation, Arizona	Robins Kaplan LLP	1:19-op-45004-DAP
Indian Health Council	Hobbs Straus Dean & Walker	1:18-op-46316-DAP
Iowa Tribe of Kansas and Nebraska	Skikos	1:20-op-45099-DAP
Jamestown S'Klallam Tribe	Hobbs Straus Dean & Walker	1:18-op-45271-DAP
Jicarilla Apache Nation, New Mexico	Skikos	1:19-op-45385-DAP
Kenaitze Indian Tribe	Sonosky Chambers; Lieff Cabraser	1:18-op-46309-DAP
Keweenaw Bay Indian Community	Cooper Elliott	1:20-op-45150-DAP

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Kickapoo Traditional Tribe of Texas	Frazer PLC	1:20-op-45104-DAP
Kickapoo Tribe of Indians of the Kickapoo Reservation in Kansas	Skikos	1:19-op-45381-DAP
Klamath Tribes	Weitz & Luxenberg	1:19-op-45786-DAP
Kodiak Area Native Association	Hobbs Straus Dean & Walker	1:18-op-46260-DAP
Koi Nation of Northern California	Frazer PLC	1:19-op-45038-DAP
Kootenai Tribe of Idaho	Robins Kaplan LLP	1:18-op-46153-DAP
La Posta Band of Diegueno Mission Indians of the La Posta Indian Reservation, California	Skikos	1:19-op-45397-DAP
Lac Courte Oreilles Band of Lake Superior Chippewa Indians of Wisconsin	Frazer PLC	1:18-op-45932-DAP
Lac du Flambeau Band of Lake Superior Chippewa Indians of the Lac du Flambeau Reservation of Wisconsin	Frazer PLC	1:18-op-45502-DAP
Lac Vieux Desert Band of Lake Superior Chippewa Indians of Michigan	Skikos	1:18-op-46239-DAP
Leech Lake Band of the Minnesota Chippewa Tribe, Minnesota	Lockridge Grindal Nauen	1:18-op-45052-DAP
Lower Brule Sioux Tribe of the Lower Brule Reservation, South Dakota	Greene Ketchum Farrell Bailey & Tweel LLP	1:19-op-45350-DAP
Lower Sioux Indian Community in the State of Minnesota	Robins Kaplan LLP	1:18-op-45976-DAP
Lummi Tribe of the Lummi Reservation	Keller Rohrback LLP	1:18-op-45955-DAP
Lytton Rancheria of California	Levin Papantonio	1:19-op-45580-DAP
Makah Indian Tribe of the Makah Indian Reservation	Keller Rohrback LLP	1:18-op-46022-DAP
Manchester Band of Pomo Indians of the Manchester Rancheria, California	Frazer PLC	1:19-op-45038-DAP
Mashantucket Pequot Indian Tribe	Skikos	1:19-op-45405-DAP

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Mechoopda Indian Tribe of Chico Rancheria, California	Skikos	1:19-op-45403-DAP
Menominee Indian Tribe of Wisconsin	Robins Kaplan LLP	1:18-op-45426-DAP
Mentasta Traditional Council	Frazer PLC	1:20-op-45024-DAP
Mescalero Apache Tribe of the Mescalero Reservation, New Mexico	Skikos	1:19-op-45317-DAP
Miccosukee Tribe of Indians	The Moskowitz Law Firm	1:19-op-45121-DAP
Mille Lacs Band of Ojibwe	Lockridge Grindal Nauen	1:19-op-45978-DAP
Mississippi Band of Choctaw Indians	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:19-op-45279-DAP
Moapa Band of Paiute Indians of the Moapa River Indian Reservation, Nevada	Lockridge Grindal Nauen	1:19-op-45650-DAP
Modoc Nation	Robins Kaplan LLP	1:19-op-45439-DAP
Mohegan Tribe of Indians of Connecticut	Frazer PLC	1:20-op-45164-DAP
Muckleshoot Indian Tribe	Skikos	1:19-op-45213-DAP
Muscogee (Creek) Nation	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:18-op-45459-DAP
Narragansett Indian Tribe	Frazer PLC	1:20-op-45047-DAP
Native Village of Afognak	Sonosky Chambers; Leiff Cabraser	1:18-op-46309-DAP
Native Village of Port Heiden	Sonosky Chambers; Leiff Cabraser	1:18-op-46309-DAP
Navajo Nation, Arizona, New Mexico & Utah	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:18-op-45496-DAP
Nez Perce Tribe	Keller Rohrback LLP	1:18-op-45730-DAP
Nisqually Indian Tribe	Robins Kaplan LLP	1:18-op-45412-DAP
Northern Arapaho Tribe of the Wind River Reservation	Burg Simpson	1:18-op-45438-DAP

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Northern Cheyenne Tribe of the Northern Cheyenne Indian Reservation, Montana	Lockridge Grindal Nauen	1:19-op-45010-DAP
Northwestern Band of the Shoshone Nation	Porteous Hainkel & Johnson	1:20-op-45032-DAP
Norton Sound Health Corporation	Hobbs Straus Dean & Walker	1:18-op-46261-DAP
Oglala Lakota Sioux Tribe	Robins Kaplan LLP	1:18-op-45353-DAP
Omaha Tribe of Nebraska	Krupnick Campbell Malone Buser Slama Hancock, P.A.	1:18-op-45621-DAP
Oneida Nation	Levin Papantonio	1:18-op-46034-DAP
Osage Nation	The Bruehl Law Firm, PLLC	1:19-op-45821-DAP
Otoe-Missouria Tribe of Indians, Oklahoma	Skikos	1:19-op-45402-DAP
Paiute-Shoshone Tribe of the Fallon Reservation and Colony, Nevada	Frazer PLC	1:18-op-45697-DAP
Pala Band of Mission Indians	Hobbs Straus Dean & Walker	1:18-op-46341-DAP
Pascua Yaqui Tribe of Arizona	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:19-op-45366-DAP
Passamaquoddy Tribe Indian Township	Weitz & Luxenberg	1:18-op-45876-DAP
Passamaquoddy Tribe Pleasant Point	Weitz & Luxenberg	1:19-op-45100-DAP
Pawnee Nation of Oklahoma	The Bruehl Law Firm, PLLC	1:19-op-46017-DAP
Pinoleville Pomo Nation, California	Frazer PLC	1:19-op-45974-DAP
Poarch Band of Creeks	Frazer PLC	1:20-op-45231-DAP 1:20-op-45285-DAP 1:20-op-45286-DAP 1:20-op-45294-DAP
Ponca Tribe of Indians of Oklahoma	The Bruehl Law Firm, PLLC	1:18-op-45327-DAP

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Ponca Tribe of Nebraska	Krupnick Campbell Malone Buser Slama Hancock, P.A.	1:18-op-45557-DAP
Port Gamble S’Klallam Tribe	Hobbs Straus Dean & Walker	1:18-op-45271-DAP
Potter Valley Tribe, California	Frazer PLC	1:19-op-45038-DAP
Prairie Band Potawatomi Nation	Skikos	1:20-op-45139-DAP
Prairie Island Indian Community in the State of Minnesota	Robins Kaplan LLP	1:18-op-45975-DAP
Pueblo of Pojoaque, New Mexico	Frazer PLC	1:19-op-45975-DAP
Puyallup Tribe of the Puyallup Reservation	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:19-op-45660-DAP
Pyramid Lake Paiute Tribe of the Pyramid Lake Reservation, Nevada	Frazer PLC	1:18-op-45696-DAP
Quapaw Nation	Greene Ketchum Farrell Bailey & Tweel LLP	1:19-op-45460-DAP
Quechan Tribe of the Fort Yuma Indian Reservation, California & Arizona	Skikos	1:20-op-45108DAP
Quileute Tribe of the Quileute Reservation	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:20-op-45196-DAP
Quinault Indian Nation	Robins Kaplan LLP	1:18-op-46154-DAP; 1:19-op-45948
Red Cliff Band of Lake Superior Chippewa Indians of Wisconsin	Frazer PLC	1:18-op-46116-DAP
Red Lake Band of Chippewa Indians, Minnesota	Baron & Budd	1:18-op-45959-DAP
Redwood Valley or Little River Band of Pomo Indians of the Redwood Valley Rancheria California	Ceiba Legal, LLP	1:18-op-45916-DAP
Reno-Sparks Indian Colony, Nevada	Frazer PLC	1:18-op-45699-DAP
Resighini Rancheria, California	Frazer PLC	1:19-op-45038-DAP

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Rincon Band of Luiseno Mission Indians of the Rincon Reservation, California	Robins Kaplan LLP	1:18-op-46151-DAP
Riverside San Bernardino County Indian Health Inc.	Berkey Williams; Lieff Cabraser	1:19-op-45025-DAP
Robinson Rancheria	Ceiba Legal, LLP	1:18-op-45912-DAP
Rosebud Sioux Tribe of the Rosebud Indian Reservation, South Dakota	Robins Kaplan LLP	1:18-op-45095-DAP
Round Valley Indian Tribes, Round Valley Reservation, California	Ceiba Legal, LLP	1:18-op-45915-DAP
Sac & Fox Nation of Missouri in Kansas and Nebraska	Skikos	1:20-op-45161-DAP
Sac & Fox Nation, Oklahoma	The Bruehl Law Firm, PLLC	1:19-op-46012-DAP
Saginaw Chippewa Indian Tribe of Michigan	Robins Kaplan LLP	1:19-op-45841-DAP
Saint Regis Mohawk Tribe	Keller Rohrback LLP	1:19-op-45018-DAP
San Carlos Apache Tribe of the San Carlos Reservation, Arizona	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:19-op-45366-DAP
Santa Rosa Indian Community of the Santa Rosa Rancheria, California	Skikos	1:20-op-45163-DAP
Santee Sioux Nation, Nebraska	Krupnick Campbell Malone Buser Slama Hancock, P.A.	1:18-op-45621-DAP
Sault Ste. Marie Tribe of Chippewa Indians, Michigan	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:19-op-45078-DAP
Scotts Valley Band of Pomo Indians of California	Ceiba Legal, LLP	1:18-op-45914-DAP
Seminole Tribe of Florida	The Moskowitz Law Firm	1:19-op-45912-DAP
Seneca Nation of Indians	McHugh Fuller Law Group	1:18-op-45746-DAP
Shakopee Mdewakanton Sioux Community of Minnesota	Robins Kaplan LLP	1:18-op-45977-DAP

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Shinnecock Indian Nation	Frazer PLC	1:18-op-46142-DAP
Shoshone-Bannock Tribes of the Fort Hall Reservation	Skikos	1:19-op-45373-DAP
Sisseton-Wahpeton Oyate of the Lake Traverse Reservation, South Dakota	Robins Kaplan LLP	1:18-op-45095-DAP
Sokaogon Chippewa Community, Wisconsin	Skikos	1:19-op-45410-DAP
Southcentral Foundation	Sonosky Chambers; Leiff Cabraser	1:18-op-46268-DAP
Southeast Alaska Regional Health Corporation	Hobbs Straus Dean & Walker	1:18-op-46149-DAP
Spirit Lake Tribe, North Dakota	Robins Kaplan LLP	1:18-op-45520-DAP
Squaxin Island Tribe of the Squaxin Island Reservation	Robins Kaplan LLP	1:18-op-45531-DAP
St. Croix Chippewa Indians of Wisconsin	Frazer PLC	1:18-op-45367-DAP
Standing Rock Sioux Tribe of North & South Dakota	Robins Kaplan LLP	1:18-op-45220-DAP
Stockbridge Munsee Community, Wisconsin	Skikos	1:19-op-45032-DAP
Suquamish Indian Tribe of the Port Madison Reservation	Hobbs Straus Dean & Walker	1:18-op-45271-DAP
Swinomish Indian Tribal Community	Lieff Cabraser Heimann & Bernstein	1:18-op-45892-DAP
Sycuan Band of the Kumeyaay Nation	Robins Kaplan LLP	1:19-op-45582-DAP
Tanana Chiefs Conference (including Council of Athabascan Tribal Governments)	Sonosky Chambers; Leiff Cabraser	1:18-op-46268-DAP
Te-Moak Tribe of Western Shoshone Indians of Nevada (Four constituent bands: Battle Mountain Band; Elko Band; South Fork Band and Wells Band)	Frazer PLC	1:18-op-46016-DAP; 1:18-op-46017; 1:20-op-45165
Thlopthlocco Tribal Town	The Bruehl Law Firm, PLLC	1:19-op-46021-DAP

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Three Affiliated Tribes of the Fort Berthold Reservation, North Dakota	Skikos	1:19-op-45376-DAP
Tohono O'odham Nation of Arizona	Skikos	1:19-op-45411-DAP
Tonto Apache Tribe of Arizona	Skikos	1:19-op-45398-DAP
Torres Martinez Desert Cahuilla Indians, California	Robins Kaplan LLP	1:18-op-46152-DAP
Tulalip Tribes of Washington	Keller Rohrback LLP	1:18-op-45589-DAP
Tule River Indian Tribe of the Tule River Reservation, California	Skikos	1:19-op-45579-DAP
Tunica-Biloxi Indian Tribe	Simmons Hanly Conroy	1:18-op-45996-DAP
Turtle Mountain Band of Chippewa Indians of North Dakota	Robins Kaplan LLP	1:18-op-45521-DAP
United Keetoowah Band of Cherokee Indians in Oklahoma	McHugh Fuller Law Group	1:19-op-45600-DAP
Upper Sioux Community, Minnesota	Robins Kaplan LLP	1:18-op-45974-DAP
Walker River Paiute Tribe, Nevada	Frazer PLC	1:18-op-45698-DAP
Wampanoag Tribe of Gay Head (Aquinnah)	Frazer PLC	1:19-op-45844-DAP 1:20-op-45170-DAP
White Earth Band of the Minnesota Chippewa Tribe, Minnesota	Hill Peterson Carper Bee & Deitzler	1:19-op-45357-DAP
White Mountain Apache Tribe of the Fort Apache Reservation, Arizona	Fields PLLC	1:20-op-45243-DAP
Winnebago Tribe of Nebraska	Krupnick Campbell Malone Buser Slama Hancock, P.A.	1:18-op-45621-DAP
Wyandotte Nation	Levin Papantonio	1:19-op-45601-DAP
Yerington Paiute Tribe of the Yerington Colony & Campbell Ranch, Nevada	Feazell & Tighe LLP	1:18-op-46355-DAP
Yukon Kuskokwim Health Corporation	Sonosky Chambers; Leiff Cabraser	1:18-op-46268-DAP
Yurok Tribe of the Yurok Reservation, California	Lieff Cabraser Heimann & Bernstein	1:18-op-45311-DAP

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Zuni Tribe of the Zuni Reservation, New Mexico	Sonosky, Chambers, Sachse, Endreson & Perry LLP	1:20-op-45114-DAP

EXHIBIT A-2²

Non-Litigating Tribes

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Absentee-Shawnee Tribe of Indians of Oklahoma		
<i>Agdaagux Tribe of King Cove*</i>		
Agua Caliente Band of Cahuilla Indians of the Agua Caliente Indian Reservation, California		
Ak-Chin Indian Community		
<i>Akiachak Native Community</i>		
Alabama-Coushatta Tribe of Texas		
Alabama-Quassarte Tribal Town		
<i>Alatna Village</i>		
<i>Algaaciq Native Village (St. Mary's)</i>		
<i>Allakaket Village</i>		
Alturas Indian Rancheria, California		
<i>Alutiiq Tribe of Old Harbor [previously listed as Native Village of Old Harbor and Village of Old Harbor]</i>		
<i>Angoon Community Association</i>		
<i>Anvik Village</i>		
<i>Arctic Village (See Native Village of Venetie Tribal Government)</i>		
Assiniboine and Sioux Tribes of the Fort Peck Indian Reservation, Montana		
Augustine Band of Cahuilla Indians, California		
<i>Beaver Village</i>		
Berry Creek Rancheria of Maidu Indians of California		
Big Lagoon Rancheria, California		
Big Pine Paiute Tribe of the Owens Valley		
<i>Birch Creek Tribe</i>		

² Mylan is relying on the representations of the TLC regarding the accuracy of this list. Any ambiguity or inaccuracy should be construed against the TLC.

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Bishop Paiute Tribe		
Blue Lake Rancheria, California		
Bois Forte (Nett Lake) Band of the Minnesota Chippewa Tribe, Minnesota		
Bridgeport Indian Colony		
Buena Vista Rancheria of Me-Wuk Indians of California		
Burns Paiute Tribe		
Cabazon Band of Mission Indians, California		
Cachil DeHe Band of Wintun Indians of the Colusa Indian Community of the Colusa Rancheria, California		
Caddo Nation of Oklahoma		
Cahuilla Band of Indians		
California Valley Miwok Tribe, California		
Campo Band of Diegueno Mission Indians of the Campo Indian Reservation, California		
Capitan Grande Band of Diegueno Mission Indians of California (Barona Group of Capitan Grande Band of Mission Indians of the Barona Reservation, California; Viejas (Baron Long) Group of Capitan Grande Band of Mission Indians of the Viejas Reservation, California)		
Cedarville Rancheria, California		
<i>Central Council of the Tlingit & Haida Indian Tribes</i>		
<i>Chalkyitsik Village</i>		
Cheesh-Na Tribe [previously listed as Native Village of Chistochina]		
Chemehuevi Indian Tribe of the Chemehuevi Reservation, California		
<i>Chevak Native Village</i>		
Chickahominy Indian Tribe		
Chickahominy Indian Tribe—Eastern Division		
Chickaloon Native Village		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Chicken Ranch Rancheria of Me-Wuk Indians of California	Frazer PLC	
<i>Chignik Bay Tribal Council [previously listed as Native Village of Chignik]</i>		
<i>Chignik Lake Village</i>		
<i>Chilkat Indian Village (Klukwan)</i>		
<i>Chilkoot Indian Association (Haines)</i>		
<i>Chinik Eskimo Community (Golovin)</i>		
<i>Chuloonawick Native Village</i>		
<i>Circle Native Community</i>		
Cocopah Tribe of Arizona		
Cold Springs Rancheria of Mono Indians of California		
Colorado River Indian Tribes of the Colorado River Indian Reservation, Arizona and California		
Confederated Tribes of Siletz Indians of Oregon		
Confederated Tribes of the Chehalis Reservation		
Confederated Tribes of the Coos, Lower Umpqua and Siuslaw Indians		
Cowlitz Indian Tribe		
<i>Craig Tribal Association [previously listed as Craig Community Association]</i>		
Crow Creek Sioux Tribe of the Crow Creek Reservation, South Dakota		
Crow Tribe of Montana		
<i>Curyung Tribal Council</i>		
Delaware Tribe of Indians		
<i>Douglas Indian Association</i>		
Duckwater Shoshone Tribe of the Duckwater Reservation, Nevada		
Eastern Shawnee Tribe of Oklahoma		
<i>Egegik Village</i>		
Eklutna Native Village		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Elem Indian Colony of Pomo Indians of the Sulphur Bank Rancheria, California		
Elk Valley Rancheria, California		
<i>Emmonak Village</i>		
Enterprise Rancheria of Maidu Indians of California		
<i>Evansville Village (aka Bettles Field)</i>		
Eyak Native Village		
Federated Indians of Graton Rancheria, California		
Fort Bidwell Indian Community of the Fort Bidwell Reservation of California		
Fort Independence Indian Community of Paiute Indians of the Fort Independence Reservation, California		
Fort McDermitt Paiute and Shoshone Tribes of the Fort McDermitt Indian Reservation, Nevada and Oregon		
Fort McDowell Yavapai Nation, Arizona		
Fort Mojave Indian Tribe of Arizona, California & Nevada		
Fort Sill Apache Tribe of Oklahoma		
<i>Galena Village (aka Loudon Village)</i>		
Grand Portage Band of the Minnesota Chippewa Tribe, Minnesota		
Greenville Rancheria		
Grindstone Indian Rancheria of Wintun-Wailaki Indians of California		
<i>Gulkana Village Council [previously listed as Gulkana Village]</i>		
Habematolel Pomo of Upper Lake, California		
Hannahville Indian Community, Michigan		
Havasupai Tribe of the Havasupai Reservation, Arizona		
<i>Healy Lake Village</i>		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Hoh Indian Tribe		
<i>Holy Cross Tribe [previously listed as Holy Cross Village]</i>		
<i>Hoonah Indian Association Start Printed Page 7558</i>		
<i>Hughes Village</i>		
<i>Huslia Village</i>		
<i>Hydaburg Cooperative Association</i>		
<i>Igiugig Village</i>		
Iipay Nation of Santa Ysabel, California		
Inaja Band of Diegueno Mission Indians of the Inaja and Cosmit Reservation, California		
<i>Inupiat Community of the Arctic Slope</i>		
Ione Band of Miwok Indians of California		
Iowa Tribe of Oklahoma		
<i>Iqumiut Traditional Council [previously listed as Iqurmut Traditional Council]</i>		
<i>Ivanof Bay Tribe [previously listed as Ivanoff Bay Tribe and Ivanoff Bay Village]</i>		
Jackson Band of Miwuk Indians		
Jamul Indian Village of California		
Jena Band of Choctaw Indians		
<i>Kaguyak Village</i>		
Kaibab Band of Paiute Indians of the Kaibab Indian Reservation, Arizona		
<i>Kaktovik Village (aka Barter Island)</i>		
Kalispel Indian Community of the Kalispel Reservation		
Karuk Tribe		
Kashia Band of Pomo Indians of the Stewarts Point Rancheria, California		
<i>Kasigluk Traditional Elders Council</i>		
Kaw Nation, Oklahoma		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Ketchikan Indian Community		
Kewa Pueblo, New Mexico		
Kialegee Tribal Town		
Kickapoo Tribe of Oklahoma		
<i>King Island Native Community</i>		
<i>King Salmon Tribe</i>		
Kiowa Indian Tribe of Oklahoma	The Bruehl Law Firm, PLLC	
<i>Klawock Cooperative Association</i>		
Kletsel Dehe Band of Wintun Indians		
Knik Tribe		
<i>Kokhanok Village</i>		
<i>Koyukuk Native Village</i>		
La Jolla Band of Luiseno Indians, California		
Las Vegas Tribe of Paiute Indians of the Las Vegas Indian Colony, Nevada		
<i>Levelock Village</i>		
<i>Lime Village</i>		
Little River Band of Ottawa Indians, Michigan		
Little Shell Tribe of Chippewa Indians of Montana	Robins Kaplan LLP	
Little Traverse Bay Bands of Odawa Indians, Michigan		
Lone Pine Paiute-Shoshone Tribe		
Los Coyotes Band of Cahuilla and Cupeno Indians, California		
Lovelock Paiute Tribe of the Lovelock Indian Colony, Nevada		
Lower Elwha Tribal Community		
Maniilaq Association		
<i>Manley Hot Springs Village</i>		
<i>Manokotak Village</i>		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Manzanita Band of Diegueno Mission Indians of the Manzanita Reservation, California		
Mashpee Wampanoag Tribe		
Match-e-be-nash-she-wish Band of Pottawatomí Indians of Michigan		
<i>McGrath Native Village</i>		
Mesa Grande Band of Diegueno Mission Indians of the Mesa Grande Reservation, California		
Metlakatla Indian Community		
Miami Tribe of Oklahoma		
Middletown Rancheria of Pomo Indians of California		
Monacan Indian Nation		
Mooretown Rancheria of Maidu Indians of California		
Morongó Band of Mission Indians, California		
Mt. Sanford Tribal Consortium		
<i>Naknek Native Village</i>		
Nansemond Indian Nation		
<i>Native Village of Akhiok</i>		
<i>Native Village of Akutan</i>		
<i>Native Village of Aleknagik</i>		
Native Village of Ambler		
<i>Native Village of Atka</i>		
<i>Native Village of Atkasuk [previously listed as Atkasuk Village (Atkasook)]</i>		
<i>Native Village of Barrow Inupiat Traditional Government</i>		
<i>Native Village of Belkofski</i>		
<i>Native Village of Brevig Mission</i>		
Native Village of Buckland		
<i>Native Village of Cantwell</i>		
<i>Native Village of Chenega (aka Chanega)</i>		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
<i>Native Village of Chignik Lagoon</i>		
<i>Native Village of Chitina</i>		
<i>Native Village of Chuathbaluk (Russian Mission, Kuskokwim)</i>		
<i>Native Village of Council</i>		
<i>Native Village of Deering</i>		
<i>Native Village of Diomed (aka Inalik)</i>		
<i>Native Village of Eagle</i>		
<i>Native Village of Eek</i>		
<i>Native Village of Ekuk</i>		
<i>Native Village of Ekwok [previously listed as Ekwok Village]</i>		
<i>Native Village of Elim</i>		
<i>Native Village of False Pass</i>		
<i>Native Village of Fort Yukon</i>		
<i>Native Village of Gakona</i>		
<i>Native Village of Gambell</i>		
<i>Native Village of Georgetown</i>		
<i>Native Village of Goodnews Bay</i>		
<i>Native Village of Hamilton</i>		
<i>Native Village of Hooper Bay</i>		
<i>Native Village of Kanatak</i>		
<i>Native Village of Karluk</i>		
<i>Native Village of Kiana</i>		
<i>Native Village of Kipnuk</i>		
<i>Native Village of Kivalina</i>		
<i>Native Village of Kluti Kaah (aka Copper Center)</i>		
<i>Native Village of Kobuk</i>		
<i>Native Village of Kongiganak</i>		
<i>Native Village of Kotzebue</i>		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
<i>Native Village of Koyuk</i>		
<i>Native Village of Kwigillingok</i>		
<i>Native Village of Kwinhagak (aka Quinhagak)</i>		
<i>Native Village of Larsen Bay</i>		
<i>Native Village of Marshall (aka Fortuna Ledge)</i>		
<i>Native Village of Mary's Igloo</i>		
<i>Native Village of Mekoryuk</i>		
<i>Native Village of Minto</i>		
<i>Native Village of Nanwalek (aka English Bay)</i>		
<i>Native Village of Napaimute</i>		
<i>Native Village of Napakiak</i>		
<i>Native Village of Napaskiak</i>		
<i>Native Village of Nelson Lagoon</i>		
<i>Native Village of Nightmute</i>		
<i>Native Village of Nikolski</i>		
<i>Native Village of Noatak</i>		
<i>Native Village of Nuiqsut (aka Nooiksut)</i>		
<i>Native Village of Nunam Iqua [previously listed as Native Village of Sheldon's Point]</i>		
<i>Native Village of Nunapitchuk</i>		
<i>Native Village of Ouzinkie</i>		
<i>Native Village of Paimiut</i>		
<i>Native Village of Perryville</i>		
<i>Native Village of Pilot Point</i>		
<i>Native Village of Point Hope</i>		
<i>Native Village of Point Lay</i>		
<i>Native Village of Port Graham</i>		
<i>Native Village of Port Lions</i>		
<i>Native Village of Ruby</i>		
<i>Native Village of Saint Michael</i>		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
<i>Native Village of Savoonga</i>		
<i>Native Village of Scammon Bay</i>		
<i>Native Village of Selawik</i>		
<i>Native Village of Shaktoolik</i>		
<i>Native Village of Shishmaref</i>		
<i>Native Village of Shungnak</i>		
<i>Native Village of Stevens</i>		
<i>Native Village of Tanacross</i>		
<i>Native Village of Tanana</i>		
<i>Native Village of Tatitlek</i>		
<i>Native Village of Tazlina</i>		
<i>Native Village of Teller</i>		
<i>Native Village of Tetlin</i>		
<i>Native Village of Tuntutuliak</i>		
<i>Native Village of Tununak</i>		
<i>Native Village of Tyonek</i>		
<i>Native Village of Unalakleet</i>		
<i>Native Village of Unga</i>		
<i>Native Village of Venetie Tribal Government (Arctic Village and Village of Venetie)</i>		
<i>Native Village of Wales</i>		
<i>Native Village of White Mountain</i>		
<i>Nenana Native Association</i>		
<i>New Koliganek Village Council</i>		
<i>New Stuyahok Village</i>		
<i>Newhalen Village</i>		
<i>Newtok Village</i>		
<i>Nikolai Village</i>		
<i>Ninilchik Village</i>		
<i>Nome Eskimo Community</i>		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
<i>Nondalton Village</i>		
Nooksack Indian Tribe		
Noorvik Native Community		
Northfork Rancheria of Mono Indians of California		
<i>Northway Village</i>		
Nottawaseppi Huron Band of the Potawatomi, Michigan		
<i>Nulato Village</i>		
<i>Nunakauyarmiut Tribe</i>		
Ohkay Owingeh, New Mexico		
Oneida Indian Nation		
Onondaga Nation		
<i>Organized Village of Grayling (aka Holikachuk)</i>		
<i>Organized Village of Kake</i>		
<i>Organized Village of Kasaan</i>		
<i>Organized Village of Kwethluk</i>		
<i>Organized Village of Saxman</i>		
<i>Orutsararmiut Traditional Native Council [previously listed as Orutsararmuit Native Village (aka Bethel)]</i>		
<i>Oscarville Traditional Village</i>		
Ottawa Tribe of Oklahoma		
Paiute Indian Tribe of Utah (Cedar Band of Paiutes, Kanosh Band of Paiutes, Koosharem Band of Paiutes, Indian Peaks Band of Paiutes, and Shivwits Band of Paiutes)		
Pamunkey Indian Tribe		
Paskenta Band of Nomlaki Indians of California		
<i>Pauloff Harbor Village</i>		
Pauma Band of Luiseno Mission Indians of the Pauma & Yuima Reservation, California		
Pechanga Band of Luiseno Mission Indians of the Pechanga Reservation, California		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
<i>Pedro Bay Village</i>		
Penobscot Nation		
Peoria Tribe of Indians of Oklahoma		
<i>Petersburg Indian Association</i>		
Picayune Rancheria of Chukchansi Indians of California		
<i>Pilot Station Traditional Village</i>		
Pit River Tribe, California (includes XL Ranch, Big Bend, Likely, Lookout, Montgomery Creek and Roaring Creek Rancherias)		
<i>Pitka's Point Traditional Council [previously listed as Native Village of Pitka's Point]</i>		
<i>Platinum Traditional Village</i>		
Pokagon Band of Potawatomi Indians, Michigan and Indiana		
<i>Portage Creek Village (aka Ohgsenakale)</i>		
<i>Pribilof Islands Aleut Communities of St. Paul & St. George Islands (Saint George Island and Saint Paul Island)</i>		
Pueblo of Acoma, New Mexico		
Pueblo of Cochiti, New Mexico		
Pueblo of Isleta, New Mexico		
Pueblo of Jemez, New Mexico		
Pueblo of Laguna, New Mexico		
Pueblo of Nambe, New Mexico		
Pueblo of Picuris, New Mexico		
Pueblo of San Felipe, New Mexico		
Pueblo of San Ildefonso, New Mexico		
Pueblo of Sandia, New Mexico		
Pueblo of Santa Ana, New Mexico		
Pueblo of Santa Clara, New Mexico		
Pueblo of Taos, New Mexico		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
Pueblo of Tesuque, New Mexico		
Pueblo of Zia, New Mexico		
<i>Qagan Tayagungin Tribe of Sand Point [previously listed as Qagan Tayagungin Tribe of Sand Point Village]</i>		
<i>Qawalangin Tribe of Unalaska</i>		
Quartz Valley Indian Community of the Quartz Valley Reservation of California		
Ramona Band of Cahuilla, California		
<i>Rampart Village</i>		
Rappahannock Tribe, Inc.		
Redding Rancheria, California		
Sac & Fox Tribe of the Mississippi in Iowa		
<i>Saint George Island (See Pribilof Islands Aleut Communities of St. Paul & St. George Islands)</i>		
<i>Saint Paul Island (See Pribilof Islands Aleut Communities of St. Paul & St. George Islands)</i>		
<i>Salamatof Tribe [previously listed as Village of Salamatoff]</i>		
Salt River Pima-Maricopa Indian Community of the Salt River Reservation, Arizona		
Samish Indian Nation		
San Juan Southern Paiute Tribe of Arizona		
San Manuel Band of Mission Indians, California		
San Pasqual Band of Diegueno Mission Indians of California		
Santa Rosa Band of Cahuilla Indians, California	Robins Kaplan LLP	
Santa Ynez Band of Chumash Mission Indians of the Santa Ynez Reservation, California		
Sauk-Suiattle Indian Tribe		
Seldovia Village Tribe		
Seneca-Cayuga Nation		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
<i>Shageluk Native Village</i>		
Shawnee Tribe		
Sherwood Valley Rancheria of Pomo Indians of California		
Shingle Springs Band of Miwok Indians, Shingle Springs Rancheria (Verona Tract), California		
Shoalwater Bay Indian Tribe of the Shoalwater Bay Indian Reservation		
Shoshone-Paiute Tribes of the Duck Valley Reservation, Nevada		
<i>Sitka Tribe of Alaska</i>		
<i>Skagway Village</i>		
Skokomish Indian Tribe		
Skull Valley Band of Goshute Indians of Utah		
Snoqualmie Indian Tribe		
Soboba Band of Luiseno Indians, California		
<i>South Naknek Village</i>		
Southern Ute Indian Tribe of the Southern Ute Reservation, Colorado		
Spokane Tribe of the Spokane Reservation		
<i>Stebbins Community Association</i>		
Stillaguamish Tribe of Indians of Washington		
Summit Lake Paiute Tribe of Nevada		
<i>Sun'aq Tribe of Kodiak [previously listed as Shoonaq' Tribe of Kodiak]</i>		
Susanville Indian Rancheria, California		
Table Mountain Rancheria		
<i>Takotna Village</i>		
<i>Tangirnaq Native Village [previously listed as Lesnoi Village (aka Woody Island)]</i>		
Tejon Indian Tribe		
<i>Telida Village</i>		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
The Seminole Nation of Oklahoma		
Timbisha Shoshone Tribe		
Tolowa Dee-ni' Nation		
Tonawanda Band of Seneca		
Tonkawa Tribe of Indians of Oklahoma		
<i>Traditional Village of Togiak</i>		
<i>Tuluksak Native Community</i>		
Tuolumne Band of Me-Wuk Indians of the Tuolumne Rancheria of California		
Tuscarora Nation		
Twenty-Nine Palms Band of Mission Indians of California		
<i>Twin Hills Village</i>		
<i>Ugashik Village</i>		
<i>Umkumiut Native Village [previously listed as Umkumiute Native Village]</i>		
United Auburn Indian Community of the Auburn Rancheria of California		
Upper Mattaponi Tribe		
Upper Skagit Indian Tribe		
Ute Indian Tribe of the Uintah & Ouray Reservation, Utah		
Ute Mountain Ute Tribe		
Utu Gwaitu Paiute Tribe of the Benton Paiute Reservation, California		
<i>Village of Alakanuk</i>		
<i>Village of Anaktuvuk Pass</i>		
<i>Village of Aniak</i>		
<i>Village of Atmautluak</i>		
<i>Village of Bill Moore's Slough</i>		
<i>Village of Chefornak</i>		
<i>Village of Clarks Point</i>		

Federally Recognized Tribe/Entity Name	Law Firm	Case No. (if applicable)
<i>Village of Crooked Creek</i>		
<i>Village of Dot Lake</i>		
<i>Village of Iliamna</i>		
<i>Village of Kalskag</i>		
<i>Village of Kaltag</i>		
<i>Village of Kotlik</i>		
<i>Village of Lower Kalskag</i>		
<i>Village of Ohogamiut</i>		
<i>Village of Red Devil</i>		
<i>Village of Sleetmute</i>		
<i>Village of Solomon</i>		
<i>Village of Stony River</i>		
<i>Village of Venetie (See Native Village of Venetie Tribal Government)</i>		
<i>Village of Wainwright</i>		
Washoe Tribe of Nevada & California		
Wichita and Affiliated Tribes, Oklahoma		
Wilton Rancheria, California		
Winnemucca Indian Colony of Nevada		
Wiyot Tribe, California		
<i>Wrangell Cooperative Association</i>		
Yakutat Tlingit Tribe		
Yankton Sioux Tribe of South Dakota		
Yavapai-Apache Nation of the Camp Verde Indian Reservation, Arizona		
Yavapai-Prescott Indian Tribe		
Yocha Dehe Wintun Nation, California		
Yomba Shoshone Tribe of the Yomba Reservation, Nevada		
Ysleta del Sur Pueblo		
<i>Yupiit of Andreafski</i>		

* Italics indicate tribes that are members of a litigating tribal organization or consortium, whose share will be recovered through the respective organization

EXHIBIT B

Alleged Harms

The following expert reports that were served in connection with the case captioned *In re: National Prescription Opiate Litigation*, No. 1:17-md-2804 (N.D. Ohio) provide non-exclusive examples of Alleged Harms:

1. Expert report of Professor David Cutler, dated March 25, 2019.
2. Expert report of Dr. Jeffrey B. Liebman, dated March 25, 2019.
3. Expert report of Professor Thomas McGuire regarding damages to Bellwethers, dated March 25, 2019.
4. Report of Professor Thomas McGuire regarding public nuisance, dated March 25, 2019.
5. Expert reports of G. Caleb Alexander, dated April 16, 2021.
6. Expert reports of David Cutler, dated April 16, 2019; supplemental expert report of David Cutler, dated April 21, 2021; and second supplemental expert report of David Cutler, dated May 10, 2021.
7. Expert report of David Herzberg, dated April 16, 2021.
8. Expert reports of Katherine M. Keyes, Ph.D., dated April 16, 2021; supplemental expert report of Katherine M. Keyes, Ph.D, dated June 2, 2021.
9. Expert reports of Dr. Anna Lembke, M.D., dated April 16, 2021.
10. Expert report of Harvey Rosen, dated April 16, 2021.
11. Expert report of Nancy Young, dated April 16, 2021.

EXHIBIT C

List of Tribes and Tribal Allocation Voting Percentages

RECOMMENDATION OF THE HONORABLE LAYN PHILLIPS REGARDING THE INTERTRIBAL ALLOCATION MATRIX

Native American Tribes participated in the Purdue Mediation process and reached agreement with the other non-Federal Public Claimants on value allocation for the Tribes.

Following the Mediation, the Tribal Leadership Committee ("TLC") contacted me to request an opportunity to present for approval the Intertribal Allocation Matrix. I agreed to hear the presentation and requested materials to review in advance of the presentation. In response to my request, I received the following documents:

- 1) PowerPoint summary of the intertribal allocation model
- 2) One-page summary of the model titled, "Tribal Allocation Matrix Narrative
- 3) Excel spreadsheet with the allocation to the tribes.

In addition, I sent the TLC my preliminary thoughts and inquiries regarding the Intertribal Allocation Matrix for their consideration prior to the presentation that occurred on April 2, 2021.


The TLC presented the Intertribal Allocation Matrix to attorney Clay Cogman and me on April 2, 2021. We had sufficient time to thoroughly discuss the allocation model and the TLC addressed to my satisfaction all questions and issues that were raised.

I note here for context that in a typical mediation setting, I would have had the opportunity to hear from other constituencies for the purpose of assisting me in my analysis by providing me alternative perspectives designed to test the premises and assumptions of the underlying methodology. That did not occur here, as I have only spoken to the TLC about the Matrix.

That said, based on the foregoing, I find that the Intertribal Allocation Matrix provides a satisfactorily reasonable and transparent methodology for the allocation of Purdue settlement funds among Native American Tribes.

Dated: May 11, 2011

By:



Layn R. Phillips

Schedule E
Tribal Allocation Matrix

The Tribal Nation's allocation matrix is built around six data points: MMEs (morphine milligram equivalents) imputed to each Tribe; drug and prescription opioid overdose rates imputed to each Tribe; Indian Health Service (IHS) user population for each Tribe; citizenship population for each Tribe; relative poverty rates imputed to each Tribe; and relative cost of living imputed to each Tribe. Data are "imputed" to a Tribe by estimation based on population when the data is only available on a county or statewide basis. In the case of MMEs and drug overdose rates, the imputation of the data to a tribal population is multiplied by a "disproportionate impact" adjustment reflecting the higher incidence of opioid use disorder and prescription opioid overdose deaths in tribal communities.

Two computations are undertaken for all Tribes, and then combined together. 85% of a Tribe's matrix share is calculated by considering its imputed MME rate (50%), overdose rates (40%), and poverty rate (10%) as applied to its IHS user population. 15% of a Tribe's matrix share is calculated by considering the same three elements, similarly weighted, as applied to the Tribe's citizenship data. Once these two matrix results are combined, the resulting share is further adjusted by each Tribe's relative cost of living. COLA adjustments are done on a regional basis and are weighted at 10%, resulting in modest adjustments ranging from 1.3% down to 2.4% up.

Data for Alaska Tribes was initially computed on a statewide basis, and the resulting matrix share for Alaska was then subdivided among Alaska Tribes and tribal organizations participating in the Alaska Tribal Health Compact (employing the same methodology historically used to allocate certain other tribal health care funds across Alaska tribal health care providers).

The matrix allocates individual amounts to each California Tribe, although four intertribal health care providers in California have also separately filed litigation. Each such intertribal provider will engage in discussions with its member tribes and agree on an amount that the member tribes will allocate from their funds to the intertribal provider.

Tribal citizenship data used in the matrix was subject to a tribal verification process (except for Alaska, where data was drawn from the U.S. Census). In instances where IHS user population data for multiple Tribes was not allocated by IHS to individual Tribes, user populations were prorated across the Tribes within an IHS service unit based on the Tribes' relative tribal citizenship.

**Mylan acknowledges and expressly agrees that it had no role whatsoever in the inter-tribal allocation, the inter-tribal allocation matrix, or the underlying metrics and methodology used to determine the allocation. The application of the inter-tribal allocation to this Agreement shall not constitute a position by Mylan, nor shall it restrict Mylan's ability to take positions in contexts unrelated to this Agreement.*

Allocation of Settlement Among Tribes

6/18/2021

Federally Recognized Tribe Name	Division of Funds (Allocation %)
Total	100.0000%
Absentee-Shawnee Tribe of Indians of Oklahoma	0.5575%
Agua Caliente Band of Cahuilla Indians of the Agua Caliente Indian Reservation, California	0.0406%
Ak-Chin Indian Community	0.0635%
Alabama-Coushatta Tribe of Texas	0.0293%
Alabama-Quassarte Tribal Town	0.0111%
ALL Alaskan Tribes:	9.2643%
Alaska Native Tribal Health Consortium	1.8883%
*Aleutian Pribilof Islands Association	0.0674%
*Arctic Slope Native Association	0.2825%
*Bristol Bay Area Health Corporation	0.4733%
Chickaloon Native Village	0.0105%
*Chugachmiut	0.1055%
*Copper River Native Association	0.0922%
*Eastern Aleutian Tribes	0.1017%
Eldina Native Village	0.0125%
Eyak Native Village	0.0202%
*Kodiak Area Native Association	0.1817%
*Kemsitze Indian Tribe	0.1544%
*Ketchikan Indian Community	0.1033%
Kwik Tribe	0.0118%
*Manilaq Association	0.4026%
Metlakatla Indian Community	0.0703%
*Mt. Sanford Tribal Consortium	0.0268%
*Norton Sound Health Corporation	0.5929%
*Southcentral Foundation	1.5145%
*Southeast Alaska Regional Health Corporation	0.5865%
Seldovia Village Tribe	0.0322%
*Tanana Chiefs Conference (including Council of Athabascan Tribal Governments)	0.9318%
Yakutat Tlingit Tribe	0.0290%
*Yukon Kuskokwim Health Corporation	1.4987%
Native Village of Chitina	0.0115%
Ninilchik Village	0.0289%
Native Village of Tanana	0.0190%
Native Village of Tyonek	0.0145%
Altura: Indian Rancheria, California	0.0008%
Apache Tribe of Oklahoma	0.1334%
Arapaho Tribe of the Wind River Reservation, Wyoming	0.3444%
Aroostook Band of Micmacs	0.0370%
Assiniboine and Sioux Tribes of the Fort Peck Indian Reservation, Montana	0.3789%
Augustine Band of Cahuilla Indians, California	0.0013%
Bad River Band of the Lake Superior Tribe of Chippewa Indians of the Bad River Reservation, Wisconsin	0.1533%
Bay Mills Indian Community, Michigan	0.0714%
Bear River Band of the Rohnerville Rancheria, California	0.0507%
Berry Creek Rancheria of Maidu Indians of California	0.1121%
Big Lagoon Rancheria, California	0.0027%
Big Pine Paiute Tribe of the Owens Valley	0.0320%
Big Sandy Rancheria of Western Mono Indians of California	0.0328%
Big Valley Band of Pomo Indians of the Big Valley Rancheria, California	0.1214%
Bishop Paiute Tribe	0.1041%
Blackfeet Tribe of the Blackfeet Indian Reservation of Montana	0.5378%

Federally Recognized Tribe Name	Division of Funds (Allocation %)
Blue Lake Rancheria, California	0.0038%
Bois Forte (Nett Lake) Band of the Minnesota Chippewa Tribe, Minnesota	0.0820%
Bridgeport Indian Colony	0.0026%
Buena Vista Rancheria of Me-Wuk Indians of California	0.0034%
Burns Paiute Tribe	0.0116%
Cabazon Band of Mission Indians, California	0.0017%
Cachil DeHe Band of Winnun Indians of the Colusa Indian Community of the Colusa Rancheria, California	0.0056%
Caddo Nation of Oklahoma	0.1084%
Calisto Tribe of the Laytonville Rancheria	0.0207%
Cahuilla Band of Indians	0.0368%
California Valley Miwok Tribe, California	0.0044%
Campo Band of Diegueno Mission Indians of the Campo Indian Reservation, California	0.0241%
Catawba Indian Nation	0.0743%
Cayuga Nation	0.0070%
Cedarville Rancheria, California	0.0019%
Chemehuevi Indian Tribe of the Chemehuevi Reservation, California	0.0181%
Cher-Ae Heights Indian Community of the Trinidad Rancheria, California	0.0200%
Cherokee Nation	12.1894%
Cheyenne and Arapaho Tribes, Oklahoma	0.7723%
Cheyenne River Sioux Tribe of the Cheyenne River Reservation, South Dakota	0.2906%
Chickahominy Indian Tribe	0.0315%
Chickahominy Indian Tribe—Eastern Division	0.0085%
Chickasaw Nation	2.1567%
Chicken Ranch Rancheria of Me-Wuk Indians of California	0.0026%
Chippewa Cree Indians of the Rocky Boy's Reservation, Montana	0.2330%
Chitimacha Tribe of Louisiana	0.0347%
Choctaw Nation of Oklahoma	5.4805%
Citizen Potawatomi Nation, Oklahoma	1.4669%
Cloverdale Rancheria of Pomo Indians of California	0.0518%
Cocopah Tribe of Arizona	0.0366%
Coeur D'Alene Tribe	0.2865%
Cold Springs Rancheria of Mono Indians of California	0.0108%
Colorado River Indian Tribes of the Colorado River Indian Reservation, Arizona and California	0.2784%
Comanche Nation, Oklahoma	0.6989%
Confederated Salish and Kootenai Tribes of the Flathead Reservation	0.6040%
Confederated Tribes and Bands of the Yakama Nation	0.6242%
Confederated Tribes of Siletz Indians of Oregon	0.4294%
Confederated Tribes of the Chehalis Reservation	0.0887%
Confederated Tribes of the Colville Reservation	0.4214%
Confederated Tribes of the Coos, Lower Umpqua and Siuslaw Indians	0.0541%
Confederated Tribes of the Goshute Reservation, Nevada and Utah	0.0144%
Confederated Tribes of the Grand Ronde Community of Oregon	0.2456%
Confederated Tribes of the Umatilla Indian Reservation	0.1554%
Confederated Tribes of the Warm Springs Reservation of Oregon	0.3374%
Coquille Indian Tribe	0.0926%
Coushatta Tribe of Louisiana	0.0264%
Cow Creek Band of Umpqua Tribe of Indians	0.1532%
Cowlitz Indian Tribe	0.4024%
Coyote Valley Band of Pomo Indians of California	0.0337%
Crow Creek Sioux Tribe of the Crow Creek Reservation, South Dakota	0.1504%
Crow Tribe of Montana	0.7579%
Delaware Nation, Oklahoma	0.0342%
Delaware Tribe of Indians	0.3134%

Federally Recognized Tribe Name	Division of Funds (Allocation %)
Dry Creek Rancheria Band of Pomo Indians, California	0.0709%
Duckwater Shoshone Tribe of the Duckwater Reservation, Nevada	0.0224%
Eastern Band of Cherokee Indians	0.9560%
Eastern Shawnee Tribe of Oklahoma	0.0548%
Eastern Shoshone Tribe of the Wind River Reservation, Wyoming	0.1459%
Elem Indian Colony of Pomo Indians of the Sulphur Bank Rancheria, California	0.0101%
Elk Valley Rancheria, California	0.0063%
Ely Shoshone Tribe of Nevada	0.0550%
Enterprise Rancheria of Maidu Indians of California	0.1825%
Erwiapayp Band of Kumeayay Indians, California	0.0004%
Federated Indians of Graton Rancheria, California	0.0770%
Flandreau Santee Sioux Tribe of South Dakota	0.0224%
Fond du Lac Band of the Minnesota Chippewa Tribe, Minnesota	0.3382%
Forest County Potawatomi Community, Wisconsin	0.0266%
Fort Belknap Indian Community of the Fort Belknap Reservation of Montana	0.1662%
Fort Bidwell Indian Community of the Fort Bidwell Reservation of California	0.0088%
Fort Independence Indian Community of Paiute Indians of the Fort Independence Reservation, California	0.0104%
Fort McDermitt Paiute and Shoshone Tribes of the Fort McDermitt Indian Reservation, Nevada and Oregon	0.0212%
Fort McDowell Yavapai Nation, Arizona	0.0852%
Fort Mojave Indian Tribe of Arizona, California & Nevada	0.1614%
Fort Sill Apache Tribe of Oklahoma	0.0194%
Gila River Indian Community of the Gila River Indian Reservation, Arizona	2.5642%
Grand Portage Band of the Minnesota Chippewa Tribe, Minnesota	0.0211%
Grand Traverse Band of Ottawa and Chippewa Indians, Michigan	0.1041%
Greenville Rancheria	0.0942%
Grindstone Indian Rancheria of Wintun-Wailaki Indians of California	0.0255%
Guidiville Rancheria of California	0.0137%
Habematolei Pomo of Upper Lake, California	0.0275%
Hannahville Indian Community, Michigan	0.0279%
Havasupai Tribe of the Havasupai Reservation, Arizona	0.0325%
Ho-Chunk Nation of Wisconsin	0.2791%
Hoh Indian Tribe	0.0032%
Hoop Valley Tribe, California	0.2647%
Hopi Tribe of Arizona	0.4475%
Hopland Band of Pomo Indians, California	0.0723%
Houlton Band of Maliseet Indians	0.0350%
Hualapai Indian Tribe of the Hualapai Indian Reservation, Arizona	0.2240%
Ipai Nation of Santa Ysabel, California	0.0136%
Inaja Band of Diegueno Mission Indians of the Inaja and Cosmit Reservation, California	0.0008%
Ione Band of Miwok Indians of California	0.1215%
Iowa Tribe of Kansas and Nebraska	0.0527%
Iowa Tribe of Oklahoma	0.0959%
Jackson Band of Miwok Indians	0.0054%
Jamestown S'Kallam Tribe	0.0344%
Jumil Indian Village of California	0.0082%
Jena Band of Choctaw Indians	0.0116%
Jicarilla Apache Nation, New Mexico	0.2812%
Kaibab Band of Paiute Indians of the Kaibab Indian Reservation, Arizona	0.0158%
Kalispel Indian Community of the Kalispel Reservation	0.0374%
Karuk Tribe	0.2540%
Kashia Band of Pomo Indians of the Stewart Point Rancheria, California	0.0043%
Kew Nation, Oklahoma	0.1314%
Kewa Pueblo, New Mexico	0.1155%

Federally Recognized Tribe Name	Division of Funds (Allocation %)
Keweenaw Bay Indian Community, Michigan	0.1080%
Kialagee Tribal Town	0.0174%
Kickapoo Traditional Tribe of Texas	0.0175%
Kickapoo Tribe of Indians of the Kickapoo Reservation in Kansas	0.0580%
Kickapoo Tribe of Oklahoma	0.5597%
Kiowa Indian Tribe of Oklahoma	0.4367%
Klamath Tribes	0.1776%
Kletsel Dehe Band of Wintun Indians	0.0363%
Koi Nation of Northern California	0.0140%
Kootenai Tribe of Idaho	0.0097%
La Jolla Band of Luiseno Indians, California	0.0372%
La Posta Band of Diegueno Mission Indians of the La Posta Indian Reservation, California	0.0030%
Lac Courte Oreilles Band of Lake Superior Chippewa Indians of Wisconsin	0.1611%
Lac du Flambeau Band of Lake Superior Chippewa Indians of the Lac du Flambeau Reservation of Wisconsin	0.2145%
Lac Vieux Desert Band of Lake Superior Chippewa Indians of Michigan	0.0310%
Las Vegas Tribe of Paiute Indians of the Las Vegas Indian Colony, Nevada	0.3560%
Leech Lake Band of the Minnesota Chippewa Tribe, Minnesota	0.3876%
Little River Band of Ottawa Indians, Michigan	0.0925%
Little Shell Tribe of Chippewa Indians of Montana	0.2023%
Little Traverse Bay Bands of Odawa Indians, Michigan	0.1765%
Lone Pine Paiute-Shoshone Tribe	0.0210%
Los Coyotes Band of Cahuilla and Cupeno Indians, California	0.0157%
Lovelock Paiute Tribe of the Lovelock Indian Colony, Nevada	0.0173%
Lower Brule Sioux Tribe of the Lower Brule Reservation, South Dakota	0.0499%
Lower Elwha Tribal Community	0.0686%
Lower Sioux Indian Community in the State of Minnesota	0.0236%
Lummi Tribe of the Lummi Reservation	0.2100%
Lytton Rancheria of California	0.0238%
Makah Indian Tribe of the Makah Indian Reservation	0.1833%
Manchester Band of Pomo Indians of the Manchester Rancheria, California	0.0819%
Manzanita Band of Diegueno Mission Indians of the Manzanita Reservation, California	0.0046%
Mashantucket Pequot Indian Tribe	0.0369%
Mashpee Wampanoag Tribe	0.0687%
Match-e-be-nash-she-wish Band of Pottawatomi Indians of Michigan	0.0175%
Mechoopda Indian Tribe of Chico Rancheria, California	0.1655%
Menominee Indian Tribe of Wisconsin	0.2586%
Mesa Grande Band of Diegueno Mission Indians of the Mesa Grande Reservation, California	0.0337%
Mescalero Apache Tribe of the Mescalero Reservation, New Mexico	0.2753%
Miami Tribe of Oklahoma	0.0514%
Miccosukee Tribe of Indians	0.0269%
Middletown Rancheria of Pomo Indians of California	0.0260%
Mille Lac Band of the Minnesota Chippewa Tribe, Minnesota	0.1295%
Mississippi Band of Choctaw Indians	0.4540%
Moapa Band of Paiute Indians of the Moapa River Indian Reservation, Nevada	0.0431%
Modoc Nation	0.0054%
Mohegan Tribe of Indians of Connecticut	0.0666%
Monacan Indian Nation	0.0588%
Mooretown Rancheria of Maidu Indians of California	0.1949%
Morongo Band of Mission Indians, California	0.0795%
Muckleshoot Indian Tribe	0.2826%
Muscogee (Creek) Nation	2.8659%
Nantsemond Indian Nation	0.0071%
Narragansett Indian Tribe	0.0435%

Federally Recognized Tribe Name	Division of Funds (Allocation %)
Navajo Nation, Arizona, New Mexico & Utah	15.2307%
Nez Perce Tribe	0.2349%
Nisqually Indian Tribe	0.0661%
Nockmuck Indian Tribe	0.0494%
Northern Cheyenne Tribe of the Northern Cheyenne Indian Reservation, Montana	0.2535%
Northfork Rancheria of Mono Indians of California	0.1192%
Northwestern Band of the Shoshone Nation	0.0046%
Ojibwa Band of the Potawatomi, Michigan	0.0735%
Oglala Sioux Tribe	0.9582%
Ohkay Owingeh, New Mexico	0.2226%
Omaha Tribe of Nebraska	0.1098%
Onida Indian Nation	0.0792%
Onida Nation	0.6249%
Onondaga Nation	0.0286%
Osage Nation	0.2998%
Otoe-Missouria Tribe of Indians, Oklahoma	0.1412%
Ottawa Tribe of Oklahoma	0.0294%
Paiute Indian Tribe of Utah (Cedar Band of Paiutes, Kanosh Band of Paiutes, Koosharem Band of Paiutes, Indian Peaks Band of Paiutes, and Shivwits Band of Paiutes)	0.0864%
Paiute-Shoshone Tribe of the Fallon Reservation and Colony, Nevada	0.1593%
Pala Band of Mission Indians	0.0654%
Pamunkey Indian Tribe	0.0149%
Paseo Yaqui Tribe of Arizona	0.6028%
Paskenta Band of Nontaki Indians of California	0.0061%
Pastamaquoddy Tribe Indian Township	0.0601%
Pastamaquoddy Tribe Pleasant Point	0.0758%
Pauma Band of Luiseno Mission Indians of the Pauma & Yuima Reservation, California	0.0135%
Pawnee Nation of Oklahoma	0.1674%
Pechanga Band of Luiseno Mission Indians of the Pechanga Reservation, California	0.1620%
Penobscot Nation	0.1004%
Peoria Tribe of Indians of Oklahoma	0.0425%
Picayune Rancheria of Chukchansi Indians of California	0.0820%
Pineville Pomo Nation, California	0.0269%
Pit River Tribe, California (includes XL Ranch, Big Bend, Likely, Lookout, Montgomery Creek and Roaring Creek Ranches)	0.1144%
Poarch Band of Creeks	0.1346%
Pokagon Band of Potawatomi Indians, Michigan and Indiana	0.1197%
Ponca Tribe of Indians of Oklahoma	0.2376%
Ponca Tribe of Nebraska	0.1290%
Port Gamble SKallam Tribe	0.0841%
Porter Valley Tribe, California	0.0005%
Prairie Band Potawatomi Nation	0.0680%
Prairie Island Indian Community in the State of Minnesota	0.0030%
Pueblo of Acoma, New Mexico	0.1776%
Pueblo of Cochiti, New Mexico	0.0602%
Pueblo of Inleta, New Mexico	0.9641%
Pueblo of Jemez, New Mexico	0.4715%
Pueblo of Laguna, New Mexico	0.3010%
Pueblo of Nambe, New Mexico	0.0678%
Pueblo of Picuris, New Mexico	0.0148%
Pueblo of Pojoaque, New Mexico	0.0364%
Pueblo of San Felipe, New Mexico	0.1962%
Pueblo of San Ildefonso, New Mexico	0.0515%
Pueblo of Sandia, New Mexico	0.0539%

Federally Recognized Tribe Name	Division of Funds (Allocation %)
Pueblo of Santa Ana, New Mexico	0.1216%
Pueblo of Santa Clara, New Mexico	0.0972%
Pueblo of Taos, New Mexico	0.1254%
Pueblo of Tesuque, New Mexico	0.0368%
Pueblo of Zia, New Mexico	0.1135%
Puyallup Tribe of the Puyallup Reservation	0.3461%
Pyramid Lake Paiute Tribe of the Pyramid Lake Reservation, Nevada	0.2112%
Quapaw Nation	0.0677%
Quartz Valley Indian Community of the Quartz Valley Reservation of California	0.0209%
Quechan Tribe of the Fort Yuma Indian Reservation, California & Arizona	0.2304%
Quileute Tribe of the Quileute Reservation	0.0445%
Quinault Indian Nation	0.1554%
Ramona Band of Cahuilla, California	0.0016%
Rappahannock Tribe, Inc.	0.0068%
Red Cliff Band of Lake Superior Chippewa Indians of Wisconsin	0.0680%
Red Lake Band of Chippewa Indians, Minnesota	0.3333%
Redding Rancheria, California	0.3258%
Redwood Valley or Little River Band of Pomo Indians of the Redwood Valley Rancheria California	0.0214%
Reno-Sparks Indian Colony, Nevada	0.4667%
Resighini Rancheria, California	0.0117%
Rincon Band of Luiseno Mission Indians of the Rincon Reservation, California	0.0301%
Robinson Rancheria	0.0577%
Rosebud Sioux Tribe of the Rosebud Indian Reservation, South Dakota	0.3908%
Round Valley Indian Tribes, Round Valley Reservation, California	0.1304%
Sac & Fox Nation of Missouri in Kansas and Nebraska	0.0066%
Sac & Fox Nation, Oklahoma	0.4786%
Sac & Fox Tribe of the Mississippi in Iowa	0.0652%
Saginaw Chippewa Indian Tribe of Michigan	0.1612%
Saint Regis Mohawk Tribe	0.3164%
Salt River Pima-Maricopa Indian Community of the Salt River Reservation, Arizona	0.3690%
Samish Indian Nation	0.0508%
San Carlos Apache Tribe of the San Carlos Reservation, Arizona	0.9842%
San Juan Southern Paiute Tribe of Arizona	0.0052%
San Manuel Band of Mission Indians, California	0.0212%
San Pasqual Band of Diegueno Mission Indians of California	0.0096%
Santa Rosa Band of Cahuilla Indians, California	0.0163%
Santa Rosa Indian Community of the Santa Rosa Rancheria, California	0.0567%
Santa Ynez Band of Chumash Mission Indians of the Santa Ynez Reservation, California	0.0489%
Santee Sioux Nation, Nebraska	0.0407%
Sauk-Sioux Indian Tribe	0.0041%
Sault Ste. Marie Tribe of Chippewa Indians, Michigan	0.7720%
Sooth Valley Band of Pomo Indians of California	0.0140%
The Seminole Nation of Oklahoma	0.4506%
Seminole Tribe of Florida	0.4524%
Seneca Nation of Indians	0.4387%
Seneca-Cayuga Nation	0.0727%
Shakopee Mdewakanton Sioux Community of Minnesota	0.0040%
Shawnee Tribe	0.0385%
Sherwood Valley Rancheria of Pomo Indians of California	0.0390%
Shingle Springs Band of Miwok Indians, Shingle Springs Rancheria (Verona Tract), California	0.0578%
Shinnecock Indian Nation	0.0136%
Shoalwater Bay Indian Tribe of the Shoalwater Bay Indian Reservation	0.0388%
Shoshone-Bannock Tribes of the Fort Hall Reservation	0.2571%

Federally Recognized Tribe Name	Division of Funds (Allocation %)
Shoshone-Paiute Tribes of the Duck Valley Reservation, Nevada	0.1061%
Sisseton-Wahpeton Oyate of the Lake Traverse Reservation, South Dakota	0.2461%
Skokomish Indian Tribe	0.0492%
Skull Valley Band of Goshute Indians of Utah	0.0031%
Snoqualmie Indian Tribe	0.0268%
Soboba Band of Luiseno Indians, California	0.1192%
Sokaogon Chippewa Community, Wisconsin	0.0119%
Southern Ute Indian Tribe of the Southern Ute Reservation, Colorado	0.0816%
Spirit Lake Tribe, North Dakota	0.1358%
Spokane Tribe of the Spokane Reservation	0.1194%
Squaxin Island Tribe of the Squaxin Island Reservation	0.0474%
St. Croix Chippewa Indians of Wisconsin	0.0720%
Standing Rock Sioux Tribe of North & South Dakota	0.2451%
Sellagumish Tribe of Indians of Washington	0.0069%
Stockbridge Munsee Community, Wisconsin	0.0656%
Summit Lake Paiute Tribe of Nevada	0.0045%
Suquamish Indian Tribe of the Port Madison Reservation	0.0385%
Susanville Indian Rancheria, California	0.0940%
Swinomish Indian Tribal Community	0.0685%
Sycuan Band of the Kumeyaay Nation	0.0050%
Table Mountain Rancheria	0.0008%
Tejon Indian Tribe	0.0230%
Te-Moak Tribe of Western Shoshone Indians of Nevada (Four constituent bands: Battle Mountain Band; Elko Band; South Fork Band and Wells Band)	0.1564%
Thlopthlocco Tribal Town	0.0385%
Three Affiliated Tribes of the Fort Berthold Reservation, North Dakota	0.2170%
Timbisha Shoshone Tribe	0.0061%
Tohono O'odham Nation of Arizona	1.4176%
Tolowa Dee-ni' Nation	0.1350%
Tonawanda Band of Seneca	0.0103%
Tonkawa Tribe of Indians of Oklahoma	0.0387%
Tonto Apache Tribe of Arizona	0.0187%
Torres Martinez Desert Cahuilla Indians, California	0.0498%
Tulalip Tribes of Washington	0.3139%
Tule River Indian Tribe of the Tule River Reservation, California	0.1030%
Tunica-Biloxi Indian Tribe	0.0163%
Tuolumne Band of Me-Wuk Indians of the Tuolumne Rancheria of California	0.0252%
Turtle Mountain Band of Chippewa Indians of North Dakota	0.4382%
Tuscarora Nation	0.0127%
Twenty-Nine Palms Band of Mission Indians of California	0.0023%
United Auburn Indian Community of the Auburn Rancheria of California	0.3284%
United Keetoowah Band of Cherokee Indians in Oklahoma	0.1820%
Upper Mattaponi Tribe	0.0194%
Upper Sioux Community, Minnesota	0.0055%
Upper Skagit Indian Tribe	0.0250%
Ute Indian Tribe of the Uintah & Ouray Reservation, Utah	0.3345%
Ute Mountain Ute Tribe	0.1348%
Utu-Utu Gwairu Paiute Tribe of the Benton Paiute Reservation, California	0.0030%
Capitan Grande Band of Diegueno Mission Indians of California (Barona Group of Capitan Grande Band of Mission Indians of the Barona Reservation, California; Vieja (Baron Long) Group of Capitan Grande Band of Mission Indians of the Vieja Reservation, California)	0.0639%
Walker River Paiute Tribe, Nevada	0.0922%
Wampanoag Tribe of Gay Head (Aquinnah)	0.0216%
Washoe Tribe of Nevada & California	0.2416%

FederallyRecognizedTribeName	Division of Funds (Allocation %)
White Earth Band of the Minnesota Chippewa Tribe, Minnesota	0.3129%
White Mountain Apache Tribe of the Fort Apache Reservation, Arizona	1.2832%
Wichita and Affiliated Tribes, Oklahoma	0.1054%
Wilton Rancheria, California	0.0764%
Winnebago Tribe of Nebraska	0.1438%
Winnemucca Indian Colony of Nevada	0.0121%
Wiyot Tribe, California	0.0513%
Wyandotte Nation	0.0858%
Yankton Sioux Tribe of South Dakota	0.1301%
Yavapai-Apache Nation of the Camp Verde Indian Reservation, Arizona	0.1642%
Yavapai-Prescott Indian Tribe	0.0463%
Yerington Paiute Tribe of the Yerington Colony & Campbell Ranch, Nevada	0.0546%
Yocha Debe Wintun Nation, California	0.0091%
Yomba Shoshone Tribe of the Yomba Reservation, Nevada	0.0162%
Ysleta del Sur Pueblo	0.0531%
Yurok Tribe of the Yurok Reservation, California	0.4941%
Zuni Tribe of the Zuni Reservation, New Mexico	0.4432%

* 50% of the allocation to this entity shall be made available to federally recognized tribes served by the entity.

EXHIBIT D

TAFT XV Trust Agreement

[Attached Below]

TRIBAL ABATEMENT FUND TRUST XV TRUST

TRUST AGREEMENT

DATED AS OF _____

***Pursuant to the Mylan Tribal Settlement Agreement Between
the Tribal Leadership Committee and Mylan***

Dated April 4, 2025

TRIBAL ABATEMENT FUND TRUST XV

TABLE OF CONTENTS

	<u>Page</u>
ARTICLE 1 AGREEMENT OF TRUST	2
Section 1.1 Creation and Name.	2
Section 1.2 Purposes	2
Section 1.3 Transfer of Assets.	3
Section 1.4 Acceptance of Assets.	3
Section 1.5 Tribe Beneficiaries.	3
Section 1.6 Jurisdiction.	4
ARTICLE 2 POWERS AND TRUST ADMINISTRATION	4
Section 2.1 Powers.	4
Section 2.2 General Administration.	6
Section 2.3 Accounting.	6
Section 2.4 Tribal Opioid Abatement Reporting.	7
Section 2.5 Beneficiary Reporting.	7
Section 2.6 Limitation of the Directors' Authority.	7
ARTICLE 3 ACCOUNTS, INVESTMENTS, ADMINISTRATIVE EXPENSES	7
Section 3.1 Accounts.	7
Section 3.2 Investment Guidelines	8
Section 3.3 Payment of TAFT XV Operating Expenses.	8
ARTICLE 4 ABATEMENT DISTRIBUTIONS	8
Section 4.1 Abatement Distributions	8
Section 4.2 Manner of Payment of Abatement Distributions.	8
Section 4.3 Delivery of Abatement Distributions.	9
ARTICLE 5 DIRECTORS AND DELAWARE TRUSTEE	10
Section 5.1 Number of Directors; Managing Director.	10
Section 5.2 Term of Service, Successor Directors.	10
Section 5.3 Directors' Meetings.	12
Section 5.4 Compensation and Expenses of Directors	13
Section 5.5 Directors' Independence.	13
Section 5.6 Standard of Care; Exculpation.	13
Section 5.7 Protective Provisions.	14
Section 5.8 Indemnification.	15
Section 5.9 Bond.	16
Section 5.10 Delaware Trustee.	16
Section 5.11 Meeting Minutes; Rights of Inspection.	18
Section 5.12 Trust Protector.	18
ARTICLE 6 GENERAL PROVISIONS	19
Section 6.1 Irrevocability	19

Section 6.2	Term; Termination.....	19
Section 6.3	Taxes.....	20
Section 6.4	Modification.....	21
Section 6.5	Communications	22
Section 6.6	Severability	22
Section 6.7	Notices.....	22
Section 6.8	Successors and Assigns.....	24
Section 6.9	Limitation on Transferability; Tribe Beneficiaries' Interests	24
Section 6.10	Exemption from Registration.....	24
Section 6.11	Entire Agreement; No Waiver	24
Section 6.12	Headings	24
Section 6.13	Governing Law	25
Section 6.14	Dispute Resolution.....	25
Section 6.15	Sovereign Immunity.....	25
Section 6.16	Effectiveness.....	25
Section 6.17	Counterpart Signatures.....	25

TRIBAL ABATEMENT FUND

TRUST XV AGREEMENT

This Tribal Abatement Fund Trust XV (“**TAFT XV**” or the “**Trust**”) Agreement (together with all Exhibits hereto, this “**Trust Agreement**”), dated and effective as of October 31, 2025 (the “Effective Date”), is entered into in furtherance of the administration of the Mylan Tribal Settlement Agreement between the Tribal Leadership Committee (“**TLC**”), Participating Tribes, and Viartis Inc. (“**Mylan**”) (collectively, the “**Parties**”), dated April 4, 2025 (as may be further modified, amended, or supplemented from time to time, and together with all exhibits and schedules thereto, the “**Mylan Tribal Settlement Agreement**” or “**MTSA**”),¹ in the matter of *In re National Prescription Opiate Litigation*, MDL No. 2804, Case No. 17-md-2804 in the United States District Court for the Northern District of Ohio (the “**Court**”). This Trust Agreement is entered into by the trustees of the Tribal Abatement Fund Trust XV who are further identified on the signature pages hereto (together with any successor trustee serving in such capacity, the “**Directors**”),² the Delaware Trustee (together with any successor serving in such capacity, the “**Delaware Trustee**”) and the Trust Protector, the individual who is further identified on the signature pages hereto (together with any successor serving in such capacity, the “**Trust Protector**”).

RECITALS

WHEREAS, the Mylan Settlement Trust has been established pursuant to the sealed order of the Court filed March 11, 2025 (the “**QSF Order**”), to aid in the administration of the Parties’ settlement;

WHEREAS, the Parties entered into the MTSA, dated as of April 4, 2025, subject to certain required participation acceptances by the Tribes as set forth in the MTSA;

WHEREAS, the TLC has notified Mylan that the required participation acceptances have occurred and, as a result, the “Effective Date” under the MTSA has occurred;

WHEREAS, the MTSA provides that following the Effective Date, David R. Cohen and Judge Layn Phillips (the “**Tribal Allocation Appointees**”) will determine the Final Tribal Allocation Distribution Percentages, which shall be incorporated herein as **Exhibit 1** of this Trust Agreement;

WHEREAS, pursuant to the QSF Order, David R. Cohen, Special Master to Judge Polster in MDL No. 2804 (the “**Special Master**”) was appointed as Trust Administrator of the Mylan Settlement Trust and is authorized to receive Mylan’s payments under the MTSA and to direct funds to be distributed to the Tribes, as provided in the MTSA;

WHEREAS, in accordance with the MTSA, TAFT XV has been established for the

¹ Capitalized terms used but not herein defined shall have the meaning ascribed to them in the Mylan Tribal Settlement Agreement or any Exhibits attached hereto, as applicable.

² The initial Directors shall be Kevin Washburn, Mary Smith and Kathy Hannan; the initial Trust Protector shall be Professor Stacy Leeds.

distribution to and abatement reporting by Tribe Beneficiaries, as defined in Section 1.5(a), in accordance with the terms of the MTSA and this Trust Agreement.

WHEREAS, pursuant to the MTSA, TAFT XV shall (a) receive distributions from the Mylan Settlement Trust, (b) make Abatement Distributions (as defined below) to Tribe Beneficiaries in accordance with this Trust Agreement and the TAFT XV Trust Distribution Procedures (“TDP”) attached hereto as **Exhibit 4** (the “**TAFT XV TDP**”), and (c) carry out such other matters as are set forth in the Trust Documents (as defined below).

WHEREAS, pursuant to the MTSA, the Trust shall (a) distribute Trust Assets in accordance with this Trust Agreement and the TAFT XV TDP; (b) pay TAFT XV Operating Expenses, as defined in Section 1.2(f)(ii); (c) hold and maintain the TAFT XV Operating Reserve, as defined in Section 1.2(f)(ii); and (d) hold, manage, protect and invest all Trust Assets received by the Trust for the benefit of the Tribe Beneficiaries, pending distribution to Tribe Beneficiaries, satisfaction of TAFT XV obligations, or payment of TAFT XV Operating Expenses.

WHEREAS, the Trust is intended to qualify as a “qualified settlement fund” within the meaning of Section 1.468B-1 *et seq.* of the Treasury Regulations promulgated under Section 468B of the Internal Revenue Code of 1986, as amended (the “**Code**,” and such regulations, the “**QSF Regulations**”) and corresponding or similar provisions of relevant state or local law.

NOW, THEREFORE, it is hereby agreed as follows:

ARTICLE 1

AGREEMENT OF TRUST

Section 1.1 Creation and Name. There is hereby created a trust known as the “**Tribal Abatement Fund Trust XV**” or “**TAFT XV**.” The Directors may transact the business and affairs of the Trust in the name of TAFT XV. It is the intention of the Parties hereto that the Trust constitutes a statutory trust under Chapter 38 of Title 12 of the Delaware Code, 12 Del. C. Section 3801 *et seq.* (the “**Act**”) and that this Trust Agreement together with all Exhibits hereto (collectively, the “**Trust Documents**”) constitute the governing instruments of the Trust. The Directors and the Delaware Trustee are hereby authorized and directed to execute and file a Certificate of Trust with the Delaware Secretary of State in the form attached hereto as **Exhibit 2**.

Section 1.2 Purposes. The purposes of the Trust are, among other things, to:

- (a) receive distributions from the Mylan Settlement Trust;
- (b) hold, manage, protect and invest the Trust Assets in accordance with the terms of the Trust Documents, for the benefit of the Tribe Beneficiaries;
- (c) engage in any lawful act or activity, including, without limitation, to enter into leasing, financing or other agreements with third parties, that is consistent with, necessary or incidental to the Trust Documents;
- (d) qualify at all times as a “qualified settlement fund” within the meaning of the QSF Regulations and corresponding or similar provisions of relevant state or local law;

- (e) engage in any lawful activity necessary or incidental to the foregoing; and
- (f) use the Trust Assets to:
 - (i) make Abatement Distributions (as defined below) to Tribe Beneficiaries in accordance with this Trust Agreement and the TAFT XV TDP;
 - (ii) hold and maintain reserves to pay the fees and expenses incurred with administering the Trust (including the TAFT XV TDP) and managing the Trust Assets (together, the “**TAFT XV Operating Expenses**”) of the Trust (such reserves, the “**TAFT XV Operating Reserve**”), which shall be funded with cash and cash equivalents held by the Trust in accordance with the Trust Documents;
 - (iii) pay TAFT XV obligations and the TAFT XV Operating Expenses from the TAFT XV Operating Reserve; and
 - (iv) replenish periodically, until the dissolution of the Trust, the TAFT XV Operating Reserve from cash held or received by the Trust to the extent deemed necessary by the Directors to satisfy and pay estimated future TAFT XV Operating Expenses in accordance with the Trust Documents.

Section 1.3 Transfer of Assets. Pursuant to the MTSA, the Trust shall receive distributions from the Mylan Settlement Trust (together with any income or gain earned thereon, collectively, the “**Trust Assets**”). The Trust Assets shall not be subject to attachment, disgorgement or recoupment by any person, except there shall be allowed a reversion of Trust Assets to Mylan only to the extent set forth in Section 4.2.

Section 1.4 Acceptance of Assets.

(a) In furtherance of the purposes of the Trust, the Directors, in their capacity as trustees, on behalf of the Trust, accept the transfer to the Trust of the initial TAFT XV funding from the Mylan Settlement Trust and shall accept the subsequent funding and transfers contemplated by the MTSA, subject to the terms of the Trust Documents. Except as otherwise provided in Section 4.2, Mylan will have no equitable or legal interest in, or with respect to, the Trust Assets or the Trust.

(b) Notwithstanding anything to the contrary herein, no provision in this Trust Agreement or the TAFT XV TDP shall be construed or implemented in a manner that would cause the Trust to fail to qualify as one or more “qualified settlement funds” within the meaning of the QSF Regulations or under corresponding or similar provisions of relevant state or local law.

(c) In this Trust Agreement and the TAFT XV TDP, the words “must,” “will,” and “shall” are intended to have the same mandatory force and effect, while the word “may” is intended to be permissive rather than mandatory.

Section 1.5 Tribe Beneficiaries.

- (a) The beneficial owners (within the meaning of the Act) of the Trust are the tribes or

tribal organizations identified as Participating Tribes on **Exhibit 1** hereto (together with the tribe or tribal entity organization added to such **Exhibit 1** after the Effective Date in accordance with the MTSA, each, a “**Tribe Beneficiary**” and, collectively, the “**Tribe Beneficiaries**”).

(b) The Tribe Beneficiaries shall have only such rights with respect to the Trust and its assets as are set forth in this Trust Agreement and the TAFT XV TDP and no greater or other rights, including upon dissolution, liquidation or winding up of the Trust, shall be deemed to apply to such Tribe Beneficiaries.

(c) The Tribe Beneficiaries shall be subject to the terms of this Trust Agreement, including, without limitation, Article 4 and the terms of the TAFT XV TDP.

Section 1.6 Jurisdiction. The Court shall have continuing jurisdiction over the Trust, provided, however, the courts of the State of Delaware, including any federal court located therein, shall also have jurisdiction over the Trust.

ARTICLE 2

POWERS AND TRUST ADMINISTRATION

Section 2.1 Powers.

(a) The Directors in their capacity as trustees are and shall act as fiduciaries to the Trust in accordance with the provisions of this Trust Agreement. The Directors shall, at all times, administer the Trust in accordance with the purposes set forth in Section 1.2 above. Subject to the limitations set forth in the Trust Documents, the Directors shall have the power to take any and all actions that in the judgment of the Directors are necessary or proper to fulfill the purposes of the Trust, including, without limitation, each power expressly granted in this Section 2.1, any power reasonably incidental thereto and any trust power now or hereafter permitted under the laws of the State of Delaware. In the event of any ambiguity or conflict between the terms of this Trust Agreement and the TAFT XV TDP, the TAFT XV TDP shall control.

(b) Except as required by applicable law or the Trust Documents, the Directors need not obtain the order or approval of any court for the exercise of any power or discretion conferred hereunder.

(c) Without limiting the generality of Section 2.1(a) above, and except as limited in the Trust Documents and by applicable law, the Directors shall have the power to:

- (i) receive and hold the Trust Assets and exercise all rights with respect thereto;
- (ii) invest the monies and other Trust Assets held from time to time by the Trust, subject to the limitations set forth in Section 3.2 below;
- (iii) enter into leasing, financing or other agreements with third parties as deemed by the Directors in their discretion to be useful in carrying out the purposes of the Trust;
- (iv) determine and pay obligations and liabilities of the Trust and the TAFT XV Operating Expenses;

- (v) establish accounts and reasonable reserves within the Trust, as deemed by the Directors in their discretion to be necessary, prudent or useful in administering the Trust;
- (vi) bring any action in any court of competent jurisdiction, including the Court;
- (vii) initiate, prosecute, defend and resolve all legal actions and other proceedings related to any Trust Asset, liability or responsibility of the Trust;
- (viii) supervise and administer the Trust in accordance with the Trust Documents, including, without limitation, to monitor the Abatement Distribution (as defined below) recipients' compliance with the TAFT XV TDP requirements for Approved Tribal Opioid Abatement Uses and Approved Administrative Expenses (as defined in the TAFT XV TDP);
- (ix) appoint such officers and retain such employees, consultants, advisors, attorneys, independent contractors, experts and agents and engage in such legal, financial, administrative, accounting, investment, auditing and alternative dispute resolution services and activities as the Trust requires, and delegate to such persons such powers and authorities as the fiduciary duties of the Directors permit and as the Directors, in their discretion, deem advisable or necessary in order to carry out the terms of this Trust Agreement;
- (x) pay reasonable compensation and expenses to any of the Trust's employees, consultants, advisors, independent contractors, experts and agents for legal, financial, administrative, accounting, investment, auditing and alternative dispute resolution services and activities as the Trust requires;
- (xi) compensate the Directors, Delaware Trustee, the Trust Protector, and their employees, consultants, advisors, independent contractors, experts and agents, and reimburse the Directors, the Delaware Trustee and the Trust Protector for all reasonable out-of-pocket costs and expenses incurred by such persons in connection with the performance of their duties hereunder;
- (xii) execute and deliver such instruments as the Directors consider necessary or desirable in administering the Trust;
- (xiii) enter into such other arrangements with third parties as are deemed by the Directors to be advisable or necessary in carrying out the purposes of the Trust; provided that such arrangements do not conflict with any other provision of this Trust Agreement;
- (xiv) in accordance with Section 5.8 below, defend, indemnify and hold harmless (and purchase insurance indemnifying) the Trust Indemnified Parties (as defined in Section 5.6(a) below) to the maximum extent permitted by law;

- (xv) delegate any or all of the authority herein conferred with respect to the investment of all or any portion of the Trust Assets to any one or more reputable institutional investment advisors or investment managers without liability for any action taken or omission made because of any such delegation, except as provided in Section 5.6 below; provided that such investment advisors and investment managers shall be in compliance with the Investment Guidelines (as defined in Section 3.2) at all times;
- (xvi) make, join, pursue (by litigation or otherwise), abandon, collect, compromise or settle, or otherwise resolve, in the name of the Trust any claim, right, action or cause of action of the Trust, before any court of competent jurisdiction and without approval of the Court;
- (xvii) contract for the establishment and continuing maintenance of (a) a secure method of internet-based communications for the Trust and the Tribe Beneficiaries as described in Section 6.5 herein (the “**Tribal Opioid Settlement Portal**”) and (b) a public-facing website to publish all information required to be published under the Trust Documents (the “**Tribal Opioid Settlement Website**”); and
- (xviii) exercise any and all rights of the Directors, and take any and all actions as are permitted, in accordance with and subject to the terms of this Trust Agreement.

(d) The Directors shall not have the power to cause the Trust to guarantee any debt of other persons.

(e) Except as otherwise set forth in the Trust Documents and MTSA, but without prior or further authorization, the Directors may control and exercise authority over the Trust Assets and over the protection, conservation and disposition thereof. No person dealing with the Trust shall be obligated to inquire into the authority of the Directors in connection with the protection, conservation or disposition of the Trust Assets.

Section 2.2 General Administration. The Directors shall act in accordance with the Trust Documents. The mailing address of the Trust is Tribal Abatement Fund Trust XV, P.O. Box 65097, Washington, DC 20035. The Directors may change the location of the principal office and may establish other offices at other locations. The Directors shall provide notice to the Tribe Beneficiaries upon establishment of any office by posting such information in the Tribal Opioid Settlement Portal (or by other means approved by the Directors).

Section 2.3 Accounting. The fiscal year of the Trust shall begin on January 1 and shall end on December 31 of each calendar year. The Directors shall maintain the books and records relating to the Trust Assets and income and the payment of expenses of and liabilities against the Trust. The detail of these books and records and the duration of time during which the Directors shall keep such books and records shall be such as to allow the Directors to make a full and accurate accounting of all Trust Assets, as well as to comply with applicable provisions of law and standard accounting practices necessary or appropriate to produce an annual report containing special-purpose financial statements of the Trust, including, without limitation, the assets and liabilities of

the Trust as of the end of such fiscal year and the additions, deductions and cash flows for such fiscal year (the “**Annual Report**”); provided, however, that the Directors shall maintain such books and records until the wind-up of the Trust’s affairs and satisfaction of all of the Trust’s liabilities.

Section 2.4 Tribal Opioid Abatement Reporting.

(a) Within one hundred and twenty (120) days following the end of each calendar year, the Directors shall (i) cause to be prepared and delivered to the Mylan Settlement Trust and to Mylan an annual report on the Approved Tribal Opioid Abatement Uses with respect to such period, together with such additional information as the Directors determine necessary or appropriate in their discretion (each, a “**Tribal Opioid Abatement Report**”), and (ii) post a copy of the Tribal Opioid Abatement Report on the Tribal Opioid Settlement Website.

(b) For the avoidance of doubt, the Directors shall not be required to include in any TAFT XV Tribal Opioid Abatement Report any abatement matters except those that pertain to TAFT XV exclusively.

Section 2.5 Beneficiary Reporting.

(a) Reporting of Approved Tribal Opioid Abatement Uses by the Tribe Beneficiaries shall be required to the extent set forth in the TAFT XV TDP. The Directors shall establish the form, content, and due dates of periodic reports with respect to Approved Tribal Opioid Abatement Uses to be submitted by the Tribe Beneficiaries (each, a “**Beneficiary Abatement Use Report**”) to the Directors through the Tribal Opioid Settlement Portal (or delivered by other means approved by the Directors). The Directors may prescribe a modified reporting regime for certain Tribe Beneficiaries based upon appropriate standards to be developed by the Directors, provided such modified reporting regime is not inconsistent with the Trust’s reporting obligations, as determined by the Directors in their discretion. The Directors shall endeavor to implement appropriate mechanisms, in their discretion consistent with the Trust Documents, to obtain efficiency in reporting by Tribe Beneficiaries with respect to TAFT XV and other comparable opioid abatement trusts benefitting the Tribe Beneficiaries. Each Beneficiary Abatement Use Report shall contain the information necessary to:

- (i) enable the Trust to satisfy the Tribal Opioid Abatement Report requirements described in Section 2.5(a) above.

Section 2.6 Limitation of the Directors’ Authority. The Directors are not authorized to engage in any trade or business with respect to the Trust Assets or proceeds therefrom. The foregoing limitation shall not prevent the Directors from managing the investment of the Trust Assets.

ARTICLE 3

ACCOUNTS, INVESTMENTS, ADMINISTRATIVE EXPENSES

Section 3.1 Accounts.

(a) The Directors shall maintain one or more accounts (“**Trust Accounts**”) on behalf

of the Trust with one or more financial depository institutions (each, a “**Financial Institution**”). Candidates for the positions of Financial Institution shall fully disclose to the Directors any interest in or relationship with Mylan or a named defendant in MDL No. 2804, their affiliated persons, or any Released Entities. Any such interest or relationship shall not be an automatic disqualification for the position, but the Directors shall take any such interest or relationship into account in selecting a Financial Institution.

(b) The Directors may, from time to time, create such accounts and reasonable reserves within the Trust Accounts as authorized in this Section 3.1 and as they may deem necessary, prudent or useful in order to provide for Abatement Distributions (as defined herein) to the Tribe Beneficiaries and the payment of TAFT XV Operating Expenses and may, with respect to any such account or reserve, restrict the use of money therein for a specified purpose (the “**Trust Subaccounts**”). Any such Trust Subaccounts established by the Directors shall be held as Trust Assets and are not intended to be subject to separate entity tax treatment as a “disputed claims reserve” within the meaning of the Code or the Treasury Regulations, or a “disputed ownership fund” within the meaning of the Treasury Regulations, or otherwise.

(c) The Directors may replace any retained Financial Institution with a successor Financial Institution at any time and such successor shall be subject to the considerations set forth in Section 3.1(a).

Section 3.2 Investment Guidelines. The Directors may invest the Trust Assets in accordance with the Investment Guidelines, attached hereto as **Exhibit 3** (the “**Investment Guidelines**”). Notwithstanding any contrary provision of the Trust Documents, this Section 3.2 and the Investment Guidelines cannot be modified or amended.

Section 3.3 Payment of TAFT XV Operating Expenses. All TAFT XV Operating Expenses shall be payable out of the TAFT XV Operating Reserve. None of the Directors, the Delaware Trustee, the Trust Protector, the Tribe Beneficiaries, Mylan, nor any of their employees, officers, consultants, advisors, independent contractors, experts or agents shall be personally liable for the payment of any TAFT XV Operating Expense or any other liability of the Trust. In their discretion, the Directors may incur and pay TAFT XV Operating Expenses after making appropriate allocations of common charges that are incurred for the benefit of TAFT XV and other tribal opioid abatement entities created prior to or after the Effective Date (for example, the Tribal Opioid Settlement Website).

ARTICLE 4

ABATEMENT DISTRIBUTIONS

Section 4.1 Abatement Distributions. The Directors shall make Abatement Distributions only as and to the extent set forth in this Article 4 and the TAFT XV TDP (the “**Abatement Distributions**”). Abatement Distributions shall be used by the Tribe Beneficiaries as described in Section 3 of the TAFT XV TDP.

Section 4.2 Manner of Payment of Abatement Distributions.

(a) The Directors shall endeavor to provide ten (10) days’ notice to the Tribe Beneficiaries of any upcoming Abatement Distribution through the Tribal Opioid Settlement

Portal (or by other means approved by the Directors); provided, however, that the Directors may shorten such notice period in their discretion.

(b) Abatement Distributions shall be made to Participating Tribes in accordance with the Final Tribal Allocation Distribution Percentages to be set forth on **Exhibit 1** hereto. Abatement Distributions shall be made to Tribes that become Participating Tribes after the Effective Date in accordance with Section IV.E of the MTSA.

(c) Abatement Distributions may be made by the Directors or by a disbursement agent retained by the Trust to make Abatement Distributions on its behalf (the “**Disbursement Agent**”). Abatement Distributions shall be made in accordance with the TAFT XV TDP on the dates approved for distribution by the Directors.

(d) The Directors may cause Abatement Distributions to be withheld with respect to any Tribe Beneficiary that has failed to deliver timely a completed Beneficiary Abatement Use Report by the applicable due date. The Directors shall allow for a reasonable period of time to cure any delinquent Beneficiary Abatement Use Report and may continue to withhold distributions to a Tribe Beneficiary until all such delinquent Beneficiary Abatement Use Reports of such Tribe Beneficiary have been cured.

(e) If the Directors determine, in their discretion, that making the final Abatement Distribution immediately prior to the termination and dissolution of the Trust is not cost-effective with respect to the final amounts to be distributed to the Tribe Beneficiaries, the Directors shall have the authority to direct such final Abatement Distribution, in full, to a tax-exempt organization that has opioid abatement as part of its mission, such as the National Indian Health Board, as selected by the Directors in their discretion. The Directors shall instruct the tax-exempt organization to use the Abatement Distribution solely for opioid abatement purposes.

(f) Notwithstanding the foregoing, the Directors shall cause Trust Assets to revert to Mylan only to the extent required by Section IV.E of the MTSA.

(g) Prior to disbursing funds to any Participating Tribe, the Directors shall obtain from each Participating Tribe any required payment documentation (including, as needed, wire instructions and W-9 forms).

Section 4.3 Delivery of Abatement Distributions.

(a) All Abatement Distributions under this Trust Agreement shall be made (i) in accordance with the electronic transfer information or (ii) by check at the address provided by the Tribe Beneficiaries in accordance with the TAFT XV TDP. Changes to such electronic transfer information or address, as applicable, must be provided to the Trust or the Disbursement Agent in writing at least five (5) business days prior to any upcoming Abatement Distribution date; provided, however, that the Directors and Disbursement Agent shall have the authority, in their discretion, to seek further direction from the Tribe Beneficiaries regarding the transfer information of Abatement Distributions under this Trust Agreement.

(b) In the event that any Abatement Distribution is undeliverable, no further Abatement Distribution shall be made unless and until the Directors have been notified of the then current

wire instructions or address, as applicable, as directed by such Tribe Beneficiary, at which time such distribution shall be made without interest. The Directors shall take reasonable efforts to obtain a current address or wire instructions, as applicable, for any Tribe Beneficiary with respect to which any distribution is undeliverable, but shall have no obligation to make further inquiry with respect to designated recipients of such Tribe Beneficiaries.

(c) No Trust Asset or any unclaimed property shall escheat to any federal, state or local government or any other entity.

ARTICLE 5

DIRECTORS AND DELAWARE TRUSTEE

Section 5.1 Number of Directors; Managing Director.

(a) **Number.** In addition to the Delaware Trustee appointed pursuant to Section 5.10, there shall be three (3) Directors. The initial Directors shall be those persons named on the signature page hereof.

(b) **Managing Director.** At their first meeting, the initial Directors shall designate one of their number to serve as the Managing Director of the Trust, with such administrative duties as the Directors may determine (the “**Managing Director**”). The Directors may change the designation of the individual to serve as Managing Director from time to time as circumstances warrant. The Managing Director or, in the Managing Director’s absence, another Director selected by the Directors shall preside at meetings of the Directors. The Managing Director, or the Director presiding over such meeting, shall be responsible for taking meeting minutes at each meeting of the Directors and for performing such other administrative duties and services as shall be assigned to or required of the Managing Director by the Directors. The Managing Director shall maintain a list of current Directors, including their addresses and contact information.

Section 5.2 Term of Service, Successor Directors.

(a) **Term.** Each Director shall serve until the earlier of (i) his or her death, (ii) his or her resignation or removal pursuant to Section 5.2(c) below, or (IV) the termination of the Trust pursuant to the terms of this Trust Agreement. The term of a newly appointed Director shall commence upon his or her acceptance as such.

(b) **Appointment of Successor Directors.**

- (i) In the event of a vacancy in the position of one (1) Director for any reason, the vacancy shall be filled by the unanimous vote of the remaining Directors. In the event that the remaining Directors cannot agree on a successor Director within thirty (30) days, each of the remaining Directors shall propose a Director candidate and the Trust Protector (as defined in Section 5.12(a) below) shall select one such candidate as the Successor Director.
- (ii) In the event of a vacancy in the position of two (2) Directors for any reason, the remaining Director and the Trust Protector shall, after consultation,

jointly appoint two (2) successor Directors, both of whom shall each be acceptable to both of the remaining Director and the Trust Protector. In the event the remaining Director and the Trust Protector cannot agree on two (2) successor Directors, the selection of two (2) successor Directors shall be resolved in accordance with the dispute resolution provisions of Section 6.14.

- (iii) In the event of a vacancy in the position of three (3) Directors for any reason, the Trust Protector shall recommend three (3) successor Directors for the Delaware Court of Chancery to appoint and any costs relating thereto shall be borne by the Trust.
- (iv) Notice of the appointment of any successor Director(s) shall be filed with the Court and shall be published on the Tribal Opioid Settlement Website when it is filed with the Court.
- (v) In filling any vacancy in the position of one or more Directors, the remaining Director(s) and/or the Trust Protector shall apply the following standard to any successor Director: the successor Director shall be a disinterested, independent individual with experience in one or more of the following areas: public policy/public health, tribal health or welfare, tribal self-determination, administration or self-governance, other tribal affairs, ethics and compliance, finance, general business and/or corporate governance.
- (vi) Immediately upon the appointment of any successor Director(s), all rights, titles, duties, powers and authority of the predecessor Director(s) hereunder shall be vested in, and undertaken by, the successor Director (s) without any further act. No successor Director(s) shall be liable personally for any act or omission of his or her predecessor Director. No successor Director shall have any duty to investigate the acts or omissions of his or her predecessor Director.

(c) **Resignation or Removal.** A Director may resign by giving written notice to either of the other Directors. Such notice shall specify a date when such resignation shall take effect, which, except in the case of incapacity or disability, shall not be less than ninety (90) days after the date such notice is given, where practicable. A Director may be removed by unanimous vote of the remaining Directors in the event that he or she becomes unable to discharge his or her duties hereunder due to accident, physical deterioration, mental incompetence or for other good cause, provided such Director has received reasonable notice and an opportunity to be heard by the remaining Directors. Other good cause shall mean fraud, self-dealing, intentional misrepresentation, willful misconduct, indictment for or conviction of a felony in each case whether or not connected to the Trust, any substantial failure to comply with the administration of the Trust or a consistent pattern of neglect and failure to perform or participate in performing the duties of a Director hereunder. For the avoidance of doubt, any removal of a Director pursuant to this Section 5.2(c) shall require the approval of the Court and shall take effect at such time as the Court shall determine.

Section 5.3 Directors' Meetings.

(a) **Regular Meetings.** The Directors shall hold regular meetings not less than quarterly, which may be held without notice at such times and at such places as may be determined from time to time by the Directors. For the avoidance of doubt, the Delaware Trustee shall not be required or permitted to attend any meetings of the Directors contemplated by this Section 5.3.

(b) **Special Meetings.** Special meetings of the Directors may be called by any Director by giving written notice to each other Director not less than one (1) business day prior to the date of the meeting. Any such notice shall include the time, place and purpose of the meeting, given to each Director by overnight courier, personal delivery, facsimile, electronic mail or other similar means of communication. Notice shall be addressed or delivered to each Director at the Director's address as shown upon the records of the Trust or as may have been given to Directors by the Director for purposes of notice. If a Director's address is not shown on such records or is not readily ascertainable, notice to the Director may be given care of the principal office of the Trust. Notice by overnight courier shall be deemed to have been given one (1) business day after the time that written notice is provided to such overnight courier. Any other written notice shall be deemed to have been given at the time it is personally delivered to the recipient or actually transmitted by the person giving the notice by electronic means to the recipient.

(c) **Action and Quorum.** In all matters pertaining to the affairs of the Trust, the Directors shall act by a vote of a majority of the number of Directors then in office, which such majority shall constitute a quorum of the Directors for the transaction of business, except to adjourn as provided in Section 5.3(f).

(d) **Participation in Meetings by Telephone Conference.** Directors may participate in a meeting of the Directors by conference telephone or similar communications equipment (which shall include virtual meetings via video conferencing software), as long as all Directors participating in such meeting can hear one another. Participation by a Director in a meeting pursuant to this Section 5.3(d) shall constitute presence in person at such meeting.

(e) **Waiver of Notice.** Notice of a meeting need not be given to any Director who signs a waiver of notice, whether before or after the meeting. All such waivers shall be filed with the Trust records or made a part of the minutes of the meeting. Attendance at a meeting by a Director shall constitute a waiver of notice of such meeting except when the Director attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business on the ground that the meeting was not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any Director meeting need be specified in any waiver of notice.

(f) **Adjournment.** A majority of the Directors present, whether or not a quorum exists, may adjourn any Directors meeting to another time and place.

(g) **Action by Unanimous Written Consent.** Any action required or permitted to be taken at any meeting of the Directors may be taken without a meeting, if all of the Directors then in office consent thereto in writing or by Electronic Transmission, which writing may be executed in one or more counterparts, and the writing or Electronic Transmission are filed with the meeting minutes of the Directors. As used herein, "**Electronic Transmission**" means any form of communication not directly involving the physical transmission of paper that creates a record that

may be retained, retrieved and reviewed by a recipient thereof and that may be directly reproduced in paper form by such a recipient through an automated process.

Section 5.4 Compensation and Expenses of Directors. The Directors shall receive compensation from the Trust for their services as Directors. The Trust shall also, upon receipt of appropriate documentation, reimburse all reasonable out-of-pocket costs and expenses incurred by each Director in the course of carrying out their duties as Directors in accordance with reasonable policies and procedures as may be adopted from time to time, including in connection with attending meetings of the Directors. The amounts paid to the Directors for compensation and expenses shall be disclosed in the Annual Report.

Section 5.5 Directors' Independence.

(a) The Directors shall not, during their service, hold a financial interest in, act as attorney or agent for, or serve as any other professional for Mylan or a defendant in MDL No. 2804, their affiliated persons, or any Released Entities. No Director shall act as an attorney for any Tribe in a matter that (i) directly or indirectly relates to claims arising from the use of opioids by any person, or (ii) is directly adverse to the claims of another Tribe. For the avoidance of doubt, this provision shall not apply to the Delaware Trustee.

(b) The Directors, and the Delaware Trustee, shall be indemnified by the Trust in acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order or other paper or document believed by them to be genuine and to have been signed or presented by the proper party or parties.

(c) Persons dealing with the Trust, the Directors, and the Delaware Trustee with respect to the affairs of the Trust, shall have recourse only to the Trust Assets to satisfy any liability incurred by the Trust, the Directors, or the Delaware Trustee to such person in carrying out the terms of this Trust Agreement, and neither the Directors, the Delaware Trustee, the Tribe Beneficiaries, nor any of their professionals, advisors, officers, agents, consultants or lawyers shall have any personal obligation to satisfy any such liability.

Section 5.6 Standard of Care; Exculpation.

(a) As used herein, the term “**Trust Indemnified Party**” shall mean each Director, the Delaware Trustee, the Trust Protector, the Special Master, the Tribal Allocation Appointees, and each of their respective members, officers, employees, agents, consultants, lawyers, advisors or professionals (collectively, the “**Trust Indemnified Parties**”).

(b) To the maximum extent permitted by applicable law, the Trust Indemnified Parties shall not have or incur any liability for actions taken or omitted in their capacities as Trust Indemnified Parties, or on behalf of the Trust, except those acts found by a final, non-appealable order by a court of competent jurisdiction (a “**Final Order**”) to be arising out of their willful misconduct, bad faith, gross negligence or fraud, and shall be entitled to indemnification and reimbursement for reasonable fees and expenses in defending any and all of their actions or inactions in their capacity as Trust Indemnified Parties, or on behalf of the Trust, and for any other liabilities, losses, damages, claims, costs and expenses arising out of or due to the implementation or administration of the MTSA or the Trust Agreement (other than taxes in the nature of income

taxes imposed on compensation paid to such persons), in each case, except for any actions or inactions found by a Final Order to be arising out of their willful misconduct, bad faith, gross negligence or fraud. Any valid indemnification claim of any of the Trust Indemnified Parties shall be satisfied from the Trust.

(c) To the extent that, at law or in equity, the Trust Indemnified Parties have duties (including fiduciary duties) or liability related thereto, to the Trust or the Tribe Beneficiaries, it is hereby understood and agreed by the Parties hereto and the Tribe Beneficiaries that such duties and liabilities are eliminated to the fullest extent permitted by applicable law, and replaced by the duties and liabilities expressly set forth in this Trust Agreement with respect to the Trust Indemnified Parties; provided, however, that, with respect to the Trust Indemnified Parties other than the Delaware Trustee, the duties of care and loyalty are not eliminated but are limited and subject to the terms of this Trust Agreement, including but not limited to this Section 5.6 and its subparts.

(d) The Trust will maintain appropriate insurance coverage for the protection of the Trust Indemnified Parties as determined by the Directors in their discretion.

Section 5.7 Protective Provisions.

(a) Every provision of this Trust Agreement relating to the conduct or affecting the liability of or affording protection to Trust Indemnified Parties shall be subject to the provisions of this Section 5.7.

(b) In the event the Directors retain counsel (including at the expense of TAFT XV), the Directors shall be afforded the benefit of the attorney-client privilege with respect to all communications with such counsel, and in no event shall the Directors be deemed to have waived any right or privilege, including, without limitation, the attorney-client privilege even if the communications with counsel had the effect of guiding the Directors in the performance of duties hereunder. A successor to any of the Directors shall succeed to and hold the same respective rights and benefits of the predecessor for purposes of privilege, including the attorney-client privilege. No Tribe Beneficiary or other party may raise any exception to the attorney-client privilege discussed herein as any such exceptions are hereby waived by all Parties.

(c) To the extent that, at law or in equity, the Directors have duties (including fiduciary duties) and liabilities relating hereto, to the Trust or to the Tribe Beneficiaries, it is hereby understood and agreed by the Parties and the Tribe Beneficiaries that such duties and liabilities are eliminated to the fullest extent permitted by applicable law, including Section 3806 of the Act, and replaced by the duties and liabilities expressly set forth in this Trust Agreement with respect to the Directors; provided, however, that the duties of care and loyalty are not eliminated but are limited and subject to the terms of this Trust Agreement, including but not limited to Section 5.6 herein.

(d) No Trust Indemnified Party shall be personally liable under any circumstances, except for their own willful misconduct, bad faith, gross negligence or fraud as determined by a Final Order.

(e) No provision of this Trust Agreement shall require the Trust Indemnified Parties to expend or risk their own personal funds or otherwise incur financial liability in the performance

of their rights, duties and powers hereunder.

(f) In the exercise or administration of the Trust hereunder, the Trust Indemnified Parties (i) may act directly or through their respective agents or attorneys pursuant to agreements entered into with any of them, and the Trust Indemnified Parties shall not be liable for the default or misconduct of such agents or attorneys if such agents or attorneys have been selected by the Trust Indemnified Parties in good faith and with due care, and (ii) may consult with counsel, accountants and other professionals to be selected by them in good faith and with due care and employed by them, and shall not be liable for anything done, suffered or omitted in good faith by them in accordance with the advice or opinion of any such counsel, accountants or other professionals.

Section 5.8 Indemnification.

(a) To the maximum extent permitted by applicable law, the Trust Indemnified Parties shall be entitled to indemnification and reimbursement for reasonable fees and expenses (including attorneys' fees and costs but excluding taxes in the nature of income taxes imposed on compensation paid to the Trust Indemnified Parties) in defending any and all of their actions or inactions in their capacity as Trust Indemnified Parties, or on behalf of the Trust, and for any other liabilities, losses, damages, claims, costs and expenses arising out of or due to the implementation or administration of the MTSA or the Trust Agreement (other than taxes in the nature of income taxes imposed on compensation paid to such persons), in each case, except for any actions or inactions found by a Final Order to be arising out of their willful misconduct, bad faith, gross negligence or fraud. Any valid indemnification claim of any of the Trust Indemnified Parties shall be satisfied from the Trust.

(b) Reasonable expenses, costs and fees (including attorneys' fees and costs) incurred by or on behalf of the Trust Indemnified Parties in connection with any action, suit or proceeding, whether civil, administrative or arbitral, from which they are indemnified by the Trust shall be paid by the Trust in advance of the final disposition thereof upon receipt of an undertaking, by or on behalf of the Trust Indemnified Parties, to repay such amount in the event that it shall be determined ultimately by a Final Order of the Court that the Trust Indemnified Parties or any other potential indemnitee are not entitled to be indemnified by the Trust.

(c) The Directors shall purchase and maintain appropriate amounts and types of insurance on behalf of the Trust Indemnified Parties, as determined by the Directors, which may include liability asserted against or incurred by such individual in that capacity or arising from his or her status as a Trust Indemnified Party, and/or as an employee, agent, lawyer, advisor or consultant of any such person.

(d) The indemnification provisions of this Trust Agreement with respect to any Trust Indemnified Party shall survive the termination of such Trust Indemnified Party from the capacity for which such Trust Indemnified Party is indemnified. Termination or modification of this Trust Agreement shall not affect any indemnification rights or obligations in existence at such time. In making a determination with respect to entitlement to indemnification of any Trust Indemnified Party hereunder, the person, persons or entity making such determination shall presume that such Trust Indemnified Party is entitled to indemnification under this Trust Agreement, and any person seeking to overcome such presumption shall have the burden of proof to overcome the

presumption.

(e) The rights to indemnification hereunder are not exclusive of other rights which any Trust Indemnified Party may otherwise have at law or in equity, including common law rights to indemnification or contribution.

Section 5.9 Bond. The Directors and the Delaware Trustee shall not be required to post any bond or other form of surety or security unless otherwise ordered by the Court.

Section 5.10 Delaware Trustee.

(a) There shall at all times be a Delaware Trustee. The Delaware Trustee shall either be (i) a natural person who is at least twenty-one (21) years of age and a resident of the State of Delaware or (ii) a legal entity that has its principal place of business in the State of Delaware, otherwise meets the requirements of applicable Delaware law to be eligible to serve as the Delaware Trustee, and shall act through one or more persons authorized to bind such entity. The initial Delaware Trustee shall be Wilmington Trust, National Association. If at any time the Delaware Trustee shall cease to be eligible in accordance with the provisions of this Section 5.10, it shall resign immediately in the manner and with the effect hereinafter specified in Section 5.10(c) below. For the avoidance of doubt, the Delaware Trustee will only have such rights, duties and obligations as expressly provided by reference to the Delaware Trustee hereunder. The Directors shall have no liability for the acts or omissions of any Delaware Trustee.

(b) The Delaware Trustee shall not be entitled to exercise any powers, nor shall the Delaware Trustee have any of the duties and responsibilities, of the Directors set forth herein. The Delaware Trustee shall be a trustee of the Trust for the sole and limited purpose of fulfilling the requirements of Section 3807(a) of the Act and for taking such actions as are required to be taken by a Delaware Trustee under the Act. The duties (including fiduciary duties), liabilities and obligations of the Delaware Trustee shall be limited to accepting legal process served on the Trust in the State of Delaware and the execution of any certificates required to be filed with the Secretary of State of the State of Delaware that the Delaware Trustee is required to execute under Section 3811 of the Act. There shall be no other duties (including fiduciary duties) or obligations, express or implied, at law or in equity, of the Delaware Trustee. To the extent that, at law or in equity, the Delaware Trustee has duties (including fiduciary duties) and liabilities relating to the Trust or the Tribe Beneficiaries, such duties and liabilities are replaced by the duties and liabilities of the Delaware Trustee expressly set forth in this Trust Agreement. The Delaware Trustee shall have no liability for the acts or omissions of any trustee or any Director. Any permissive rights of the Delaware Trustee to do things enumerated in this Trust Agreement shall not be construed as a duty and, with respect to any such permissive rights, the Delaware Trustee shall not be answerable for other than its willful misconduct, bad faith, gross negligence or fraud. The Delaware Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Trust Agreement at the request or direction of the Directors or any other person pursuant to the provisions of this Trust Agreement unless the Directors or such other person shall have offered to the Delaware Trustee security or indemnity (satisfactory to the Delaware Trustee in its discretion) against the costs, expenses and liabilities that may be incurred by it in compliance with such request or direction. The Delaware Trustee shall be entitled to request and receive written instructions from the Directors and shall have no responsibility or liability for any losses or damages of any nature that may arise from any action taken or not taken by the Delaware Trustee in accordance with the

written direction of the Directors. The Delaware Trustee may, at the expense of the Trust, request, rely on and act in accordance with officer's certificates and/or opinions of counsel, and shall incur no liability and shall be fully protected in acting or refraining from acting in accordance with such officer's certificates and opinions of counsel.

(c) The Delaware Trustee shall serve until such time as the Directors remove the Delaware Trustee or the Delaware Trustee resigns and a successor Delaware Trustee is appointed by the Directors in accordance with the terms of Section 5.10(d) below. The Delaware Trustee may resign at any time upon the giving of at least sixty (60) days' advance written notice to the Directors; provided that such resignation shall not become effective unless and until a successor Delaware Trustee shall have been appointed by the Directors in accordance with Section 5.10(d) below; provided, further, that if any amounts due and owing to the Delaware Trustee hereunder remain unpaid for more than ninety (90) days, the Delaware Trustee shall be entitled to resign immediately by giving written notice to the Directors. If the Directors do not act within such sixty (60) -day period, the Delaware Trustee, at the expense of the Trust, may apply to the Court of Chancery of the State of Delaware or any other court of competent jurisdiction for the appointment of a successor Delaware Trustee.

(d) Upon the resignation or removal of the Delaware Trustee, the Directors shall appoint a successor Delaware Trustee by delivering a written instrument to the outgoing Delaware Trustee. Any successor Delaware Trustee must satisfy the requirements of Section 3807 of the Act. Any resignation or removal of the Delaware Trustee and appointment of a successor Delaware Trustee shall not become effective until a written acceptance of appointment is delivered by the successor Delaware Trustee to the outgoing Delaware Trustee and the Directors, and any fees and expenses due to the outgoing Delaware Trustee are paid. Following compliance with the preceding sentence, the successor Delaware Trustee shall become fully vested with all of the rights, powers, duties and obligations of the outgoing Delaware Trustee under this Trust Agreement, with like effect as if originally named as Delaware Trustee, and the outgoing Delaware Trustee shall be discharged of his or her duties and obligations under this Trust Agreement. The successor Delaware Trustee shall make any related filings required under the Act, including filing a Certificate of Amendment to the Certificate of Trust of TAFT XV in accordance with Section 3810 of the Act.

(e) Notwithstanding anything herein to the contrary, any business entity into which the Delaware Trustee may be merged or converted or with which it may be consolidated or any entity resulting from any merger, conversion or consolidation to which the Delaware Trustee shall be a party, or any entity succeeding to all or substantially all of the corporate trust business of the Delaware Trustee, shall be the successor of the Delaware Trustee hereunder, without the execution or filing of any paper or any further act on the part of any of the Parties hereto.

(f) The Delaware Trustee shall be entitled to compensation for its services as agreed pursuant to a separate fee agreement between the Trust and the Delaware Trustee, which compensation shall be paid by the Trust. Such compensation is intended for the Delaware Trustee's services as contemplated by this Trust Agreement. The terms of this paragraph shall survive termination of this Trust Agreement and/or the earlier resignation or removal of the Delaware Trustee.

(g) The Delaware Trustee shall neither be responsible for, nor chargeable with,

knowledge of the terms and conditions of any other agreement, instrument, or document, other than this Trust Agreement, whether or not an original or a copy of such agreement has been provided to the Delaware Trustee. The Delaware Trustee shall have no duty to know or inquire as to the performance or nonperformance of any provision of any other agreement, instrument or document, other than this Trust Agreement. Neither the Delaware Trustee nor any of its directors, officers, employees, agents or affiliates shall be responsible for, nor have any duty to monitor, the performance or any action of the Trust, the Directors or any other person, or any of their directors, members, officers, agents, affiliates or employee, nor shall it have any liability in connection with the malfeasance or nonfeasance by such party. The Delaware Trustee may assume performance by all such persons of their respective obligations. The Delaware Trustee shall have no enforcement or notification obligations relating to breaches of representations or warranties of any other person. The Delaware Trustee shall have no responsibilities (except as expressly set forth herein) as to the validity, sufficiency, value, genuineness, ownership or transferability of any Trust Asset, written instructions, or any other documents in connection therewith, and will not be regarded as making, nor be required to make, any representations thereto.

(h) The Delaware Trustee shall not be responsible or liable for any failure or delay in the performance of its obligations under this Trust Agreement arising out of, or caused directly or indirectly by, circumstances beyond its control, including, without limitation, any act or provision of any present or future law or regulation or governmental authority; acts of God; earthquakes; fires; floods; wars; terrorism; civil or military disturbances; sabotage; epidemics; riots; interruptions, loss or malfunctions of utilities, computer (hardware or software) or communications service; accidents; labor disputes; acts of civil or military authority or governmental actions; or the unavailability of the Federal Reserve Bank wire or telex or other wire or communication facility.

Section 5.11 Meeting Minutes; Rights of Inspection.

(a) The minutes of proceedings of the Directors shall be kept in written form (which may be electronic) at such place or places designated by the Directors, or, in the absence of such designation, at the principal office of the Trust.

(b) Every Director shall have the absolute right at any reasonable time to inspect and copy all books, records and documents of every kind and to inspect the physical properties of the Trust.

Section 5.12 Trust Protector.

(a) Notwithstanding any other provision of this Trust Agreement, there shall at all times be one Trust Protector to serve in accordance with the provisions of this Section 5.12. The Trust Protector shall be a Trust Indemnified Party. The initial Trust Protector shall be Dean Stacy Leeds.

(b) Any Trust Protector acting hereunder may resign at any time (i) by delivering written notice thereof to the Directors then serving; provided that notice to one Director shall constitute notice to all Directors then serving, or (ii) if there are no Directors then serving, by delivering written notice to the Delaware Trustee.

(c) A Trust Protector may be removed for good reason upon the unanimous consent of

three (3) Directors then serving; provided, however, if there are less than three (3) Directors then serving, the Trust Protector shall not be removed except upon order of the Court. If a vacancy in the position of Trust Protector exists for any reason, the Directors may, upon unanimous consent of the Directors then serving, appoint a new Trust Protector. If the Directors do not appoint a new Trust Protector within thirty (30) days, then the Directors shall petition the Delaware Court of Chancery to appoint a successor Trust Protector to serve and any costs relating to the petition shall be borne by the Trust; provided, however, that if there are no Directors serving at the time of the Trust Protector vacancy, then the Delaware Trustee shall petition the Delaware Court of Chancery as provided above. At no time may Mylan or any party related to Mylan or its affiliates be eligible to serve as Trust Protector. A vacancy in the position of Trust Protector shall not limit the Directors from exercising any powers afforded them under the Trust Documents.

(d) The Trust Protector shall have only the authority set forth in Section 5.2(b), which authority may not be expanded by an amendment or modification of this Trust Agreement.

(e) The Trust Protector shall exercise the Trust Protector's authority in a fiduciary capacity and in a way that the Trust Protector reasonably believes to be in accordance with the purposes of this Trust Agreement. The Trust Protector shall not be under any duty to inquire into or ensure the performance by the Directors of their duties and shall not be liable for any loss to such trust (unless such loss results from actions in bad faith or the willful misconduct of the Trust Protector).

(f) The Directors shall have no liability for the selection of, or exercise of authority by, the Trust Protector.

(g) The Trust Protector shall be entitled to:

- (i) receive reasonable compensation and reimbursement for reasonable expenses for serving as Trust Protector;
- (ii) retain advisors to advise and assist in carrying out the duties of the Trust Protector and the costs thereof shall be borne by the Trust; and
- (iii) receive and review minutes of the meetings or other actions of the Directors, but only at such time as the Trust Protector is required to act pursuant to Section 5.2(b).

ARTICLE 6

GENERAL PROVISIONS

Section 6.1 Irrevocability. To the fullest extent permitted by applicable law, the Trust is irrevocable. Subject to Section IV.E of the MTSA (regarding when certain funds will revert to Mylan), Mylan shall not (i) retain any ownership or residual interest whatsoever with respect to any Trust Assets, including, but not limited to, the funds transferred to fund the Trust, and (ii) shall not have any rights or role with respect to the management or operation of the Trust, or the Directors' administration of the Trust.

Section 6.2 Term; Termination.

(a) The term for which the Trust is to exist shall commence on the date of the filing of the Certificate of Trust and shall terminate pursuant to the provisions of this Section 6.2.

(b) The Trust shall automatically dissolve as soon as practicable but no later than ninety (90) days after the date on which the Court approves the dissolution upon the satisfaction of the purposes of the Trust, wherein (i) all reasonably expected assets have been collected by the Trust, (ii) all Abatement Distributions have been made to the extent set forth in Section 4.2(b), (iii) necessary arrangements and reserves have been made to discharge all anticipated remaining Trust obligations and TAFT XV Operating Expenses in a manner consistent with the MTSA and the Trust Documents, and (iv) a final accounting has been filed and approved by the Court (the “**Dissolution Date**”).

(c) On the Dissolution Date or as soon as reasonably practicable thereafter, after the wind-up of the Trust’s affairs by the Directors and payment of all of the Trust’s liabilities have been provided for as required by applicable law including Section 3808 of the Act, all monies remaining in the Trust shall be distributed to the Tribe Beneficiaries in accordance with Section 4.2(b), except as otherwise provided in Section 4.2(e).

(d) Following the dissolution and distribution of the assets of the Trust, the Trust shall terminate, and the Directors, or any one of them, shall execute and cause a Certificate of Cancellation of the Certificate of Trust of TAFT XV to be filed in accordance with the Act. Notwithstanding anything to the contrary contained in this Trust Agreement, the existence of the Trust as a separate legal entity shall continue until the filing of such Certificate of Cancellation. A certified copy of the Certificate of Cancellation shall be given to the Delaware Trustee for its records promptly following such filing.

Section 6.3 Taxes.

(a) The Trust is intended to qualify as one or more “qualified settlement funds” within the meaning of the **QSF Regulations**, and, to the extent permitted under applicable law, for state and local income tax purposes. Notwithstanding anything to the contrary herein, no provision in this Trust Agreement or the TAFT XV TDP shall be construed or implemented in a manner that would cause the Trust to fail to qualify as one or more “qualified settlement funds” within the meaning of the QSF Regulations or under corresponding or similar provisions of relevant state or local law. The Trust shall be treated as a qualified settlement fund from the earliest date possible, and the Parties agree to any relation-back election required to treat the Trust as a qualified settlement fund from the earliest date possible.

(b) The Managing Director shall be the “administrator” of the Trust within the meaning of Treasury Regulation Section 1.468B-2(k)(3) and, in such capacity, such administrator shall (i) prepare and timely file, or cause to be prepared and timely filed, such income tax and other tax returns and statements required to be filed and shall timely pay all taxes required to be paid by the Trust out of the Trust Assets, which assets may be sold by the Directors to the extent necessary to satisfy tax liabilities of the Trust, (ii) be responsible for all tax reporting, filing and withholding requirements for the Trust and comply with all applicable tax reporting, filing and withholding obligations, (iii) send copies of any tax filings and returns of the Trust to Mylan, in accordance with the MTSA, (iv) cooperate in the provision of documentation to Mylan in accordance with Section IV.G.2.a of the MTSA, and (v) obtain federal and state taxpayer identification numbers

for the Trust and provide the same to the Directors and Mylan.

(c) Subject to Section 6.3(a) and (b) above and (d) below, following the Effective Date, the Directors shall be responsible for all of the Trust's tax matters, including, without limitation, tax audits, claims, defenses and proceedings. Subject to Section IV.G.2.g of the MTSA, the Directors shall be responsible for causing the Trust to satisfy all requirements necessary to maintain qualification of the Trust as one or more "qualified settlement funds" within the meaning of the QSF Regulations and under corresponding or similar provisions of relevant state or local law. The Directors shall take no action that could cause the Trust to fail to qualify as one or more "qualified settlement funds" within the meaning of the QSF Regulations or under corresponding or similar provisions of relevant state or local law or that is inconsistent with such treatment.

(d) The "taxable year" of the Trust shall be the "calendar year" as such terms are defined in Section 441 of the Code. The Trust shall use the accrual method of accounting as defined in Section 446(c) of the Code.

(e) Notwithstanding anything in this Trust Agreement or the Mylan Tribal Settlement Agreement to the contrary, neither the Directors nor any other person shall on behalf of or in connection with the Trust seek a private letter ruling, technical advice memorandum or any other ruling or guidance from the Internal Revenue Service or any other taxing authority on any matter without consulting with and obtaining the prior written consent of Mylan.

Section 6.4 Modification.

(a) Material modifications to this Trust Agreement may be made only pursuant to an order of the Court; provided, however, that the Directors may amend this Trust Agreement by unanimous consent of the Directors from time to time without the consent, approval or other authorization of, but with notice to, the Court, to make: (i) minor modifications or clarifying amendments necessary to enable the Directors to effectuate the provisions of this Trust Agreement; or (ii) modifications to satisfy any requirements, conditions or guidelines contained in any opinion, directive, order, statute, ruling or regulation of any federal, state or foreign governmental entity. Notwithstanding the foregoing proviso, no amendment or waiver of this Trust Agreement shall modify this Trust Agreement in a manner that is inconsistent with the Mylan Tribal Settlement Agreement. The Directors shall provide to the Tribe Beneficiaries notice of any proposed modification to this Trust Agreement, whether material or minor, through the TAFT Portal at the time of notice to the Court and not less than ten (10) business days before such modification becomes effective; provided, however, that the Directors may shorten such notice period only in the event that a ten (10)-day notice period would be materially adverse to the Trust and the Tribe Beneficiaries. The Directors shall provide Mylan with a copy of any such notice of any proposed modification to this Trust Agreement at the same time as notice is provided to the Tribe Beneficiaries.

(b) Notwithstanding anything set forth in this Trust Agreement to the contrary, none of this Trust Agreement, nor any document related thereto shall be modified or amended in any way that could jeopardize or impair (i) the Trust's status as a "qualified settlement fund" within the meaning of the QSF Regulations or under corresponding or similar provisions of relevant state or local law, or (ii) the rights, duties, liabilities and obligations of the Delaware Trustee without the written consent of the Delaware Trustee.

Section 6.5 Communications. The Directors shall establish and maintain the Tribal Opioid Settlement Portal (or other means of communication approved by the Directors) so as to (a) enable Tribe Beneficiaries to deliver the required documentation under the Beneficiary Abatement Use Reports in an electronic format and (b) enable secure communications between the Directors and the Tribe Beneficiaries.

Section 6.6 Severability. If any provision of this Trust Agreement or application thereof to any person or circumstance shall be determined by a Final Order to be invalid or unenforceable to any extent, the remainder of this Trust Agreement, or the application of such provisions to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby, and such provision of this Trust Agreement shall be valid and enforced to the fullest extent permitted by law.

Section 6.7 Notices.

(a) Any notices or other communications required or permitted hereunder to the following parties shall be in writing and delivered at the addresses designated below, or sent by email or facsimile pursuant to the instructions listed below, or mailed by overnight courier, addressed as follows, or to such other address or addresses as may hereafter be furnished in writing to each of the other parties listed below in compliance with the terms hereof.

To the Directors:
Dr. Kathy Hopinkah Hannan
Tribal Abatement Fund Trust XV
P.O. Box 65097
Washington, DC 20035
Email: Directors@tribalopioidsettlements.com

Mary L. Smith
Tribal Abatement Fund Trust XV
P.O. Box 65097
Washington, DC 20035
Email: Directors@tribalopioidsettlements.com

Kevin Washburn
Tribal Abatement Fund Trust XV
P.O. Box 65097
Washington, DC 20035
Email: Directors@tribalopioidsettlements.com

with a copy (which shall not constitute notice) to:
Brown Rudnick LLP
7 Times Square
New York, NY 11036
Attn: David J. Molton, Esq., Barbara J. Kelly, Esq.
Email: dmolton@brownrudnick.com, bkelly@brownrudnick.com

To the Delaware Trustee:

Wilmington Trust, N.A.
1100 North Market Street
Wilmington, DE 19890
Attn: Russell L. Crane
Email: rcrane@wilmingtontrust.com
with a copy (which shall not constitute notice) to:
Morris James, LLP
500 Delaware Avenue, Suite 1500
Wilmington, DE 19801
Attn: Ross Antonacci, Esq.
Email: RAntonacci@morrisjames.com

To the Trust Protector:

Stacy Leeds
c/o Leeds Consulting LLC
11177 N. Highway 10
Tahlequah, OK 74464

with a copy (which shall not constitute notice) to:
Brown Rudnick LLP
7 Times Square
New York, NY 11036
Attn: David J. Molton, Esq., Barbara J. Kelly, Esq.
Email: dmolton@brownrudnick.com, bkelly@brownrudnick.com

To Mylan:

Douglas Miner
Viatris Inc.
General Counsel, North America
1000 Mylan Boulevard
Canonsburg, PA 15317
Tel: +1-724-514-1483
douglas.miner@viatris.com

with a copy to Mylan's attorneys at:

Rebecca Mandel
Adam Levin
HOGAN LOVELLS US LLP
Columbia Square
555 Thirteenth Street, NW
Washington, DC 20004
rebecca.mandel@hoganlovells.com
adam.levin@hoganlovells.com

(b) All such notices and communications, if mailed, shall be effective when physically delivered at the designated addresses, or if electronically transmitted, shall be effective upon transmission.

Section 6.8 Successors and Assigns. The provisions of this Trust Agreement shall be binding upon and inure to the benefit of the Trust, the Directors, the Delaware Trustee and their respective successors and assigns, except that none of such persons may assign or otherwise transfer any of its, or their, rights or obligations under this Trust Agreement except, in the case of the Directors, as contemplated by Section 2.1 and Section 5.2 above, and in the case of the Delaware Trustee, as contemplated by Section 5.10 above.

Section 6.9 Limitation on Transferability; Tribe Beneficiaries' Interests. Tribe Beneficiaries' interests in the Trust shall not (a) be assigned, conveyed, hypothecated, pledged or otherwise transferred, voluntarily or involuntarily, directly or indirectly, and any purported assignment, conveyance, pledge or transfer shall be null and void *ab initio*; provided, however, that nothing set forth in this Trust Agreement shall be deemed to preclude Tribe Beneficiaries from directing their Abatement Distribution to a tribal organization or an inter-tribal consortium or from aggregating their Abatement Distributions or otherwise directing their Abatement Distributions for common Approved Tribal Opioid Abatement Uses and/or common Tribal Abatement Strategies; (b) be evidenced by a certificate or other instrument; (c) possess any voting rights; (d) give rise to any right or rights to participate in the management or administration of the Trust or the Trust Assets; (e) entitle the holders thereof to seek the removal or replacement of a Director, whether by petition to the Court or any other court or otherwise; (f) entitle the holders thereof to receive any interest on Abatement Distributions; nor (g) give rise to any rights to seek a partition or division of the Trust Assets. In accordance with the Act, Tribe Beneficiaries shall have no interest of any kind in any of the Trust Assets; rather, Tribe Beneficiaries shall have an undivided beneficial interest only in cash assets of the Trust but only to the extent such cash assets are declared by the Directors to be distributable as Abatement Distributions in accordance with the Trust Documents. For the avoidance of doubt, Tribe Beneficiaries shall only have such rights as expressly set forth in this Trust Agreement.

Section 6.10 Exemption from Registration. The Parties hereto intend that the rights of the Tribe Beneficiaries arising under this Trust Agreement shall not be "securities" under applicable laws, but none of the Parties hereto represent or warrant that such rights shall not be securities or shall be entitled to exemption from registration under applicable securities laws.

Section 6.11 Entire Agreement; No Waiver. The entire agreement of the Parties relating to the subject matter of this Trust Agreement is contained herein and in the documents referred to herein, and this Trust Agreement and such documents supersede any prior oral or written agreements concerning the subject matter hereof. No failure to exercise or delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege hereunder preclude any further exercise thereof or of any other right, power or privilege. The rights and remedies herein provided are cumulative and are not exclusive of rights under law or in equity.

Section 6.12 Headings. The headings used in this Trust Agreement are inserted for convenience only and do not constitute a portion of this Trust Agreement, nor in any manner affect

the construction of the provisions of this Trust Agreement.

Section 6.13 Governing Law. This Trust Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to the conflicts of law provisions thereof which would purport to apply the law of any other jurisdiction. For the avoidance of doubt, none of the following provisions of Delaware law shall apply to the extent inconsistent with the terms of the Trust Documents: (a) the filing with any court or governmental body or agency of trustee accounts or schedules of trustee fees and charges, (b) affirmative requirements to post bonds for Directors, officers, agents or employees of a trust, (c) the necessity for obtaining court or other governmental approval concerning the acquisition, holding or disposition of property, (d) fees or other sums payable to Directors, officers, agents or employees of a trust, (e) the allocation of receipts and expenditures to income or principal, (f) restrictions or limitations on the permissible nature, amount or concentration of trust investments or requirements relating to the titling, storage or other manner of holding of Trust Assets, (g) the existence of rights or interests (beneficial or otherwise) in Trust Assets, (h) the ability of beneficial owners or other persons to terminate or dissolve a trust, and (i) the establishment of fiduciary or other standards or responsibilities or limitations on the acts or powers of Directors or beneficial owners that are inconsistent with the limitations on liability or authorities and powers of the Directors set forth or referenced in this Trust Agreement. Section 3540 of Title 12 of the Act shall not apply to the Trust.

Section 6.14 Dispute Resolution. The MTSA shall govern the resolution of any dispute under this Trust Agreement.

Section 6.15 Sovereign Immunity. Nothing set forth in the Trust Documents shall be construed as a waiver of a claim of sovereign immunity in any dispute resolution, action or proceeding, including, without limitation, any dispute resolution, action or proceeding occurring after the Effective Date.

Section 6.16 Effectiveness. This Trust Agreement is effective as of the Effective Date.

Section 6.17 Counterpart Signatures. This Trust Agreement may be executed in any number of counterparts, each of which shall constitute an original, but such counterparts shall together constitute but one and the same instrument. A signed copy of this Trust Agreement or any amendment hereto delivered by facsimile, email or other means of Electronic Transmission shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the Parties have executed this Trust Agreement as of the date first set forth above to be effective as of the Effective Date.

[Signature Pages to TAFT XV Agreement follow]

EXHIBIT 1
PARTICIPATING TRIBES and FINAL TRIBAL ALLOCATION DISTRIBUTION
PERCENTAGES

[See Exhibit C from Tribe MSA]

EXHIBIT 2
FORM OF CERTIFICATE OF TRUST OF THE
TRIBAL ABATEMENT FUND TRUST XV

This Certificate of Trust of the TRIBAL ABATEMENT FUND TRUST XV (the “*Trust*”) is being duly executed and filed by the undersigned Directors of the Trust, to form a statutory trust under the Delaware Statutory Trust Act (12 Del. Code § 3801 *et seq.*) (the “*Act*”).

Name. The name of the statutory trust formed hereby is:

TRIBAL ABATEMENT FUND TRUST XV

Delaware Trustee. The name and business address of the Delaware Trustee of the Trust in the State of Delaware is:

Effective Date. This Certificate of Trust shall be effective upon filing.

IN WITNESS WHEREOF, the undersigned, being all of the trustees of the Trust, have duly executed this Certificate of Trust in accordance with Section 3811(a) of the Act.

TRUSTEES:	DELAWARE TRUSTEE:
in his/her capacity as a trustee and not individually.	
in his/her capacity as a trustee and not individually.	By:
	Name:
in his/her capacity as a trustee and not individually.	Title:

EXHIBIT 3 INVESTMENT GUIDELINES

In General. Only the following investments will be permitted:

- (i) Demand and time deposits, such as certificates of deposit, in banks or other savings institutions whose deposits are federally insured;
- (ii) U.S. Treasury bills, bonds, and notes, including, but not limited to, long-term U.S. Treasury bills, bonds, notes, and other Government Securities as defined under Section 2(a)(16) of the Investment Company Act of 1940, 15 U.S.C. § 80a-2(a)(16), including, but not limited to, Fannie Mae, Freddie Mac, Federal Home Loan Bank, and Federal Farm Credit;
- (iii) Repurchase agreements for U.S. Treasury bills, bonds, and notes;
- (iv) Commercial Paper (rated A1/P-1 by Standard & Poor's and Moody's);
- (v) AA or AAA corporate bonds (with the rating awarded by at least two of the three major rating agencies (Standard & Poor's, Moody's, or Fitch)); or
- (vi) Open-ended mutual funds owning only assets described in subparts (i) through (v) of this subsection.

The value of bonds of any single company and its affiliates owned by the Trust directly rather than through a mutual fund shall not exceed 10% of the investment portfolio at time of purchase; this restriction does not apply to any of the following: Repurchase Agreements; Money Market Funds; U.S. Treasuries; and U.S. Government Agencies.

Any such investments shall be made consistently with the Uniform Prudent Investor Act. The determination of the rating of any investments shall be made by the Trust's financial advisor on the date of acquisition of any such investment or on the date of re-investment. The Trust's financial advisor shall reconfirm that all investments of Trust Assets still meet the original rating requirement on a quarterly basis. If the Trust's financial advisors determine that any particular investment no longer meets the rating requirement, there shall be a substitution of that investment with an investment that meets the ratings requirement as promptly as practicable, but in no event later than the next reporting period. Previously purchased securities downgraded below AA may be held for a reasonable and prudent period of time if the Trust's financial advisor believes it is in the interest of the Trust to do so.

The borrowing of funds or securities for the purpose of leveraging, shorting, or other investments is prohibited. Investment in non-U.S. dollar denominated bonds is prohibited. The standing default investment instruction for all cash in any account or subaccount that holds any Trust Assets in cash shall be invested in the BlackRock Fed Fund (CUSIP 09248U700).

See example fund-level requirements table on following page.

Fund Level Requirements

- 1. OTC Derivatives Counterparty Exposure – Not allowed
- 2. Non-U.S. dollar denominated bonds – Not allowed

TYPE OF INVESTMENT	ELIGIBLE	PROHIBITED	COMMENTS
U.S. Treasury Securities	X		
U.S. Agency Securities	X		
Mortgage-Related Securities		x	
Asset-Backed Securities		x	
Corporate Securities (public)	X		
Municipal bonds	X		

DERIVATIVES:	No investment, including futures, options and other derivatives, may be purchased if its return is directly or indirectly determined by an investment prohibited elsewhere in these guidelines.		
Futures		X	
Options		X	
Currency Forwards		X	
Currency Futures		X	
Currency Options		X	
Currency Swaps		X	
Interest Rate Swaps		X	
Total Return Swaps		X	
Structured Notes		X	
Collateralized Debt Obligations		X	
Credit Default Swaps		X	
Mortgage-Related Derivatives		X	
FOREIGN / NON-U.S. DOLLAR:			
Foreign CDs		X	
Foreign U.S. Dollar Denominated Securities		X	
Non-U.S. Dollar Denominated Bonds		X	
Supranational U.S. Dollar Denominated Securities		X	
COMMINGLED VEHICLES (except STIF):			
Collective Funds		X	
Commingled Trust Funds (open ended mutual funds only)		X	
Common Trust Funds		X	
Registered Investment Companies		X	
MONEY MARKET SECURITIES:			
Qualified STIF		X	
Interest Bearing Bank Obligations Insured by a Federal or State Agency	X		
Commercial Paper		X	
Master Note Agreements and Demand Notes		X	
Repurchase Agreements		X	
OTHER:			
Bank Loans		X	
Convertibles (e.g., Lyons)		X	
Municipal Bonds	X		
Preferred Stock		X	
Private Placements (excluding 144A)	X		
Rule 144A Issues	X		
Zero Coupon Bonds	X		
Commodities		X	
Catastrophe Bonds		X	

EXHIBIT 4

TRIBAL ABATEMENT FUND TRUST XV TRUST DISTRIBUTION PROCEDURES

Issue	Description
1. APPLICABILITY OF AGREEMENT	These terms shall apply to the consideration received and distributed by (A) the Tribal Abatement Fund Trust XV (“TAFT XV”) under the Mylan Tribal Settlement Agreement between the Tribal Leadership Committee (“TLC”), Participating Tribes,³ and Mylan dated April 4, 2025 (“Mylan Tribal Settlement Agreement”), entered into in connection with the matter of <i>In re National Prescription Opiate Litigation</i>, MDL No. 2804, Case No. 17-md-2804 in the United States District Court for the Northern District of Ohio (the “Court”); and (B) any trust where the terms of such trust agreement expressly adopt these Tribal Opioid Litigation Settlement Trust Distribution Procedures (“TDP”) (each of (A) and (B), a “Tribe Trust” and collectively, the “Tribe Trusts”). The Tribe Trusts shall benefit the Tribe Beneficiaries to the extent set forth in the respective trust agreement of the Tribe Trust (with all applicable exhibits and schedules, each a “Trust Agreement” and collectively, the “Trust Agreements”). The distributions made pursuant to this TDP are the exclusive distributions that will be made by the Tribe Trusts and the Tribe Beneficiaries will have no further or other recourse against any party other than what is provided for under this TDP. The terms set forth herein will be deemed incorporated into the Trust Agreements, <i>provided, however</i>, each Trust Agreement may have a unique Schedule T for allocation of distributions among Tribes. These terms set forth the manner in which the Tribe Trusts shall make Abatement Distributions to the Tribe Beneficiaries, which may be used exclusively on the parameters set forth herein.
2. PURPOSE	These TDPs are intended to establish the mechanisms for the distribution and allocation of funds distributed by the Tribe Trusts to the Tribe Beneficiaries. All such funds described in the foregoing sentence are referred to herein as “Abatement Funds” and shall be used to abate the opioid crisis in accordance with the terms hereof, with recognition of the culturally appropriate activities, practices, teachings or ceremonies that may, in the

³ Capitalized terms used but not herein defined shall have the meaning ascribed to them in the Mylan Tribal Settlement Agreement or the TAFT XV Trust Agreement, as applicable.

Issue	Description
	judgment of a Tribe Beneficiary, be aimed at or supportive of remediation and abatement of the opioid crisis within a tribal community. Specifically, (i) no less than ninety five percent (95%) of the Abatement Funds distributed under the Trust Agreements shall be used by Tribe Beneficiaries for abatement of the opioid crisis by funding opioid or substance use disorder related projects or programs that fall within the scope of Schedules B and D (the “Approved Tribal Opioid Abatement Uses”); and (ii) no more than five percent (5%) of the Abatement Funds may be used to fund administrative expenses incurred in connection with the spending of Abatement Funds for Approved Tribal Opioid Abatement Uses (“Approved Administrative Expenses,” and, together with the Approved Tribal Opioid Abatement Uses, “Approved Uses”). For the avoidance of doubt, Schedule D is a non-exhaustive, illustrative list of culturally appropriate activities, practices, teachings or ceremonies that may, in the judgment of a Tribe Beneficiary, be aimed at or supportive of remediation and abatement of the opioid crisis within a tribal community. The Tribe Trusts shall distribute Abatement Funds to Tribe Beneficiaries for Approved Uses. Notwithstanding anything in these TDPs that might imply to the contrary, projects or programs that constitute Approved Tribal Opioid Abatement Uses may be provided by Tribe Beneficiaries, tribal organizations, tribal agencies or subdivisions or nongovernmental parties and funded from Abatement Funds.
3. DISBURSEMENT OF ABATEMENT DISTRIBUTIONS	The trustees under each Trust Agreement shall distribute the Abatement Funds consistent with the Tribal Allocation Percentages set forth on the applicable Schedule T . Each Trust Agreement may have its own unique Schedule T .
4. ATTORNEYS’ FEES AND COSTS FUND	Reserved.
5. TRIBAL ABATEMENT FUNDING	1. The Tribe Beneficiaries will use funds received from the Tribe Trusts for programs on the approved list of abatement strategies (see Schedule B) and also for culturally appropriate activities, practices, teachings or ceremonies that are, in the judgment of a Tribe Beneficiary, aimed at or supportive of remediation and abatement of the opioid crisis within a tribal community. A list of representative examples of such culturally appropriate abatement strategies, practices, and programs is attached hereto as Schedule D (the “Tribal

Issue	Description
	Abatement Strategies”). The separate allocation of abatement funding and illustrative list of Tribal Abatement Strategies recognizes that American Indian and Alaska Native Tribes and the communities they serve possess unique cultural histories, practices, wisdom, and needs that are highly relevant to the health and well-being of American Indian and Alaska Native people and that may play an important role in both individual and public health efforts and responses in Native communities. 2. The Tribe Beneficiaries agree that Abatement Funds distributed pursuant to the Trust Agreements shall be used to abate the opioid crisis in accordance with the terms of these TDPs.
6. COMPLIANCE, REPORTING, AUDIT AND ACCOUNTABILITY	1. The trustees of the Tribe Trusts shall impose appropriate reporting requirements on the Tribe Beneficiaries to ensure that Abatement Funds are used only for Approved Uses. The trustees may authorize modified reporting requirements for Tribe Beneficiaries with allocations below a certain level. 2. The Tribe Trusts shall prepare an annual report (an “Annual Report”). 3. The Court shall have continuing jurisdiction over the Tribe Trusts, provided however, the courts of the State of Delaware, including any federal court located therein, shall also have jurisdiction over the Tribe Trusts. 4. The trustees shall have the power to take any and all actions that in the judgment of the trustees are necessary or proper to fulfill the purposes of the Trust Agreements, including the requirement that 100% of the Abatement Funds distributed shall be used to abate the opioid crisis in accordance with the terms hereof. 5. Notwithstanding any other provision of these TDPs, the trustees of the Tribe Trusts shall implement these TDPs in accordance with the Indian Self-Determination and Education Assistance Act of 1975, 25 U.S.C. 5301 <i>et seq.</i> and, for the avoidance of doubt, a Tribe Beneficiary, tribal organization or inter-tribal consortium may charge its federally-approved indirect cost rate consistent with such Act with respect to opioid abatement programs carried out by such Tribe Beneficiary, tribal organization or inter-tribal consortium.

Schedule B

Approved Uses

Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use Disorder or Mental Health (SUD/MH) conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

PART ONE: TREATMENT

A. TREAT OPIOID USE DISORDER (OUD)

Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use Disorder or Mental Health (SUD/MH) conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following⁴:

1. Expand availability of treatment for OUD and any co-occurring SUD/MH conditions, including all forms of Medication-Assisted Treatment (MAT) approved by the U.S. Food and Drug Administration.
2. Support and reimburse evidence-based services that adhere to the American Society of Addiction Medicine (ASAM) continuum of care for OUD and any co-occurring SUD/MH conditions
3. Expand telehealth to increase access to treatment for OUD and any co-occurring SUD/MH conditions, including MAT, as well as counseling, psychiatric support, and other treatment and recovery support services.
4. Improve oversight of Opioid Treatment Programs (OTPs) to assure evidence-based or evidence-informed practices such as adequate methadone dosing and low threshold approaches to treatment.
5. Support mobile intervention, treatment, and recovery services, offered by qualified professionals and service providers, such as peer recovery coaches, for persons with OUD and any co-occurring SUD/MH conditions and for persons who have experienced an opioid overdose.
6. Treatment of trauma for individuals with OUD (e.g., violence, sexual assault, human trafficking, or adverse childhood experiences) and family members (e.g., surviving family members after an overdose or overdose fatality), and training of health care personnel to identify and address such trauma.

⁴ As used in this Schedule B, words like “expand,” “fund,” “provide” or the like shall not indicate a preference for new or existing programs. Priorities will be established through the mechanisms described in the Public Creditor Trust Distribution Procedures.

7. Support evidence-based withdrawal management services for people with OUD and any co-occurring mental health conditions.
8. Training on MAT for health care providers, first responders, students, or other supporting professionals, such as peer recovery coaches or recovery outreach specialists, including telementoring to assist community-based providers in rural or underserved areas.
9. Support workforce development for addiction professionals who work with persons with OUD and any co-occurring SUD/MH conditions.
10. Fellowships for addiction medicine specialists for direct patient care, instructors, and clinical research for treatments.
11. Scholarships and supports for behavioral health practitioners or workers involved in addressing OUD and any co-occurring SUD or mental health conditions, including but not limited to training, scholarships, fellowships, loan repayment programs, or other incentives for providers to work in rural or underserved areas.
12. Provide funding and training for clinicians to obtain a waiver under the federal Drug Addiction Treatment Act of 2000 (DATA 2000) to prescribe MAT for OUD, and provide technical assistance and professional support to clinicians who have obtained a DATA 2000 waiver.
13. Dissemination of web-based training curricula, such as the American Academy of Addiction Psychiatry's Provider Clinical Support Service-Opioids web-based training curriculum and motivational interviewing.
14. Development and dissemination of new curricula, such as the American Academy of Addiction Psychiatry's Provider Clinical Support Service for Medication-Assisted Treatment.

B. SUPPORT PEOPLE IN TREATMENT AND RECOVERY

Support people in recovery from OUD and any co-occurring SUD/MH conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

1. Provide comprehensive wrap-around services to individuals with OUD and any co-occurring SUD/MH conditions, including housing, transportation, education, job placement, job training, or childcare.
2. Provide the full continuum of care of treatment and recovery services for OUD and any co-occurring SUD/MH conditions, including supportive housing, peer support services and counseling, community navigators, case management, and connections to community-based services.
3. Provide counseling, peer-support, recovery case management and residential treatment with access to medications for those who need it to persons with OUD and any co-occurring SUD/MH conditions.

4. Provide access to housing for people with OUD and any co-occurring SUD/MH conditions, including supportive housing, recovery housing, housing assistance programs, training for housing providers, or recovery housing programs that allow or integrate FDA-approved medication with other support services.
5. Provide community support services, including social and legal services, to assist in deinstitutionalizing persons with OUD and any co-occurring SUD/MH conditions.
6. Support or expand peer-recovery centers, which may include support groups, social events, computer access, or other services for persons with OUD and any co-occurring SUD/MH conditions.
7. Provide or support transportation to treatment or recovery programs or services for persons with OUD and any co-occurring SUD/MH conditions.
8. Provide employment training or educational services for persons in treatment for or recovery from OUD and any co-occurring SUD/MH conditions.
9. Identify successful recovery programs such as physician, pilot, and college recovery programs, and provide support and technical assistance to increase the number and capacity of high-quality programs to help those in recovery.
10. Engage non-profits, faith-based communities, and community coalitions to support people in treatment and recovery and to support family members in their efforts to support the person with OUD in the family.
11. Training and development of procedures for government staff to appropriately interact and provide social and other services to individuals with or in recovery from OUD, including reducing stigma.
12. Support stigma reduction efforts regarding treatment and support for persons with OUD, including reducing the stigma on effective treatment.
13. Create or support culturally appropriate services and programs for persons with OUD and any co-occurring SUD/MH conditions, including new Americans.
14. Create and/or support recovery in high schools.
15. Hire or train behavioral health workers to provide or expand any of the services or supports listed above.

C. CONNECT PEOPLE WHO NEED HELP TO THE HELP THEY NEED
(CONNECTIONS TO CARE)

Provide connections to care for people who have – or at risk of developing – OUD and any co-occurring SUD/MH conditions through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

1. Ensure that health care providers are screening for OUD and other risk factors and know how to appropriately counsel and treat (or refer if necessary) a patient for OUD treatment.
2. Fund Screening, Brief Intervention and Referral to Treatment (SBIRT) programs to reduce the transition from use to disorders, including SBIRT services to pregnant women who are uninsured or not eligible for Medicaid.
3. Provide training and long-term implementation of SBIRT in key systems (health, schools, colleges, criminal justice, and probation), with a focus on youth and young adults when transition from misuse to opioid disorder is common.
4. Purchase automated versions of SBIRT and support ongoing costs of the technology.
5. Expand services such as navigators and on-call teams to begin MAT in hospital emergency departments.
6. Training for emergency room personnel treating opioid overdose patients on post-discharge planning, including community referrals for MAT, recovery case management or support services.
7. Support hospital programs that transition persons with OUD and any co-occurring SUD/MH conditions, or persons who have experienced an opioid overdose, into clinically appropriate follow-up care through a bridge clinic or similar approach.
8. Support crisis stabilization centers that serve as an alternative to hospital emergency departments for persons with OUD and any co-occurring SUD/MH conditions or persons that have experienced an opioid overdose.
9. Support the work of Emergency Medical Systems, including peer support specialists, to connect individuals to treatment or other appropriate services following an opioid overdose or other opioid-related adverse event.
10. Provide funding for peer support specialists or recovery coaches in emergency departments, detox facilities, recovery centers, recovery housing, or similar settings; offer services, supports, or connections to care to persons with OUD and any co-occurring SUD/MH conditions or to persons who have experienced an opioid overdose.
11. Expand warm hand-off services to transition to recovery services.
12. Create or support school-based contacts that parents can engage with to seek immediate treatment services for their child; and support prevention, intervention, treatment, and recovery programs focused on young people.
13. Develop and support best practices on addressing OUD in the workplace.
14. Support assistance programs for health care providers with OUD.

15. Engage non-profits and the faith community as a system to support outreach for treatment.
16. Support centralized call centers that provide information and connections to appropriate services and supports for persons with OUD and any co-occurring SUD/MH conditions.

D. ADDRESS THE NEEDS OF CRIMINAL-JUSTICE-INVOLVED PERSONS

Address the needs of persons with OUD and any co-occurring SUD/MH conditions who are involved in, are at risk of becoming involved in, or are transitioning out of the criminal justice system through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

1. Support pre-arrest or pre-arraignment diversion and deflection strategies for persons with OUD and any co-occurring SUD/MH conditions, including established strategies such as:
 1. Self-referral strategies such as the Angel Programs or the Police Assisted Addiction Recovery Initiative (PAARI);
 2. Active outreach strategies such as the Drug Abuse Response Team (DART) model;
 3. “Naloxone Plus” strategies, which work to ensure that individuals who have received naloxone to reverse the effects of an overdose are then linked to treatment programs or other appropriate services;
 4. Officer prevention strategies, such as the Law Enforcement Assisted Diversion (LEAD) model;
 5. Officer intervention strategies such as the Leon County, Florida Adult Civil Citation Network or the Chicago Westside Narcotics Diversion to Treatment Initiative; or
 6. Co-responder and/or alternative responder models to address OUD-related 911 calls with greater SUD expertise.
2. Support pre-trial services that connect individuals with OUD and any co-occurring SUD/MH conditions to evidence-informed treatment, including MAT, and related services.
3. Support treatment and recovery courts that provide evidence-based options for persons with OUD and any co-occurring SUD/MH conditions.
4. Provide evidence-informed treatment, including MAT, recovery support, harm reduction, or other appropriate services to individuals with OUD and any co-occurring SUD/MH conditions who are incarcerated in jail or prison.

5. Provide evidence-informed treatment, including MAT, recovery support, harm reduction, or other appropriate services to individuals with OUD and any co-occurring SUD/MH conditions who are leaving jail or prison have recently left jail or prison, are on probation or parole, are under community corrections supervision, or are in re-entry programs or facilities.
6. Support critical time interventions (CTI), particularly for individuals living with dual-diagnosis OUD/serious mental illness, and services for individuals who face immediate risks and service needs and risks upon release from correctional settings.
7. Provide training on best practices for addressing the needs of criminal-justice-involved persons with OUD and any co-occurring SUD/MH conditions to law enforcement, correctional, or judicial personnel or to providers of treatment, recovery, harm reduction, case management, or other services offered in connection with any of the strategies described in this section.

E. **ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND THEIR FAMILIES, INCLUDING BABIES WITH NEONATAL ABSTINENCE SYNDROME**

Address the needs of pregnant or parenting women with OUD and any co-occurring SUD/MH conditions, and the needs of their families, including babies with neonatal abstinence syndrome (NAS), through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

1. Support evidence-based or evidence-informed treatment, including MAT, recovery services and supports, and prevention services for pregnant women – or women who could become pregnant – who have OUD and any co-occurring SUD/MH conditions, and other measures to educate and provide support to families affected by Neonatal Abstinence Syndrome.
2. Expand comprehensive evidence-based treatment and recovery services, including MAT, for uninsured women with OUD and any co-occurring SUD/MH conditions for up to 12 months postpartum.
3. Training for obstetricians or other healthcare personnel that work with pregnant women and their families regarding treatment of OUD and any co-occurring SUD/MH conditions.
4. Expand comprehensive evidence-based treatment and recovery support for NAS babies; expand services for better continuum of care with infant-need dyad; expand long-term treatment and services for medical monitoring of NAS babies and their families.
5. Provide training to health care providers who work with pregnant or parenting women on best practices for compliance with federal requirements that children born with Neonatal Abstinence Syndrome get referred to appropriate services and receive a plan of safe care.

6. Child and family supports for parenting women with OUD and any co-occurring SUD/MH conditions.
7. Enhanced family supports and child care services for parents with OUD and any co-occurring SUD/MH conditions.
8. Provide enhanced support for children and family members suffering trauma as a result of addiction in the family; and offer trauma-informed behavioral health treatment for adverse childhood events.
9. Offer home-based wrap-around services to persons with OUD and any co-occurring SUD/MH conditions, including but not limited to parent skills training.
10. Support for Children's Services – Fund additional positions and services, including supportive housing and other residential services, relating to children being removed from the home and/or placed in foster care due to custodial opioid use.

PART TWO: PREVENTION

F. PREVENT OVER-PRESCRIBING AND ENSURE APPROPRIATE PRESCRIBING AND DISPENSING OF OPIOIDS

Support efforts to prevent over-prescribing and ensure appropriate prescribing and dispensing of opioids through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

1. Fund medical provider education and outreach regarding best prescribing practices for opioids consistent with the Guidelines for Prescribing Opioids for Chronic Pain from the U.S. Centers for Disease Control and Prevention, including providers at hospitals (academic detailing).
2. Training for health care providers regarding safe and responsible opioid prescribing, dosing, and tapering patients off opioids.
3. Continuing Medical Education (CME) on appropriate prescribing of opioids.
4. Support for non-opioid pain treatment alternatives, including training providers to offer or refer to multi-modal, evidence-informed treatment of pain.
5. Support enhancements or improvements to Prescription Drug Monitoring Programs (PDMPs), including but not limited to improvements that:
 1. Increase the number of prescribers using PDMPs;
 2. Improve point-of-care decision-making by increasing the quantity, quality, or format of data available to prescribers using PDMPs, by improving the interface that prescribers use to access PDMP data, or both; or

3. Enable states to use PDMP data in support of surveillance or intervention strategies, including MAT referrals and follow-up for individuals identified within PDMP data as likely to experience OUD in a manner that complies with all relevant privacy and security laws and rules.
6. Ensuring PDMPs incorporate available overdose/naloxone deployment data, including the United States Department of Transportation's Emergency Medical Technician overdose database in a manner that complies with all relevant privacy and security laws and rules.
7. Increase electronic prescribing to prevent diversion or forgery.
8. Educate Dispensers on appropriate opioid dispensing.

G. PREVENT MISUSE OF OPIOIDS

Support efforts to discourage or prevent misuse of opioids through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

1. Fund media campaigns to prevent opioid misuse.
2. Corrective advertising or affirmative public education campaigns based on evidence.
3. Public education relating to drug disposal.
4. Drug take-back disposal or destruction programs.
5. Fund community anti-drug coalitions that engage in drug prevention efforts.
6. Support community coalitions in implementing evidence-informed prevention, such as reduced social access and physical access, stigma reduction – including staffing, educational campaigns, support for people in treatment or recovery, or training of coalitions in evidence-informed implementation, including the Strategic Prevention Framework developed by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA).
7. Engage non-profits and faith-based communities as systems to support prevention.
8. Fund evidence-based prevention programs in schools or evidence-informed school and community education programs and campaigns for students, families, school employees, school athletic programs, parent-teacher and student associations, and others.
9. School-based or youth-focused programs or strategies that have demonstrated effectiveness in preventing drug misuse and seem likely to be effective in preventing the uptake and use of opioids.

10. Create of support community-based education or intervention services for families, youth, and adolescents at risk for OUD and any co-occurring SUD/MH conditions.
11. Support evidence-informed programs or curricula to address mental health needs of young people who may be at risk of misusing opioids or other drugs, including emotional modulation and resilience skills.
12. Support greater access to mental health services and supports for young people, including services and supports provided by school nurses, behavioral health workers or other school staff, to address mental health needs in young people that (when not properly addressed) increase the risk of opioid or another drug misuse.

H. PREVENT OVERDOSE DEATHS AND OTHER HARMS (HARM REDUCTION)

Support efforts to prevent or reduce overdose deaths or other opioid-related harms through evidence-based or evidence-informed programs or strategies that may include, but are not limited to, the following:

1. Increase availability and distribution of naloxone and other drugs that treat overdoses for first responders, overdose patients, individuals with OUD and their friends and family members, schools, community navigators and outreach workers, persons being released from jail or prison, or other members of the general public.
2. Public health entities providing free naloxone to anyone in the community.
3. Training and education regarding naloxone and other drugs that treat overdoses for first responders, overdose patients, patients taking opioids, families, schools, community support groups, and other members of the general public.
4. Enable school nurses and other school staff to respond to opioid overdoses, and provide them with naloxone, training, and support.
5. Expand, improve, or develop data tracking software and applications for overdoses/naloxone revivals.
6. Public education relating to emergency responses to overdoses.
7. Public education relating to immunity and Good Samaritan laws.
8. Educate first responders regarding the existence and operation of immunity and Good Samaritan laws.
9. Syringe service programs and other evidence-informed programs to reduce harms associated with intravenous drug use, including supplies, staffing, space, peer support services, referrals to treatment, fentanyl checking, connections to care, and the full range of harm reduction and treatment services provided by these programs.
10. Expand access to testing and treatment for infectious diseases such as HIV and Hepatitis C resulting from intravenous opioid use.

11. Support mobile units that offer or provide referrals to harm reduction services, treatment, recovery supports, health care, or other appropriate services to persons that use opioids or persons with OUD and any co-occurring SUD/MH conditions.
12. Provide training in harm reduction strategies to health care providers, students, peer recovery coaches, recovery outreach specialists, or other professionals that provide care to persons who use opioids or persons with OUD and any co-occurring SUD/MH conditions.
13. Support screening for fentanyl in routine clinical toxicology testing.

PART THREE: OTHER STRATEGIES

I. FIRST RESPONDERS

In addition to items in section C, D and H relating to first responders, support the following:

1. Educate law enforcement or other first responders regarding appropriate practices and precautions when dealing with fentanyl or other drugs.
2. Provision of wellness and support services for first responders and others who experience secondary trauma associated with opioid-related emergency events.

J. LEADERSHIP, PLANNING AND COORDINATION

Support efforts to provide leadership, planning, coordination, facilitations, training and technical assistance to abate the opioid epidemic through activities, programs, or strategies that may include, but are not limited to, the following:

1. Statewide, regional, local or community regional planning to identify root causes of addiction and overdose, goals for reducing harms related to the opioid epidemic, and areas and populations with the greatest needs for treatment intervention services, and to support training and technical assistance and other strategies to abate the opioid epidemic described in this opioid abatement strategy list.
2. A dashboard to (a) share reports, recommendations, or plans to spend opioid settlement funds; (b) to show how opioid settlement funds have been spent; (c) to report program or strategy outcomes; or (d) to track, share or visualize key opioid- or health-related indicators and supports as identified through collaborative statewide, regional, local or community processes.
3. Invest in infrastructure or staffing at government or not-for-profit agencies to support collaborative, cross-system coordination with the purpose of preventing overprescribing, opioid misuse, or opioid overdoses, treating those with OUD and any co-occurring SUD/MH conditions, supporting them in treatment or recovery, connecting them to care, or implementing other strategies to abate the opioid epidemic described in this opioid abatement strategy list.

4. Provide resources to staff government oversight and management of opioid abatement programs.

K. TRAINING

In addition to the training referred to throughout this document, support training to abate the opioid epidemic through activities, programs, or strategies that may include, but are not limited to, the following:

1. Provide funding for staff training or networking programs and services to improve the capability of government, community, and not-for-profit entities to abate the opioid crisis.
2. Support infrastructure and staffing for collaborative cross-system coordination to prevent opioid misuse, prevent overdoses, and treat those with OUD and any co-occurring SUD/MH conditions, or implement other strategies to abate the opioid epidemic described in this opioid abatement strategy list (e.g., health care, primary care, pharmacies, PDMPs, etc.).

L. RESEARCH

Support opioid abatement research that may include, but is not limited to, the following:

1. Monitoring, surveillance, data collection and evaluation of programs and strategies described in this opioid abatement strategy list.
2. Research non-opioid treatment of chronic pain.
3. Research on improved service delivery for modalities such as SBIRT that demonstrate promising but mixed results in populations vulnerable to opioid use disorders.
4. Research on novel harm reduction and prevention efforts such as the provision of fentanyl test strips.
5. Research on innovative supply-side enforcement efforts such as improved detection of mail-based delivery of synthetic opioids.
6. Expanded research on swift/certain/fair models to reduce and deter opioid misuse within criminal justice populations that build upon promising approaches used to address other substances (e.g. Hawaii HOPE and Dakota 24/7).
7. Epidemiological surveillance of OUD-related behaviors in critical populations including individuals entering the criminal justice system, including but not limited to approaches modeled on the Arrestee Drug Abuse Monitoring (ADAM) system.
8. Qualitative and quantitative research regarding public health risks and harm reduction opportunities within illicit drug markets, including surveys of market participants who sell or distribute illicit opioids.

9. Geospatial analysis of access barriers to MAT and their association with treatment engagement and treatment outcomes.

Schedule D

Tribal Abatement Strategies

The following is a non-exhaustive, illustrative list of culturally appropriate activities, practices, teachings or ceremonies that may, in the judgment of the Tribes, be aimed at or supportive of remediation and abatement of the opioid crisis within a tribal community.

Each of the 574 federally recognized Tribes in the United States has its own cultures, histories and traditions. Each Tribe is best suited to determine the most effective abatement strategies for the specific community it serves. The following list provides select examples of tribal abatement strategies and is not intended to limit the remediation and abatement activities for which any Tribe may utilize its share of Abatement Funds.

1. Traditional Activities Associated with Cultural Identity and Healing

Tribal cultural activities can help address historical and intergenerational trauma and feelings of cultural loss that may be underlying root causes and/or contributing factors to addiction. These can include, for example:

Utilization of traditional healers and spiritual and traditional approaches to healing;

Sweat lodges, sacred pipe ceremonies, smudging and other ceremonies;

Talking circles;

Cultural activities such as basket weaving, pottery making, drum making, canoe building, etc., depending on the Tribe;

Cultural and linguistic immersion programs.

These traditional activities may be combined with other treatment or included in integrated treatment models, as discussed below.

Example: Drum-Assisted Recovery Therapy for Native Americans (DARTNA) is supported by research. Drums are a sacred instrument in many American Indian and Alaska Native cultures and are often associated with ceremonies and healing. In addition to providing a sense of cultural connection, drumming may have physical and psychological effects that make it a promising focus for treatment.

Example: Some Tribes have utilized seasonal cultural immersion camps in lieu of or in combination with residential treatment for substance use disorder. Participants practice traditional lifeways, including hunting, fishing, living in traditional dwellings and cultural and/or spiritual practices during the course of treatment.

2. Culturally Competent Integrated Treatment Models

Example: The Swinomish Tribe designed and developed a unique treatment program called Didg^wálíč that integrates evidence-based chemical dependency

treatment with holistic, culturally competent care to successfully deal with the effects of opioid use disorder (OUD). Didg^wálič provides a full array of medical and social services, utilizing a model of care that centers on and incorporates the Tribe's culture and values. The Tribal government and individual Tribal members provide cultural leadership and advice on the use of Native language and practices in the program.

Example: The Tulalip Tribe operates the Healing Lodge, a culturally sensitive transitional home facility for tribal members who are seeking to recover from addiction. In addition to a clean and sober living environment, the facility provides transportation to and from Chemical Dependency/ Mental Wellness groups and individual counseling sessions, sober support groups and cultural activities such as sweats, powwow and family nights.

The program also connects residents with educational activities such as life skills trainings, budgeting, post generational trauma and Red Road to Wellbriety, a recovery and wellness program similar in some ways to the 12 Steps of AA but designed especially for Native American and following the teachings of the Medicine Wheel.

3. Culturally Grounded Community Prevention

Culturally competent prevention programs, tailored to each tribal community, can play an important role in stopping and reversing the spread of the opioid epidemic.

Example: The Healing of the Canoe is a collaborative project between the Suquamish Tribe, the Port Gamble S'Klallam Tribe and the University of Washington Alcohol and Drug Abuse Institute (ADAI). It has led to the development and dissemination of the Culturally Grounded Life Skills for Youth curriculum, an evidence-based, strengths- based life skills curriculum for Native youth that uses elements of a Tribe's culture to help prevent substance abuse and connect its youth to their tribal community and culture. It teaches Native youth the skills they need to navigate their life's journey without being pulled off course by alcohol or drugs, using tribal values, traditions and culture both as a compass to guide them and an anchor to ground them. By reversing the historical trauma of forced assimilation, this approach attacks the root cause of so much substance abuse among tribal youth.

Example: The Association of Village Council Presidents has responded to the opioid crisis through the Healthy Families Program, which promotes and supports whole health through the sharing, teaching, and practice of traditional values through Elluarluteng Illakutellriit - a framework illustrating the Yup'ik life cycle of traditional practices, values and beliefs from Yup'ik Elders. This framework functions alongside western and medical practices to help individuals overcome their addictions permanently.

4. Peacekeeping and Wellness Courts

Many Tribes have had success treating opioid offenders using traditional healing practices and alternative institutions, sometimes called wellness courts or peacekeeping courts.

Example: The Yurok Tribal Court, in coordination with the California State courts in Humboldt and Del Norte Counties, operates its Family Wellness Courts (FWC) for Yurok families suffering from opioid abuse problems. The FWC seeks to develop judicial practices that are consistent with Yurok tribal values and needs, combining the resources and expertise of both systems. It focuses on reintegrating tribal members into the culture and life of the Yurok community and helping them establish a drug-free lifestyle.

5. Community Workforce Development and Training

Cultural competency training as well as community workforce development can be a critical tool for addressing gaps in services, especially in rural and remote tribal communities, where it can be extremely difficult to recruit and retain qualified health care professionals.

Example: In Alaska, the Community Health Aide Program (CHAP) has increased access to medical treatment to more than 170 rural Alaskan villages utilizing a workforce development model geared toward Native people. Under CHAP, individuals selected by their communities are provided with training as community health aides and practitioners to work in rural villages under the supervision of, and in collaboration with, higher level medical professionals, often aided by telemedicine technology. As part of CHAP, behavioral health aides (BHAs) are trained as counselors, educators and advocates to help address mental health and addiction issues.

Example: Part of the Swinomish Tribe's Didg^wálič treatment model, discussed above, is training for Tribal members with a goal of building a new generation of clinically trained and culturally competent Native counselors and providers.

Schedule T
PARTICIPATING TRIBES AND TRIBAL ALLOCATION DISTRIBUTION
PERCENTAGES

[Reserved - to be added post-Effective Date]

EXHIBIT E

Tribal Participation Form **(Multi-Defendant Settlements Identified Below)**

Tribal Entity:
Authorized Official:
Address 1:
Address 2:
City, State, Zip:
Phone:
Email:

The tribal entity identified above (“**Tribe**”), in order to obtain and in consideration for the benefits provided to the Tribe pursuant to the Tribal Settlement Agreements identified in Paragraph 13 below (collectively, “**Multi-Defendant Settlements**”), and acting through the undersigned authorized official, is or may be an “Eligible Entity” as defined by the Multi-Defendant Settlements, and hereby elects to participate in all of the Multi-Defendant Settlements as a “Participating Tribe” as defined by the Multi-Defendant Settlements, release all Released Claims against all Released Entities in each of the Multi-Defendant Settlements, and agrees as follows.

1. The Tribe is aware of and has reviewed all of the Multi-Defendant Settlements identified in Paragraph 13 below, understands that all terms in this Tribal Participation Form (“**Form**”) have the meanings defined therein, and agrees that by this Form, the Tribe elects to participate in all of Multi-Defendant Settlements set forth in Paragraph 13 below and become a Participating Tribe as provided therein.
2. The Tribe agrees to the terms of all of the Multi-Defendant Settlements pertaining to Tribes as defined therein.
3. By agreeing to the terms of the Multi-Defendant Settlements and becoming a Releasor, the Tribe is entitled to the benefits provided therein, including, if applicable, monetary payments and Settlement Product beginning after the Effective Date.
4. The Tribe agrees to use any monies it receives through the Multi-Defendant Settlements solely for the purposes provided therein.
5. By signing this Participation Form, the Tribe agrees that, pursuant to the Multi-Defendant Settlements, Special Master David Cohen as Tribal Allocation Appointee will determine the final inter-tribal allocation according to the terms of the Multi-Defendant Settlements.
6. The Tribe agrees that any disputes arising out of any Multi-Defendant Settlement shall be heard before Special Master David Cohen as the arbitrator designated by the parties in the Multi-Defendant Settlements to resolve disputes through binding arbitration.
7. The Tribe has the right to enforce each of the Multi-Defendant Settlements as provided therein.

8. The Tribe, as a Participating Tribe, hereby becomes a Releasor for all purposes in each of the Multi-Defendant Settlements, including but not limited to all provisions of Section II (Release). The Tribe as Releasor includes (1) the Tribe; and (2) without limitation and to the maximum extent of the power of the Tribe to release Claims, (a) the Tribe's departments, agencies, divisions, boards, commissions, subdivisions, districts, instrumentalities of any kind and attorneys, and any person in their official capacity whether elected or appointed to serve any of the foregoing and any agency, person, or other entity claiming by or through any of the foregoing, (b) any public entities, public instrumentalities, public educational institutions, unincorporated districts, fire districts, irrigation districts, water districts, sheriffs and law enforcement districts, emergency services districts, school districts, healthcare districts, hospital districts, library districts, coroner's offices, public transportation authorities, and other special districts, of the Tribe, including those with the regulatory authority to enforce tribal controlled substances acts or the authority to bring Claims related to Covered Conduct seeking money (including abatement or remediation and/or restitution) or revoke pharmaceutical licenses, within the territory governed by the Tribe, and (c) any person or entity acting in a *parens patriae*, sovereign, quasi-sovereign, private attorney general, *qui tam*, taxpayer, or other capacity seeking relief, including but not limited to fines, penalties, or punitive damages, on behalf of or generally applicable to the general public with respect to the Tribe. All such entities and any other entity identified in the definition of Releasor provide for a release to the fullest extent of its authority. As a Releasor, the Tribe (for itself and its Releasors) hereby absolutely, unconditionally, and irrevocably covenants not to bring, file, or claim, or to cause, assist in bringing, or permit to be brought, filed, or claimed, or to otherwise seek to establish liability for any Released Claims against any Released Entity in each of the Multi-Defendant Settlements in any forum whatsoever. The releases provided for in the Multi-Defendant Settlements are intended by the Parties to be as broad as possible and shall be interpreted so as to give the Released Entities in each of the Multi-Defendant Settlements the broadest possible bar against any liability relating in any way to Released Claims and extend to the full extent of the power of each Releasor to release its Claims. The releases shall be a complete bar to any Released Claim.
9. In connection with the releases provided for in the Multi-Defendant Settlements, the Tribe (for itself and its Releasors) expressly waives, releases, and forever discharges any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or tribal or other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to § 1542 of the California Civil Code, which reads:
- General Release; extent.** A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.
10. The Tribe may hereafter discover facts other than or different from those which it knows, believes, or assumes to be true with respect to the Released Claims, but the Tribe (for itself and its Releasors) hereby expressly waives and fully, finally, and forever settles, releases, and discharges, upon the Effective Date, any and all Released Claims that may exist as of such date but which Releasors do not know or suspect to exist, whether through ignorance,

oversight, error, negligence or through no fault whatsoever, and which, if known, would materially affect the Tribe's decision to enter into the Multi-Defendant Settlements or the Tribe's decision to participate in the Multi-Defendant Settlements.

11. Within 30 days of signing the Tribal Participation Form, and prior to the Effective Date set forth in the Multi-Defendant Settlements, the Tribe shall cease all litigation activity as to each of the Defendants identified in the Multi-Defendant Settlements and provide to Special Master Cohen and his TLC designee a dismissal with prejudice of any Released Claims that it has filed. Upon the Effective Date, the with-prejudice dismissals shall be provided to the relevant Defendants pursuant to the terms of the Multi-Defendant Settlements with a stipulation for filing.
12. Nothing herein is intended to modify in any way the terms of any Multi-Defendant Settlement, to which Tribe hereby agrees. To the extent this Form is interpreted differently from the Multi-Defendant Settlements in any respect, the Multi-Defendant Settlements control.
13. The Tribe hereby ELECTS TO PARTICIPATE in the following Multi-Defendant Settlements as a Participating Tribe for which it is an Eligible Entity pursuant to the terms of those Multi-Defendant Agreements:
 - a. **Settlement Agreement for Alvogen Pharmaceutical Company dated April 4, 2025.**
 - b. **Settlement Agreement for Apotex Corp. dated April 4, 2025.**
 - c. **Settlement Agreement for Amneal Pharmaceuticals, Inc. dated April 4, 2025.**
 - d. **Settlement Agreement for Hikma Pharmaceuticals USA Inc. dated April 4, 2025.**
 - e. **Settlement Agreement for Indivior Inc. dated April 4, 2025.**
 - f. **Settlement Agreement for Viatris Inc. dated April 4, 2025 ("Mylan Settlement Agreement").**
 - g. **Settlement Agreement for Sandoz Inc. dated August 31, 2023.**
 - h. **Settlement Agreement for Sun Pharmaceutical Industries Inc. dated April 4, 2025.**
 - i. **Settlement Agreement for Zydus Pharmaceuticals (USA) Inc. dated April 4, 2025.**
 - j. **Settlement Agreement for The Kroger Co. dated July 17, 2024.**

I have all necessary power and authorization to execute this Form on behalf of the Tribe.

Signature: _____

Name: _____

Title: _____

Date: _____

EXHIBIT F

Released Entities

List of Joint Ventures, Subsidiaries, Affiliates, and Predecessors

The following is a list of subsidiaries, affiliates, and predecessor entities of Viatris Inc. as of December 31, 2024. Viatris Inc. is not a subsidiary of any other corporation.

- | | |
|--|---|
| 1. AB Medical PRS B.V. | 32. Bertek, Inc. |
| 2. Abbex AB | 33. Bertek International, Inc. |
| 3. Acepharm Ltd. | 34. Bertek Pharmaceuticals Inc. |
| 4. Acton Pharmaceuticals, Inc. | 35. Bertek Pharmaceuticals International Limited |
| 5. Agila (NZ) Pty Ltd. | 36. Beteiligungs GmbH |
| 6. Agila Australasia Pty Ltd. | 37. BGP Pharma ULC |
| 7. Agila Especialidades Farmaceutica Ltda | 38. BGP Pharmaceutical Products Ltd. |
| 8. Agila Farmaceutica Participacoes Ltda | 39. BGP Products |
| 9. Agila Jamp Canada Inc. | 40. BGP Products AB |
| 10. Agila Marketing e Distribuicao de Produtos Hospitalares Ltda | 41. BGP Products Limited |
| 11. Agila Specialties (Holdings) Cyprus Limited | 42. BGP Products Operations GmbH |
| 12. Agila Specialties Americas Limited | 43. BGP Products S.à r.l. |
| 13. Agila Specialties Global Pte. Ltd. | 44. BGP Products S.r.l. |
| 14. Agila Specialties Inc. | 45. BGP Products s.r.o. |
| 15. Agila Specialties Investment Ltd. | 46. BGP Products Switzerland GmbH |
| 16. Agila Specialties Investments Limited | 47. BGP Products, Unipessoal, LDA |
| 17. Agila Specialties Pharma Corporation | 48. Bioniche Pharma (Canada) Ltd. |
| 18. Agila Specialties Polska sp. Zo.o | 49. Bioniche Pharma Acquisition Ltd. |
| 19. Agila Specialties Private Ltd. | 50. Bioniche Pharma Group Limited |
| 20. Agila Specialties UK Ltd. | 51. Bioniche Pharma Holdings Limited |
| 21. Aktuapharma N.V. | 52. Bioniche Pharma USA Inc. |
| 22. Alaven Pharmaceutical LLC | 53. Bioniche Pharma USA LLC |
| 23. Allgemeine Beteiligungsgesellschaft Genius Deutschland mbH | 54. Bioniche Teoranta |
| 24. Alphapharm Pty. Ltd. | 55. Brand & Company |
| 25. ALVP Holdings, LLC | 56. Canton Fuels Company, LLC |
| 26. American Triumvirate Insurance Company | 57. Catalist Pty Ltd. |
| 27. Aphaarma B.V. | 58. Cenetogrel LLC |
| 28. Apothecon B.V. | 59. Chouteau Fuels Company, LLC |
| 29. Aprime N.V. | 60. Concord Biotech Limited |
| 30. Arcana Arzneimittel GmbH | 61. DAA Pharma N.V. |
| 31. Astrix Laboratories Limited | 62. DAA Pharma S.A. |
| | 63. Dafeng Mchem Pharmaceutical Chemical Co. Ltd. |
| | 64. DCI Pharma S.A. |

65. DCI Pharma S.a.r.l.
66. Delcor Asset Corporation
67. Denco Asset, LLC
68. Deogun Manufacturing Company, LLC
69. Deogun Manufacturing, LLC
70. DERMOGROUP S.r.l.
71. Dey Laboratories L.P.
72. Dey Limited Partner LLC
73. Dey Limited Partner, Inc.
74. Dey Pharma, L.P.
75. Dey, Inc.
76. Dey, L.P.
77. Docpharma B.V.B.A.
78. Docpharma Luxembourg S.a r.l.
79. Docpharma Luxembourg Saarl
80. Docpharma N.V.
81. Dow B. Hickam
82. DPT Laboratories, Ltd.
83. Ellem Lakemedel AB
84. EMD, Inc.
85. Erste Madaus Beteiligungs GmbH
86. Euro Mylan B.V.
87. Ezio Pharma, Inc.
88. Famy Life Sciences Private Limited
89. FamyGen Life Sciences, Inc.
90. Farma 1 S.r.l
91. Farma 1 S.R.L.
92. Farma Plus AS
93. Franklin Pharmaceutical LLC
94. Fundacion Mylan para la Salud
95. Fundacion Viatrix para la Salud
96. Fuzhou Airuike (R&D Co.)
97. G.D. Searle LLC
98. Galmeda GmbH
99. Ge Zhi (Hainan) Health Investment Co., Ltd.
100. Ge Zhi (Hainan) Medical Technology Co
101. Ge Zhi (Hainan) Medical Technology Co., Ltd.
102. Ge Zhi Health Management Co., Ltd.
103. Generics (U.K.) Limited
104. Generics [U.K.] Ltd.
105. Generics Pharma Hellas E.P.E.
106. Generics Pharma Hellas Ltd.
107. Genpharm General Partner, Inc.
108. Genpharm Limited Partner, Inc.
109. Genpharm ULC
110. Genpharm, L.P.
111. Gezhi (Hainan) Health Investment Co., Ltd.
112. Gezhi (Hainan) Medical Technology Co
113. Gezhi Health Management Co., Ltd.
114. Greenstone LLC
115. Hai Nan Ge Zhi Telemedicine Center Co., Ltd.
116. Hospithera N.V.
117. Idorsia (Beijing) Pharmaceuticals Ltd.
118. Integral S.A.
119. Ipex AB
120. Ipex Medical AB
121. Iris Purchaser Inc.
122. Jiangsu Matrix Pharmaceutical Chemical Ltd.
123. KORIN Grundstücksgesellschaft mbH & Co. Projekt 31 KG
124. Laboratoires Madaus S.A.S.
125. Laboratorios Anova - Produtos Famaceuticos, LDA
126. Laboratorios Delta, S.A.
127. Laboratorios Parke Davis, S.L.U.
128. Lotic.ai, Inc.
129. Madaus GmbH
130. Madaus Inc.
131. Mapi Pharma Ltd.
132. Marquis Industrial Company, LLC
133. Matrix Laboratories (Singapore) Pte Limited
134. Matrix Laboratories (Xiamen) Ltd.
135. Matrix Laboratories B.V.
136. Matrix Laboratories B.V.B.A.
137. Matrix Laboratories Inc.
138. Matrix Laboratories Limited
139. Matrix Laboratories N.V.
140. Matrix Laboratories Singapore (Pte.) Ltd.
141. Matrix Pharma Group (Xiamen) Limited
142. Mayapple Acquisition, LLC

143. McDermott Laboratories Limited
144. Mchem Research & Development Co., Ltd.
145. MEDA
146. MEDA A/S
147. Meda AB
148. Meda AS
149. MEDA Germany Holding GmbH
150. Meda Health Sales Ireland Limited
151. Meda Holding S.A.S.
152. MEDA Manufacturing GmbH
153. Meda Manufacturing S.A.S.
154. Meda OTC AB
155. Meda Oy
156. Meda Phama, S. de R.L. de C.V.
157. Meda Pharma (Thailand) Co., Ltd.
158. Meda Pharma B.V.
159. MEDA Pharma GmbH
160. MEDA Pharma GmbH & Co. KG
161. MEDA PHARMA HUNGARY KERESKEDELMI Kft.
162. Meda Pharma İlaç Sanayi ve Ticaret Limited Sirketi
163. Meda Pharma N.V.
164. Meda Pharma S.à r.l.
165. Meda Pharma S.A.S.
166. Meda Pharma S.p.A.
167. MEDA Pharma s.r.o.
168. Meda Pharma Servicios, S. de R.L. de C.V.
169. Meda Pharma South Africa (Pty) Limited
170. Meda Pharma spol. s.r.o.
171. Meda Pharma spol. s.r.o.- in liquidation
172. Meda Pharma, S.L.
173. Meda Pharmaceuticals Inc.
174. Meda Pharmaceuticals Ltd
175. Meda Pharmaceuticals MEA FZ-LLC
176. Meda Pharmaceuticals S.A.
177. MEDA Pharmaceuticals Switzerland GmbH
178. Medicine Meda Pharmaceutical Information Consultancy (Beijing) Co., Ltd.
179. Milan Holding Inc.
180. Mithra Pharmaceuticals S.A.
181. MLI Acquisition Corp. II
182. MLRE LLC
183. Moon of PA Inc.
184. MP Air Inc.
185. MP Laboratories (Mauritius) Ltd
186. MWB Pharma GmbH
187. Mygoldex Pharma Ltd.
188. Mylan
189. Mylan (Gibraltar) 1 Ltd.
190. Mylan (Gibraltar) 2 Ltd.
191. Mylan (Gibraltar) 3 Ltd.
192. Mylan (Gibraltar) 4 Limited
193. Mylan (Gibraltar) 5 Limited
194. Mylan (Gibraltar) 6 Limited
195. Mylan (Gibraltar) 7 Limited
196. Mylan (Gibraltar) 8 Limited
197. Mylan (Gibraltar) 9 Limited
198. Mylan (Proprietary) Limited
199. Mylan (Taiwan) Limited
200. Mylan AB
201. Mylan API Inc.
202. Mylan API US LLC
203. Mylan ApS
204. Mylan AS
205. Mylan ASI LLC
206. Mylan Australia 1 Pty. Ltd.
207. Mylan Australia 2 Pty. Ltd.
208. Mylan Australia Holding Pty. Ltd.
209. Mylan Australia Pty Limited
210. Mylan B.V.
211. Mylan B.V.B.A.
212. Mylan Bermuda Ltd.
213. Mylan Bertek Pharmaceuticals Inc.
214. Mylan Brasil Distribuidora de Medicamentos Ltda
215. Mylan Brasil Distribuidora de Medicamentos Ltda.
216. Mylan Canada, ULC
217. Mylan Caribe, Inc.
218. Mylan Consumer Healthcare, Inc.
219. Mylan d.o.o.

220. Mylan D.T. (U.S.) Holdings, Inc.
221. Mylan D.T. DPT Partner Sub, LLC
222. Mylan D.T., Inc.
223. Mylan Delaware Inc.
224. Mylan Denmark ApS
225. Mylan dura GmbH
226. Mylan EMEA S.A.S.
227. Mylan EOOD
228. Mylan EPD BVBA
229. Mylan EPD G.K.
230. Mylan EPD Kft.
231. Mylan EPD Lda.
232. Mylan EPD Sp. z o.o.
233. Mylan Europe B.V.B.A.
234. Mylan FCT
235. Mylan France S.A.S.
236. Mylan FZ-LLC
237. Mylan Generics France Holding S.A.S.
238. Mylan Generics Limited
239. Mylan Germany GmbH
240. Mylan GmbH
241. Mylan Group B.V.
242. Mylan Health Management LLC
243. Mylan Health Pty. Ltd.
244. Mylan Healthcare B.V.
245. MYLAN HEALTHCARE CZ s.r.o.
246. Mylan Healthcare GmbH
247. Mylan Healthcare Norge AS
248. Mylan Healthcare S.p. z o.o.
249. Mylan Healthcare Sdn. Bhd.
250. Mylan Healthcare Sp. z o.o.
251. Mylan Healthcare UAB
252. Mylan Healthcare, farmacevtsko podjetje, d.o.o.
253. Mylan Holdings Acquisition 2 Limited
254. Mylan Holdings Acquisition Limited
255. Mylan Holdings GmbH
256. Mylan Holdings I LLC
257. Mylan Holdings II LLC
258. Mylan Holdings Inc.
259. Mylan Holdings Ltd.
260. Mylan Holdings Sub Inc.
261. Mylan Hospital AS
262. Mylan Hrvatska d.o.o.
263. Mylan Hungary Kft.
264. Mylan II B.V.
265. Mylan Inc.
266. Mylan India Private Limited
267. Mylan Institutional Inc.
268. Mylan Institutional LLC
269. Mylan International Holdings, Inc.
270. Mylan Investment Holdings 4 LLC
271. Mylan Investment Holdings 5 LLC
272. Mylan Investment Holdings 6 LLC
273. Mylan Investments Limited
274. Mylan IRE Healthcare Limited
275. Mylan Ireland Holdings Limited
276. Mylan Ireland Investment Designated Activity Company
277. Mylan Ireland Limited
278. Mylan Italia S.r.l.
279. Mylan Kft.
280. Mylan Laboratories Inc.
281. Mylan Laboratories India Private Limited
282. Mylan Laboratories Limited
283. Mylan Laboratories S.A.S.
284. Mylan Laboratórios Ltda
285. Mylan LHC Inc.
286. Mylan LLC
287. Mylan Luxembourg 1 S.à.r.l.
288. Mylan Luxembourg 2 S.à.r.l.
289. Mylan Luxembourg 3 S.à.r.l.
290. Mylan Luxembourg 4 S.à.r.l.
291. Mylan Luxembourg 5 S.a.r.l.
292. Mylan Luxembourg 6 S.à.r.l.
293. Mylan Luxembourg 7 S.à.r.l.
294. Mylan Luxembourg 8 S.a.r.l.
295. Mylan Luxembourg 9 S.à r.l.
296. Mylan Luxembourg L1 S.C.S.
297. Mylan Luxembourg L2 S.C.S.
298. Mylan Luxembourg L3 S.C.S.
299. Mylan Luxembourg L4 S.C.S.
300. Mylan Luxembourg S.à r.l.
301. Mylan Malaysia SDN. BHD.
302. Mylan Medical S.A.S.
303. Mylan N.V.

304. Mylan Netherlands B.V.
305. Mylan Netherlands BV
306. Mylan New Zealand Limited
307. Mylan New Zealand Ltd.
308. Mylan Österreich GmbH
309. Mylan Oy
310. Mylan Pharma (Canada) Ltd.
311. Mylan Pharma Acquisition Limited
312. Mylan Pharma GmbH
313. Mylan Pharma Group Limited
314. Mylan Pharma Holdings Limited
315. Mylan Pharma Holdings Limited Ireland
316. Mylan Pharma LLC
317. Mylan Pharma UK Limited
318. Mylan Pharmaceutical Hong Kong Limited
319. Mylan Pharmaceutical Science and Technology (Shanghai) Co., Ltd.
320. Mylan Pharmaceuticals
321. Mylan Pharmaceuticals (Pty) Ltd.
322. Mylan Pharmaceuticals GmbH
323. Mylan Pharmaceuticals Inc.
324. Mylan Pharmaceuticals Limited
325. Mylan Pharmaceuticals LLC
326. Mylan Pharmaceuticals Private Limited
327. Mylan Pharmaceuticals Pte. Ltd.
328. Mylan Pharmaceuticals S.A.
329. Mylan Pharmaceuticals S.A.S.
330. Mylan Pharmaceuticals S.L.
331. Mylan Pharmaceuticals S.L.U.
332. Mylan Pharmaceuticals s.r.o.
333. Mylan Pharmaceuticals spol s.r.o.
334. Mylan Pharmaceuticals ULC
335. Mylan Philippines Inc.
336. Mylan Products Limited
337. Mylan S.A.
338. Mylan S.A.S.
339. Mylan S.p.A.
340. Mylan s.r.o.
341. Mylan Securitization LLC
342. Mylan Seiyaku Ltd.
343. Mylan Singapore Pte. Ltd.
344. Mylan Sp. Z.o.o.
345. Mylan Special Investments II, LLC
346. Mylan Special Investments III, LLC
347. Mylan Special Investments IV, LLC
348. Mylan Special Investments LLC
349. Mylan Special Investments V, LLC
350. Mylan Special Investments VI, LLC
351. Mylan Specialty L.P.
352. Mylan Sweden Holdings AB
353. Mylan Switzerland GmbH
354. Mylan Technologies Inc.
355. Mylan Teoranta
356. Mylan UK Healthcare Limited
357. Mylan, Lda
358. Neo-Farmaceutica, S.A.
359. New Moon B.V.
360. New Moon Holdings, LLC
361. New Mylan Delaware Financing, LLC
362. Nimes Inc.
363. Nutripharm N.A
364. Nutripharm S.A.
365. Onco Laboratories Limited
366. Onco Therapies Ltd.
367. Oy
368. Oyster Point Pharma, Inc.
369. Pacific Pharmaceuticals Ltd.
370. PEMB OFG Spain Holding, S.L.
371. PF Asia Manufacturing B.V.
372. PF OFG Ireland 1 B.V.
373. PF OFG Mexico B.V.
374. PF OFG Philippines B.V.
375. PF OFG Philippines, Inc.
376. PF OFG Spain B.V.
377. PFE Wyeth Holdings LLC
378. Pfizer Advanced Pharmaceutical Company Limited
379. Pfizer Africa & Middle East for Pharmaceuticals,
380. Pfizer Africa & Middle East for Pharmaceuticals, Veterinarian Products & Chemicals S.A.E.
381. Pfizer Asia Pacific Pte Ltd.
382. Pfizer Egypt S.A.E.
383. Pfizer Enterprise Holdings B.V.

384. Pfizer Enterprises LLC
385. Pfizer Established Medicine Italy S.r.l.
386. Pfizer GEP, S.L.U.
387. Pfizer Holdings G.K.
388. Pfizer Ilaclari Limited Sirketi
389. Pfizer Innovative Supply Point International BVBA
390. Pfizer LLC
391. Pfizer Middle East for Pharmaceuticals, Animal Health & Chemicals S.A.E
392. Pfizer OFG Germany GmbH
393. Pfizer Parke Davis (Thailand) Ltd.
394. Pfizer Parke Davis Sdn. Bhd.
395. Pfizer PFE France
396. Pfizer PFE Ireland Pharmaceuticals Holdings 1 B.V.
397. Pfizer PFE Private Limited
398. Pfizer PFE Singapore Pte. Ltd.
399. Pfizer PFE Spain Holding, S.L.
400. Pfizer PFE Switzerland GmbH
401. Pfizer PFE Turkey Holding 1 B.V.
402. Pfizer PFE US Holdings 4 LLC
403. Pfizer PFE US Holdings 5 LLC
404. Pfizer Pharmaceuticals LLC
405. Pfizer Pharmaceuticals Ltd.
406. Pfizer UPJ G.K.
407. Pfizer Upjohn Hong Kong Limited
408. Pfizer Upjohn Korea Limited
409. Pfizer Upjohn Management Co., Ltd
410. Pfizer Upjohn Management Co., Ltd.
411. Pharmazeutische Union GmbH
412. PharmLog Pharma Logistik GmbH
413. Powder Street, LLC
414. Prasfarma Oncologicos S.L.
415. Prempharm Inc.
416. Prestium Pharma, Inc.
417. QD Pharmaceuticals ULC
418. Qualimed S.A.S.
419. RCF 4 LLC
420. RCF 4, LLC
421. Recip AB
422. Recip Lakemedel AB
423. Renaissance Acquisition Holdings, LLC
424. ROTTAPHARM | MAD AUS GmbH
425. ROTTAPHARM |MAD AUS GmbH
426. Rottapharm Hellas S.A.
427. Rottapharm Limited
428. Rottapharm S.A.S.
429. Rottapharm S.p.A.
430. Sagent Agila LLC
431. Scandinavian Pharmaceuticals-Generics AB
432. Scandpharm Marketing AB
433. SCP Pharmaceuticals (Proprietary) Limited
434. SCP Pharmaceuticals (Pty) Ltd.
435. Senador Laboratories Private Limited
436. Serviphar S.A.
437. Servipharma N.V.
438. Servipharma S.A.
439. Shanghai Fine Source Co. Ltd.
440. SIA "Meda Pharma"
441. SIA "Mylan Healthcare"
442. SIA Meda Pharma
443. SIA Mylan Healthcare
444. SIM S.A.
445. Societe de Participation Pharmaceutique S.A.S.
446. Somerset Pharmaceuticals UK Limited
447. Somerset Pharmaceuticals, Inc.
448. Synerx Pharma, LLC
449. Tianish Laboratories Private Limited
450. Tropon U-Kasse GmbH
451. Troponwerke GmbH
452. UDL Laboratories, Inc.
453. Unit Dose Laboratories, Inc.
454. Upjohn (Malaysia) Sdn Bhd.
455. Upjohn (Thailand) Limited
456. Upjohn Australia Pty Ltd.
457. Upjohn Belgium B.V.
458. Upjohn Brasil Importadora e Distribuidora de Medicamentos Ltda
459. Upjohn BV
460. Upjohn Canada ULC
461. Upjohn EESV
462. Upjohn Europe Holdings B.V.

463. Upjohn Export B.V.
464. Upjohn Finance B.V.
465. Upjohn Global Holdings B.V.
466. Upjohn Group Holdings B.V.
467. Upjohn Hellas Pharmaceutical Limited Liability Company
468. Upjohn Intermediate Holdings B.V.
469. Upjohn International Holdings B.V.
470. Upjohn Manufacturing Ireland Unlimited
471. Upjohn Middle East FZ-LLC
472. Upjohn Netherlands B.V.
473. Upjohn New Zealand ULC
474. Upjohn Pharma México, S. de R.L. de C.V.
475. Upjohn Saidal Pharma
476. Upjohn South Africa Proprietary Limited
477. Upjohn SRL
478. Upjohn UK 2 Ltd.
479. Upjohn UK Limited
480. Upjohn US 1 LLC
481. Upjohn US 2 LLC
482. Upjohn US Employment Inc.
483. Upjohn US Holdings Inc.
484. Upjohn Vietnam Dutch B.V.
485. Upjohn Worldwide Holdings Inc.
486. Utah Acquisition Holdco Inc.
487. Utah Acquisition Sub Inc.
488. V Investment Co.
489. Value Pharma International
490. Value Pharma International N.V.
491. Vascucare N.V.
492. Vascumed N.V.
493. Verwaltungsgesellschaft Neurather Ring GmbH
494. Veterinarian Products & Chemicals S.A.E.
495. VI Lux Newco S.à r.l.
496. Viatris (Hainan) Investment Co., Ltd.
497. Viatris (Thailand) Limited
498. Viatris AB
499. Viatris ApS
500. Viatris Arabia Limited "LLC"
501. Viatris Arabia Regional Headquarters
502. Viatris AS
503. Viatris Asia Pacific Pte Ltd.
504. Viatris Asia Pacific Pte. Ltd.
505. Viatris Austria GmbH
506. Viatris BH
507. Viatris BH d.o.o.
508. Viatris BH, drustvo sa ogranicenom odgovornoscu za trgovinu i usluge
509. Viatris Brasil Importadora e Distribuidora De Medicamentos Ltda
510. Viatris BV
511. Viatris CZ s.r.o.
512. Viatris Egypt Pharmaceutical S.A.E.
513. Viatris Egypt S.A.E.
514. Viatris Enterprise Holding B.V.
515. Viatris Enterprises LLC
516. Viatris Farmaceutica DO Brasil Ltda.
517. VIATRIS GmbH
518. Viatris GX BV
519. Viatris Health Care
520. Viatris Healthcare
521. Viatris Healthcare (Pty) Ltd
522. Viatris Healthcare (Thailand) Limited
523. Viatris Healthcare (Thailand) Ltd.
524. Viatris Healthcare d.o.o.
525. Viatris Healthcare Drustvo SA Ogranichenom Odgovornoscu Beograd
526. Viatris Healthcare G.K
527. Viatris Healthcare G.K.
528. Viatris Healthcare GmbH
529. Viatris Healthcare Hong Kong Limited
530. Viatris Healthcare Kft.
531. Viatris Healthcare Limited
532. Viatris Healthcare Mexico S. de R.L. de C.V.
533. Viatris Healthcare NV
534. Viatris Healthcare S.L.
535. Viatris Healthcare Sdn. Bhd.
536. Viatris Healthcare spółka z o.o.
537. Viatris Healthcare, Lda.
538. Viatris Hellas Limited Liability Company
539. Viatris Hellas Pharmaceutical Limited Liability Company

540. Viatris Holdings LLC
541. Viatris Hrvatska d.o.o.
542. Viatris Ilaclari Limited Sirketi
543. Viatris Inc.
544. Viatris Innovation GmbH
545. Viatris Innovative GmbH
546. Viatris International Supply Point BV
547. Viatris Ireland Holding B.V.
548. Viatris Italia S.r.l.
549. Viatris Korea
550. Viatris Limited
551. Viatris Limited Liability Partnership
552. Viatris Limited Upjohn New Zealand ULC
553. Viatris LLC
554. Viatris Manufacturing B.V.
555. Viatris Medical
556. Viatris Mexico Holding B.V.
557. Viatris Middle East FZ-LLC
558. Viatris Netherlands B.V.
559. Viatris OÜ
560. Viatris Overseas Inc.
561. Viatris Oy
562. Viatris Pharma GmbH
563. Viatris Pharma S.r.l.
564. Viatris Pharmaceutical Co., Ltd.
565. Viatris Pharmaceutical Co., Ltd.China
566. Viatris Pharmaceutical Company Limited
567. Viatris Pharmaceuticals (Dalian) Co., Ltd.
568. Viatris Pharmaceuticals (Thailand) Limited
569. Viatris Pharmaceuticals Holding B.V.
570. Viatris Pharmaceuticals Japan G.K.
571. Viatris Pharmaceuticals Japan Inc.
572. Viatris Pharmaceuticals LLC
573. Viatris Pharmaceuticals Pty Ltd
574. Viatris Pharmaceuticals S.A.S.
575. Viatris Pharmaceuticals S.L.
576. Viatris Pharmaceuticals, Inc.
577. Viatris Pharmaceuticals, S.L.
578. Viatris Philippines Holding B.V.
579. Viatris Private Limited
580. Viatris Pty. Ltd.
581. Viatris Pty. Ltd.Upjohn Australia Pty Ltd.
582. Viatris Sante
583. Viatris Sdn Bhd.
584. Viatris Sdn. Bhd.
585. Viatris Services Kft.
586. Viatris SIA
587. Viatris Singapore Pte Ltd.
588. Viatris Slovakia s.r.o.
589. Viatris South Africa (Proprietary) Limited
590. Viatris Spain Holding B.V.
591. Viatris Specialty LLC
592. Viatris Trade sp. z o.o.
593. Viatris Turkey Holding B.V.
594. Viatris UAB
595. Viatris UK Healthcare Limited
596. Viatris Up
597. Viatris US Holdings 4 LLC
598. Viatris US Holdings 5 LLC
599. Viatris US Supply Hub LLC
600. Viatris Vietnam Limited Company
601. Viatris, farmacevtsko podjetje, d.o.o.
602. Viatris, Inc.
603. Wallace Pharmaceuticals Inc.
604. Xiamen Beacon Pharmaceutical Manufacturing Co. Ltd.
605. Xiamen Mchem Laboratories Limited
606. Xiamen Mchem Pharma Group Limited
607. Xiamen Mchem Research & Development Co. Ltd.
608. Xixia Pharmaceuticals (Proprietary) Limited
609. Xixia Pharmaceuticals (Pty) Ltd.
610. ZpearPoint AS
611. Zweite Madaus Beteiligungs GmbH

EXHIBIT G

[INTENTIONALLY OMITTED]

EXHIBIT H-1
Payment Schedule

Payment Date	Mylan Settlement Trust
Year 1-July 25, 2025	\$894,130.00
Year 2-March 1, 2026	\$894,130.00
Year 3-March 1, 2027	\$1,300,554.00
Year 4-March 1, 2028	\$1,300,554.00
Year 5-March 1, 2029	\$1,300,554.00
Year 6-March 1, 2030	\$1,300,554.00
Year 7-March 1, 2031	\$1,300,554.00
Year 8-March 1, 2032	\$1,300,554.00
Year 9-March 1, 2033	0
TOTAL	\$9,591,584.00

EXHIBIT H-2
Allocation Between TAFT and Attorney Fee Fund

Payment Year	Attorney Fee and Cost Fund	TAFT XV	Overall Total Payments (Attorney Fee and Cost Fund + TAFT XV)
Year 1-July 25, 2025	\$134,119.50	\$760,010.50	\$894,130.00
Year 2-March 1, 2026	\$134,119.50	\$760,010.50	\$894,130.00
Year 3-March 1, 2027	\$195,083.10	\$1,105,470.90	\$1,300,554.00
Year 4-March 1, 2028	\$195,083.10	\$1,105,470.90	\$1,300,554.00
Year 5-March 1, 2029	\$195,083.10	\$1,105,470.90	\$1,300,554.00
Year 6-March 1, 2030	\$195,083.10	\$1,105,470.90	\$1,300,554.00
Year 7-March 1, 2031	\$195,083.10	\$1,105,470.90	\$1,300,554.00
Year 8-March 1, 2032	\$195,083.10	\$1,105,470.90	\$1,300,554.00
Year 9-March 1, 2033	\$0	\$0	0
Totals	\$1,438,737.60	\$8,152,846.40	\$9,591,584.00